Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2011

Vapor Transport and Aerosol Dynamics in the Respiratory Airways
Geng Tian
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Engineering Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/2442

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Geng Tian
2011
All Rights Reserved

VAPOR TRANSPORT AND AEROSOL DYNAMICS IN THE RESPIRATORY
AIRWAYS

A dissertation submitted in partial fulfillment of the requirements for the degree
of Doctor of Philosophy at Virginia Commonwealth University.
by

GENG TIAN
Master of Science, Saint Mary's University, Canada, 2005
Bachelor of Science, Xi'an University of Science and Technology, China, 2002

Director: Dr. P. WORTH LONGEST
Associate Professor, Department of Mechanical and Nuclear Engineering and
Department of Pharmaceutics

Virginia Commonwealth University
Richmond, Virginia
May, 2011

ii

Acknowledgement
Working as a Ph.D. student in the Department of Mechanical and Nuclear
Engineering at Virginia Commonwealth University was a magnificent as well as
challenging experience to me. It was hardly possible for me to thrive in my
doctoral work without the precious support of these personalities. Here is a small
tribute to all those people.
First of all, I would like to express my deep and sincere gratitude to my
advisor, Dr. Worth Longest, for introducing me to the world of respiratory drug
delivery research. His immense knowledge, cheerful enthusiasm, and his logical
way of thinking have been of great value for me. His understanding,
encouragement, patience, inspiration, motivation, and personal guidance have
provided a good basis for the present dissertation. I would have been lost without
him. For me, he is not only a scientist, but also a lifetime friend and mentor.
I wish to express my gratitude to my dissertation committee members, Dr.
Ramana M. Pidaparti, Dr. Hooman V. Tafreshi, Dr. Michael Hindle, and Dr.
Rebecca Segal for their great assistance with writing this dissertation, giving wise
advice and suggestions, and so on.
I would like to thank the School of Engineering and Department of
Mechanical Engineering for their support in the form of scholarships. I am
grateful to the faculty and staff of the Department of Mechanical Engineering, for
assisting me in many different ways. I especially thank Dr. Karla Mossi, who is
our director of graduate studies.

iii

I am indebted to my many student colleagues and friends for providing a
stimulating and fun environment in which to learn and grow. I am especially
grateful to Ross L. Walenga, Landon T. Holbrook, Joshua Clarke, Ryan Tate,
Rachel Waxman, Qiang Wang, Hao Zhang, Yezuo Wang, Renishhumar Delvadia,
Casey Grey, and Dr. Guoguang Su.
I would also like to thank all my friends for helping me get through the
difficult times, and for all the emotional support, entertainment, and caring they
provided. A special thanks to Robert Rhinehart.
Finally, I want to express my appreciation to my parents, Wenmin Tian
and Hali An, my sister and her husband, Jing Tian and Elvis Essavi, for their love,
understanding, patience, endless support, and never failing faith in me. To them I
dedicate this dissertation.

iv

Table of Contents
ACKNOWLEDGEMENT ......................................................................................II
TABLE OF CONTENTS...................................................................................... IV
LIST OF TABLES............................................................................................. VIII
LIST OF FIGURES ............................................................................................... X
ABSTRACT.........................................................................................................XX
ABSTRACT.........................................................................................................XX
CHAPTER 1.

SPECIFIC AIMS ........................................................................ 1

CHAPTER 2.

BACKGROUND ........................................................................ 6

2.1

OBJECTIVE 1: TRANSIENT ABSORPTION OF INHALED VAPORS. ................ 6

2.2

OBJECTIVE 2: THE CONCEPT OF ENHANCED CONDENSATIONAL
GROWTH. ............................................................................................... 11

2.3

OBJECTIVE 3: LOCAL AND REGIONAL DEPOSITION OF PHARMACEUTICAL
AEROSOLS.............................................................................................. 13

CHAPTER 3.

TRANSIENT ABSORPTION OF INHALED VAPORS INTO

A MULTILAYER MUCUS-TISSUE-BLOOD SYSTEM................................... 16
3.1

INTRODUCTION ...................................................................................... 16

3.2

METHODS .............................................................................................. 17

3.3

RESULTS ................................................................................................ 26

v

3.4

DISCUSSION ........................................................................................... 33

CHAPTER 4.

DEVELOPMENT OF A CFD BOUNDARY CONDITION TO

MODEL TRANSIENT VAPOR ABSORPTION IN THE RESPIRATORY
AIRWAYS.............................................................................................................54
4.1

INTRODUCTION ...................................................................................... 54

4.2

METHODS .............................................................................................. 54

4.3

RESULTS ................................................................................................ 63

4.4

DISCUSSION ........................................................................................... 68

CHAPTER 5.

TRANSIENT ABSORPTION OF INHALED VAPORS IN

THE MOUTH-THROAT REGION WITH AN AIR-MUCUS-TISSUE-BLOOD
WALL BOUNDARY CONDITION .................................................................... 87
5.1

INTRODUCTION ...................................................................................... 87

5.2

METHODS .............................................................................................. 87

5.3

RESULTS ................................................................................................ 99

5.4

DISCUSSION ......................................................................................... 105

CHAPTER 6.

EVALUATION OF ENHANCED CONDENSATIONAL

GROWTH (ECG) FOR RESPIRATORY DRUG DELIVERY IN A REALISTIC
MOUTH-THROAT AND TRACHEOBRONCHIAL SINGLE PATH
MODEL...............................................................................................................126
6.1

INTRODUCTION .................................................................................... 126

6.2

METHODS ............................................................................................ 127

vi

6.3

RESULTS .............................................................................................. 136

6.4

DISCUSSION ......................................................................................... 144

CHAPTER 7.

EFFECTS OF TRANSIENT INHALATION ON ENHANCED

CONDENSATIONAL GROWTH (ECG) IN A REALISTIC MOUTH-THROAT
AND TRACHEOBRONCHIAL SINGLE PATH MODEL............................... 169
7.1

INTRODUCTION .................................................................................... 169

7.2

METHODS ............................................................................................ 170

7.3

RESULTS .............................................................................................. 173

7.4

DISCUSSION ......................................................................................... 176

CHAPTER 8.

EFFECTS OF INHALATION PROFILES ON THE

DEPOSITION OF MDI AND DPI GENERATED AEROSOLS IN A
REPRESENTATIVE MODEL OF THE MOUTH-THROAT AND
TRACHEOBRONCHIAL AIRWAYS............................................................... 186
8.1

INTRODUCTION .................................................................................... 186

8.2

METHODS ............................................................................................ 187

8.3

RESULTS .............................................................................................. 195

8.4

DISCUSSION ......................................................................................... 197

CHAPTER 9.

DEVELOPMENT OF A STOCHASTIC INDIVIDUAL PATH

MODEL FOR ASSESSING PHARMACEUTICAL AEROSOL DEPOSITION:
EFFECTS OF TRANSIENT INHALATION WAVEFORM AND SAMPLING
THE TRACHEOBRONCHIAL AIRWAYS...................................................... 207

vii

9.1

INTRODUCTION .................................................................................... 207

9.2

METHODS ............................................................................................ 208

9.3

RESULTS .............................................................................................. 212

9.4

DISCUSSION ......................................................................................... 214

CHAPTER 10.

CONCLUSIONS AND FUTURE WORK ......................... 224

10.1

TRANSIENT ABSORPTION OF INHALED VAPORS. .................................. 224

10.2

THE CONCEPT OF ENHANCED CONDENSATIONAL GROWTH................. 225

10.3

LOCAL AND REGIONAL DEPOSITION OF PHARMACEUTICAL
AEROSOLS............................................................................................ 226

LIST OF REFERENCES.................................................................................... 227
APPENDIX A..................................................................................................... 241
TRANSIENT ANALYTIC SOLUTIONS IN THE MUCUS-TISSUE-BLOOD SYSTEM .. 241
TRANSIENT ANALYTIC SOLUTIONS IN THE AIR-MUCUS-TISSUE-BLOOD
SYSTEM............................................................................................................ 247
VITA ................................................................................................................... 255

viii

List of Tables
TABLE 3.1.

THICKNESS OF MUCUS AND TISSUE IN EACH REGION. ................................. 39

TABLE 3.2.

VALUES OF TRANSPORT PARAMETERS........................................................ 40

TABLE 3.3.

BLOOD UPTAKE DIFFERENCE (%) BETWEEN STEADY STATE AND
TRANSIENT CONDITIONS FOR ACETALDEHYDE............................................ 41

TABLE 3.4.

BLOOD UPTAKE DIFFERENCE (%) BETWEEN STEADY STATE AND
TRANSIENT CONDITIONS FOR BENZENE....................................................... 41

TABLE 3.5.

REACTIVITY CONSTANTS OF COMMON CHEMICALS IN MUCUS AND
TISSUE........................................................................................................ 42

TABLE 4.1.

TWO CASES CONSIDERED. .......................................................................... 72

TABLE 4.2.

BLOOD UPTAKE DIFFERENCE (%) BETWEEN STEADY STATE AND
TRANSIENT CONDITIONS FOR ACETALDEHYDE AND BENZENE..................... 72

TABLE 4.3.

DEPOSITION FRACTION (%) IN MUCUS, TISSUE, AND BLOOD FOR
CASES 1 AND 2 CONSIDERED DURING A 2 SECONDS INHALATION. .............. 73

TABLE 5.1.

THE FIRST FIVE EIGENVALUES µN AND COEFFICIENTS WN.......................... 112

TABLE 5.2.

DEFINITION OF STEADY AND TRANSIENT CASES CONSIDERED. ................. 113

TABLE 5.3.

TOTAL DEPOSITION FRACTIONS (DF) AS PERCENTAGES IN MUCUS,
TISSUE, AND BLOOD. ................................................................................ 114

TABLE 6.1.

ALL CASES CONSIDERED. ......................................................................... 152

TABLE 6.2.

DEPOSITION EFFICIENCY (%) FOR EACH CASE. ......................................... 153

TABLE 6.3.

STOCHASTIC ANALYSIS OF DEPOSITION EFFICIENCY (%) FOR CASE 4....... 153

ix

TABLE 6.4.

COMPARISON WITH EXISTING TB CORRELATIONS (DE). .......................... 154

TABLE 6.5.

PREDICTED PULMONARY AND TOTAL DEPOSITION FRACTIONS. ................ 155

TABLE 7.1.

INLET CONDITIONS CONSIDERED. ............................................................. 178

TABLE 7.2.

PULMONARY AND TOTAL DEPOSITION FRACTIONS. .................................. 179

TABLE 8.1.

PARAMETERS DESCRIBING TRANSIENT INHALATION WAVEFORMS. .......... 198

TABLE 8.2.

WAVEFORM PARAMETERS FOR THE QD AND SD PROFILES. ..................... 198

TABLE 9.1.

DEPOSITION EFFICIENCY UNDER QD CONDITIONS FOR 3 SIP MODELS...... 216

TABLE 9.2.

DEPOSITION EFFICIENCY UNDER STEADY STATE (SS) CONDITIONS
FOR 3 SIP MODELS. ................................................................................. 216

x

List of Figures
FIGURE 3.1.

MULTILAYER SYSTEM REPRESENTING THE ABSORPTION AND
TRANSPORT OF RESPIRATORY VAPORS INTO THE WALLS OF THE
CONDUCTING AIRWAYS. ADAPTED FROM ICRP......................................... 43

FIGURE 3.2.

APPROXIMATE WALL MODEL CONSISTING OF MUCUS, TISSUE, AND
BLOOD REGIONS WITH GOVERNING EQUATIONS AND BOUNDARY
CONDITIONS. .............................................................................................. 44

FIGURE 3.3.

CONCENTRATIONS OF ACETALDEHYDE AND BENZENE OVER TIME
COMPARED WITH STEADY STATE RESULTS IN THE (A) ET2, (B) BB,
AND (C) BB REGIONS. ................................................................................. 45

FIGURE 3.4.

COMPARISON OF ANALYTICAL AND NUMERICAL TRANSIENT
SOLUTIONS FOR ACETALDEHYDE AND BENZENE CONCENTRATIONS IN
THE BB REGION.

FIGURE 3.5.

........................................................................................ 46

ACETALDEHYDE AND BENZENE CONCENTRATIONS AT THE MUCUSTISSUE INTERFACE IN THE (A) BB AND (B) BB REGIONS.............................. 47

FIGURE 3.6.

FLUX OF ACETALDEHYDE AND BENZENE INTO THE TISSUE AND
BLOOD FOR THE (A) BB AND (B) BB REGIONS. ............................................ 48

FIGURE 3.7.

UPTAKE OF ACETALDEHYDE AND BENZENE FOR TRANSIENT AND
STEADY STATE CONDITIONS IN THE (A) BB AND (B) BB REGIONS................ 49

xi

FIGURE 3.8.

PERCENT DIFFERENCES BETWEEN STEADY STATE VS. TRANSIENT
PREDICTIONS OF UPTAKE FOR ACETALDEHYDE AND BENZENE IN THE

(A) BB AND (B) BB REGIONS....................................................................... 50
FIGURE 3.9.

CONCENTRATIONS OF ACETALDEHYDE AND BENZENE AT THE
MUCUS-TISSUE INTERFACE DURING INHALATION (0 – 2 S) AND
EXHALATION (2 – 4 S) PERIODS OVER TWO BREATHING CYCLES. ................ 51

FIGURE 3.10. TISSUE UPTAKE OF ACETALDEHYDE AND BENZENE FOR TRANSIENT
CONDITIONS INCLUDING REACTIVITY IN THE (A) BB AND (B) BB
REGIONS..................................................................................................... 52

FIGURE 3.11. BLOOD UPTAKE OF ACETALDEHYDE AND BENZENE FOR TRANSIENT
CONDITIONS INCLUDING REACTIVITY IN THE (A) BB AND (B) BB
REGIONS..................................................................................................... 53

FIGURE 4.1.

(A) THE AMTB SYSTEM AND (B) THE NASAL-LARYNGEAL AIRWAY
MODEL. ...................................................................................................... 74

FIGURE 4.2.

SYSTEM SETUP FOR ANALYTIC SOLUTIONS IN THE MUCUS AND
TISSUE LAYERS........................................................................................... 75

FIGURE 4.3.

BOUNDARY CONDITIONS AT THE AIR-MUCUS INTERFACE........................... 76

FIGURE 4.4.

SYSTEM SETUP FOR (A) THE NUMERICAL SOLUTIONS AND (B) THE
HYBRID SOLUTIONS IN THE MULTILAYER SYSTEM. ..................................... 77

FIGURE 4.5.

COMPARISON OF NUMERICAL TRANSIENT AND HYBRID SOLUTIONS
FOR ACETALDEHYDE AND BENZENE CONCENTRATIONS IN THE MUCUS
AND TISSUE. ............................................................................................... 78

xii

FIGURE 4.6.

ACETALDEHYDE AND BENZENE CONCENTRATIONS AT THE AIRMUCUS AND MUCUS-TISSUE INTERFACES.................................................... 79

FIGURE 4.7.

FLUX OF ACETALDEHYDE AND BENZENE INTO THE MUCUS, TISSUE
AND BLOOD LAYERS................................................................................... 80

FIGURE 4.8.

UPTAKE OF ACETALDEHYDE AND BENZENE FOR TRANSIENT AND
STEADY STATE CONDITIONS. ...................................................................... 81

FIGURE 4.9.

PERCENT DIFFERENCES BETWEEN STEADY STATE VS. TRANSIENT
PREDICTIONS OF UPTAKE FOR ACETALDEHYDE AND BENZENE.................... 82

FIGURE 4.10. UPTAKE OF ACETALDEHYDE AND BENZENE FOR TRANSIENT
CONDITIONS INCLUDING REACTIVITY. ........................................................ 83

FIGURE 4.11. DEPOSITION FRACTION OF ACETALDEHYDE AND BENZENE VAPORS IN
MUCUS, TISSUE, AND BLOOD IN THE NASAL-LARYNGEAL AIRWAY
MODEL FOR CASES 1 AND 2 OVER A 2 SECONDS INHALATION..................... 84

FIGURE 4.12. DEF CONTOURS OF ACETALDEHYDE FOR BOTH CASES CONSIDERED. ......... 85
FIGURE 4.13. DEF CONTOURS OF BENZENE FOR BOTH CASES CONSIDERED. .................... 86
FIGURE 5.1.

SURFACE MODEL OF THE MOUTH-THROAT REGION INCLUDING THE
ORAL CAVITY, PHARYNX, LARYNX, AND A PORTION OF THE UPPER
TRACHEA.................................................................................................. 115

FIGURE 5.2.

SUBMODEL OF THE AIRWAY WALL INCLUDING AIR, MUCUS, TISSUE,
AND BLOOD (AMTB) LAYERS.

EQUATIONS GOVERNING TRANSPORT

IN THIS MULTILAYER SYSTEM ARE ALSO SHOWN. ..................................... 116

FIGURE 5.3.

GRAPHICAL USER INTERFACE (GUI) OF THE TRANSIENT
ABSORPTION OF CHEMICAL SPECIES (TAOCS) 1.0 MODEL.

xiii

WINDOWS SHOWN INCLUDE THE MAIN GUI AND INPUT PANELS FOR
TRANSPORT PROPERTIES AND FINDING THE EIGENVALUES. ...................... 117

FIGURE 5.4.

CONTOURS OF ACETALDEHYDE MASS FRACTIONS IN THE AIR PHASE
(CA) FOR ALL CASES CONSIDERED. FOR CASES WITH EITHER
TRANSIENT AIRFLOW OR WALL ABSORPTION, CONDITIONS AT 2
SECONDS ARE SHOWN.

THE INLET MASS FRACTION OF EACH

CHEMICAL SPECIES CONSIDERED WAS 5% FOR ALL CASES........................ 118

FIGURE 5.5.

CONTOURS OF BENZENE MASS FRACTIONS IN THE AIR PHASE (CA)
FOR ALL CASES CONSIDERED.

FOR CASES WITH EITHER TRANSIENT

AIRFLOW OR WALL ABSORPTION, CONDITIONS AT 2 SECONDS ARE
SHOWN..................................................................................................... 119

FIGURE 5.6.

TOTAL DEPOSITION FRACTIONS OF ACETALDEHYDE AND BENZENE
VAPORS IN MUCUS, TISSUE, AND BLOOD IN THE MT MODEL FOR

CASES 1 – 4 AFTER 2 SECONDS................................................................. 120
FIGURE 5.7.

TOTAL MUCUS DEPOSITION FRACTION OF ACETALDEHYDE AND
BENZENE FOR THE EVALUATION OF THE PERFECT ABSORPTION
CONDITION. .............................................................................................. 121

FIGURE 5.8.

DEPOSITION ENHANCEMENT FACTORS (DEFS) AND TOTAL
DEPOSITION FRACTIONS (DFS) FOR ACETALDEHYDE AND ALL CASES
CONSIDERED AFTER 2 S. ........................................................................... 122

FIGURE 5.9.

DEPOSITION ENHANCEMENT FACTORS (DEFS) AND TOTAL
DEPOSITION FRACTIONS (DFS) FOR BENZENE AND ALL CASES
CONSIDERED AFTER 2 S. ........................................................................... 123

xiv

FIGURE 5.10. MASS ABSORPTION OF ACETALDEHYDE AND BENZENE IN INDIVIDUAL
WALL LAYERS UNDER STEADY AIRFLOW CONDITIONS OVER TIME. ........... 124

FIGURE 5.11. MASS ABSORPTION RATE (G/S) OF ACETALDEHYDE AND BENZENE
INTO THE MUCUS BASED ON CASE 1 (S:S) AND CASE 4 (T:T)
CONDITIONS CONSIDERED OVER MULTIPLE BREATHS. .............................. 125

FIGURE 6.1.

GEOMETRY USED TO EVALUATE THE

ENHANCED CONDENSATIONAL

GROWTH (ECG) DELIVERY OF SUBMICROMETER AEROSOL IN THE
MOUTH-THROAT (MT) AND TRACHEAOBRONCHIAL (TB) REGIONS
EXTENDING DOWN A SINGLE PATH TO BIFURCATION 15 (B15) OF THE
RIGHT LOWER LUNG LOBE. ....................................................................... 156

FIGURE 6.2.

COMPUTATIONAL MESH OF THE MT-TB AIRWAY MODEL. ....................... 157

FIGURE 6.3.

COMPARISON OF AEROSOL DEPOSITION EFFICIENCY IN THE UPPER TB
AIRWAYS BETWEEN CFD PREDICTIONS WITH THE MT-TB
GEOMETRY CONSIDERED IN THIS STUDY AND THE EXPERIMENTAL
RESULTS ZHOU AND CHENG (2005) FOR A CAST-BASED REPLICA
MODEL. .................................................................................................... 158

FIGURE 6.4.

PREDICTED TEMPERATURE CONDITIONS FOR (A) CASES 1 AND 2, (B)
CASE 3, AND (C) CASE 4

FIGURE 6.5.

CONDITIONS.

.................................................... 159

PREDICTED RELATIVE HUMIDITY (RH) CONDITIONS FOR (A) CASES 1
AND 2, (B) CASE 3, AND (C) CASE 4 CONDITIONS. .................................... 160

FIGURE 6.6.

PREDICTED DROPLET TRAJECTORIES FOR INITIALLY 900 NM
MONODISPERSE AEROSOLS AND (A) CASE 2, (B) CASE 3, AND (C)

CASE 4 CONDITIONS. ................................................................................ 161

xv

FIGURE 6.7.

CFD PREDICTIONS OF EXITING POLYDISPERSE SIZE DISTRIBUTIONS
FOR INITIALLY 560 NM AND 900 NM MONODISPERSE AEROSOLS
UNDER CASE 2-4 CONDITIONS.................................................................. 162

FIGURE 6.8.

COMPARISONS OF THE MASS MEDIAN AERODYNAMIC DIAMETERS
(MMAD) WITH THE AEROSOL ENTERING ONE BRANCH OF EACH
BIFURCATION THROUGH BIFURCATION 15 (B15) FOR CASES 2-4.............. 163

FIGURE 6.9.

COMPARISONS OF THE MASS MEDIAN AERODYNAMIC DIAMETERS
(MMAD) WITH THE AEROSOL ENTERING ONE BRANCH OF EACH
BIFURCATION THROUGH BIFURCATION 15 (B15) FOR CASES 3 AND 4
WITH ONE-WAY AND TWO-WAY COUPLING............................................... 164

FIGURE 6.10. PARTICLE DEPOSITION LOCATIONS AND REGIONAL DEPOSITION
EFFICIENCIES (DE) OF DRUG MASS FOR AN INITIALLY 900 NM
AEROSOL AND (A) CASE 1, (B) CASE 2, (C) CASE 3, AND (D) CASE 4
CONDITIONS. ............................................................................................ 165

FIGURE 6.11. PARTICLE DEPOSITION LOCATIONS AND REGIONAL DEPOSITION
EFFICIENCIES (DE) OF DRUG MASS FOR AN INITIALLY 900 NM
AEROSOL WITH (A) CASE 3 AND TWO-WAY COUPLING AND (B) CASE

4 AND TWO- WAY COUPLING. ................................................................... 166
FIGURE 6.12. PARTICLE DEPOSITION LOCATIONS AND REGIONAL DEPOSITION
EFFICIENCIES (DE) OF DRUG MASS FOR AN INITIALLY 900 NM
AEROSOL AND (A) CASE 4 DOWN PATH 2 VS. (B) CASE 4 DOWN PATH

3............................................................................................................... 167

xvi

FIGURE 6.13. COMPARISON OF DEPOSITION EFFICIENCIES (DE) FOR INITIALLY (A)
560 AND (B) 900 NM DROPLETS................................................................ 168
FIGURE 7.1.

TRANSIENT INHALATION WAVEFORM....................................................... 180

FIGURE 7.2.

PREDICTED TEMPERATURE CONDITIONS FOR (A) STEADY STATE, (B)
T=0.5 S , AND (C) T=2 S. ........................................................................... 181

FIGURE 7.3.

PREDICTED RELATIVE HUMIDITY (RH) CONDITIONS FOR (A) STEADY
STATE, (B) T=0.5 S, AND (C) T=2 S. ......................................................... 182

FIGURE 7.4.

CFD PREDICTIONS OF EXITING POLYDISPERSE SIZE DISTRIBUTIONS
FOR INITIALLY 900 NM MONODISPERSE AEROSOL DURING (A)
STEADY STATE AND (B) TRANSIENT INHALATION (T=2 S). ........................ 183

FIGURE 7.5.

COMPARISONS OF THE MASS MEDIAN AERODYNAMIC DIAMETERS
(MMAD) WITH THE AEROSOL ENTERING ONE BRANCH OF EACH
BIFURCATION THROUGH BIFURCATION 15

(B15) FOR STEADY AND

TRANSIENT INHALATION CONDITIONS (T=2 S). ......................................... 184

FIGURE 7.6.

PARTICLE DEPOSITION LOCATIONS AND REGIONAL DEPOSITION
EFFICIENCIES (DE) OF DRUG MASS FOR AN INITIALLY 900 NM
AEROSOL FOR (A) STEADY STATE AND (B) TRANSIENT INHALATION

(T=2S)...................................................................................................... 185
FIGURE 8.1.

UPPER MT-TB GEOMETRIES FOR TESTING DRUG AEROSOL
DEPOSITION CONNECTED TO THE (A) FLOVENT MDI AND (B)

FLOVENT DISKUS DPI. THE MDI MODEL INCLUDES A NARROW AIR
PASSAGE BETWEEN THE ACTUATOR BODY AND CANISTER AND A 0.5
MM NOZZLE FOR THE INTRODUCTION OF THE PROPELLANT AND

xvii

PARTICLES/DROPLETS. THE DPI MODEL INCLUDES A 5 MM JET FOR
THE INTRODUCTION OF THE DRUG POWDER AND AIRFLOW, TWO 0.5
MM JETS, WHICH ARE CONSISTENT WITH THE FLOVENT DISKUS

INHALER, AS WELL AS THE INNER SURFACE OF THE MOUTHPIECE............. 199
FIGURE 8.2.

INHALATION WAVEFORMS FOR SD AND QD WAVEFORMS. ...................... 200

FIGURE 8.3.

COMPARISON OF EXPERIMENTAL (EXP) AND SIMULATED DEPOSITION
RESULTS WITH STEADY STATE AND SQUARE WAVEFORM INHALATION
FLOW CONDITIONS FOR THE (A) MDI AT 37 L/MIN AND (B) DPI AT 75

L/MIN. THE CFD PREDICTIONS ARE SHOWN TO MATCH THE IN VITRO
RESULTS TO A HIGH DEGREE..................................................................... 201

FIGURE 8.4.

VELOCITY VECTORS AND CONTOURS FOR SD AND QD WAVEFORMS ....... 202

FIGURE 8.5.

VELOCITY VECTORS AND CONTOURS FOR SD AND QD WAVEFORMS ....... 203

FIGURE 8.6.

VELOCITY VECTORS AND CONTOURS FOR SD AND QD WAVEFORMS ....... 204

FIGURE 8.7.

CFD PREDICTED RESULTS OF MDI DEPOSITION IN THE MT-TB
MODEL FOR (A) SD AND (B) QD INHALATION WAVEFORMS.

DEPOSITION RESULTS ARE SIMILAR BETWEEN THE TWO INHALATIONS.
HOWEVER, SIGNIFICANT DIFFERENCES ARE OBSERVED BETWEEN THE
TRANSIENT INHALATION, SHOWN HERE, AND STEADY STATE
CONDITIONS SHOWN IN FIGURE 8.3. ......................................................... 205

FIGURE 8.8.

CFD PREDICTED RESULTS OF DPI DEPOSITION IN THE MT-TB
MODEL FOR (A) SD AND (B) QD INHALATION WAVEFORMS.

DEPOSITION RESULTS ARE SIMILAR BETWEEN THE TWO INHALATIONS.
FURTHERMORE, DEPOSITION APPEARS SIMILAR BETWEEN THE

xviii

TRANSIENT INHALATION, SHOWN HERE, AND SQUARE WAVE
CONDITIONS SHOWN IN FIGURE 8.3. ......................................................... 206

FIGURE 9.1.

MT-TB SIP GEOMETRIES FOR TESTING DRUG AEROSOL DEPOSITION
FROM A FLOVENT DISKUS DPI................................................................. 217

FIGURE 9.2.

COMPARISON OF IN VITRO AND SIMULATED DEPOSITION RESULTS
WITH SQUARE WAVEFORM INHALATION FLOW CONDITIONS FOR THE

DPI AT 75 L/MIN. THE CFD PREDICTIONS ARE SHOWN TO MATCH
THE IN VITRO RESULTS TO A HIGH DEGREE. ............................................... 218

FIGURE 9.3.

STOCHASTIC INDIVIDUAL PATH (SIP) MODEL EXTENDING FROM THE
END OF THE MT-TB GEOMETRY INTO THE RIGHT LOWER LUNG.

THE

ARROW INDICATES THE SITE OF VELOCITY FIELD AND PARTICLE
PROFILE INTERPOLATION BETWEEN THE UPPER AIRWAY MODEL AND

SIP GEOMETRY. ....................................................................................... 219
FIGURE 9.4.

CFD PREDICTED RESULTS OF DPI DEPOSITION IN THE UPPER MT-TB
MODEL FOR (A) SS AND (B) QD INHALATION WAVEFORMS. ..................... 220

FIGURE 9.5.

PARTICLE DEPOSITION LOCATIONS AND REGIONAL DEPOSITION
EFFICIENCIES (DE) OF DRUG MASS FOR (A) SS FOR SIP 1, (B) QD FOR

SIP 1, (C) SS FOR SIP 2, (D) QD FOR SIP 2, (E) SS FOR SIP 3, AND
(F) QD FOR SIP 3. .................................................................................... 221
FIGURE 9.6.

COMPARISON OF STEADY STATE AND TRANSIENT DEPOSITION
EFFICIENCIES OF DRUG MASS WITHIN SPECIFIC REGIONS.

THE ERROR

BARS DENOTE +/- ONE STANDARD DEVIATION.......................................... 222

xix

FIGURE 9.7

COMPARISON OF STEADY STATE AND QD DEPOSITION EFFICIENCIES
OF DRUG MASS IN EACH BIFURCATION OF 3 SIPS. SYMBOLS
REPRESENT MEAN VALUES AND THE ERROR BARS DENOTE +/- ONE
STANDARD DEVIATION. ............................................................................ 223

xx

Abstract
VAPOR TRANSPORT AND AEROSOL DYNAMICS IN THE RESPIRATORY
AIRWAYS
By Geng Tian
A dissertation submitted in partial fulfillment of the requirements for the degree
of Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Director: Dr. P. Worth Longest
Associate Professor, Department of Mechanical Engineering and
Department of Pharmaceutics
Predicting vapor transport and aerosol dynamics in the respiratory airways
is important for analyzing both environmental exposure and respiratory drug
delivery. A large number of analytical models, computational studies, and
experiments on vapor and aerosol transport in the respiratory tract have been
conducted previously. However, a number of critical questions remain
unanswered. In this study, computational fluid dynamics (CFD) is primarily
employed with frequent comparisons to existing and new experimental data sets
to address previously unanswered issues related to the transport of vapors and
aerosol in the respiratory tract. The three objectives of this study are further
described below.
Objective 1: A CFD model was developed to predict the transient
absorption of inhaled vapors in the respiratory tract. Results indicated that

xxi

transient absorption can significantly influence the transport and uptake of vapors
in the walls of the conducting airways.
Objective 2: The concept of enhanced condensational growth (ECG)
applied to respiratory drug delivery was tested in a representative airway model
extending from the oral cavity to the end of the tracheobronchial (TB) airways.
Results indicated that ECG is an effective method to provide near full lung
retention of the aerosol. The CFD results also indicated that the ECG delivery
approach under transient inhalation conditions increased aerosol deposition in the
TB airways by only a small amount, as compared with steady state conditions.
Objective 3: The effect of transient waveforms on the transport and
deposition of pharmaceutical aerosols from inhalers in the upper airways was
considered. Results indicated that the CFD model predictions matched the in vitro
experiments to a high degree. The CFD results also indicated that it was critical to
consider transient inhalation effects when assessing aerosol deposition. The
stochastic individual path (SIP) modeling approach was then introduced and
implemented to evaluate the transport and deposition of pharmaceutical aerosols
from inhalers in medium and small TB airways. Results indicated that steady state
inhalation could be used to predict deposition efficiencies in the TB airways
between the 4th branch (B4) and the bronchioles (B15).

Chapter 1.

Specific Aims

The overall goal of this project is to investigate under-explored areas of
vapor transport and aerosol dynamics in the respiratory tract. Computational fluid
dynamics (CFD) is primarily employed with frequent comparisons to existing and
new experimental data sets. New experimental data related to this project was
developed in collaboration with the VCU Department of Pharmaceutics (Dr.
Michael Hindle) as part of an active NIH R21 grant and FDA contract.
Applications of this research include developing a better understanding of the
dosimetry of gaseous pollutants in the respiratory tract and the development of
new therapeutic techniques for treating lung diseases and systemic conditions.
Specifically, this work will develop dosimetry models for inhaled gaseous species,
optimize the use of the enhanced condensational growth approach to improve the
delivery of therapeutic aerosols to the lungs, and predict local and regional
deposition of pharmaceutically relevant polydisperse aerosols from pressurized
metered dose inhalers (MDIs) and dry powder inhalers (DPIs) throughout the
tracheobronchial (TB) airways. These applications are further described below in
the form of objectives.
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Objective 1: Transient Absorption of Inhaled Vapors.
Current models of vapor absorption in the respiratory airways assume that
transport into the walls is a steady state process. However, simple nondimensional analysis reveals that airway wall resistance makes absorption a
transient process over the course of an inhalation cycle. As a result, current
models of vapor absorption may significantly over- or under predict uptake and
dose by an order of magnitude or more. The objective of this study is to develop a
CFD model to predict the transient absorption of inhaled vapors in the respiratory
tract. This objective is divided into the following three tasks.
Task 1.1. Determine if transient absorption is significant over the course of
an inhalation cycle in a simple mucus-tissue-blood representation of the airway
wall.
Task 1.2. Develop a CFD boundary condition for predicting transient wall
absorption and uptake in a complex respiratory geometry.
Task 1.3. Apply the transient CFD boundary condition to evaluate the
effects of both transient inhalation and transient absorption on regional and local
uptake in a model upper airway geometry.
To determine if transient absorption is important, both numerical and
analytical solutions of absorption will be considered in a multilayer
approximation of the respiratory wall. The absorption of highly and moderately
soluble compounds will be considered over the time cycle of one inhalation (~ 2
seconds). Provided transient effects are important, the analytical solution will be
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extended to allow for implementation as a CFD boundary condition. This will
require the addition of an air-phase and a variable air-mucus concentration value.
The CFD boundary condition will then be applied in a mouth-throat upper airway
geometry. Comparison will be made between absorption predictions based on the
standard steady state model and the new transient boundary condition. The effects
of steady state vs. transient flow will also be evaluated. These results will provide
a new, more accurate method to predict vapor absorption in the respiratory tract.
It is expected that the transient model will ultimately improve upon the steady
state predictions by a factor of 10X or more.

Objective 2: The Concept of Enhanced Condensational Growth.
Our group has recently proposed the concept of enhanced condensational
growth (ECG) for improved respiratory drug delivery. In this approach, a
nanoaerosol containing at active agent (drug or marker) is initially generated and
inhaled past the mouth-throat (MT) resulting in low deposition and loss. The
nanoaerosol is delivered with sufficient water vapor to cause supersaturation and
aerosol growth to micrometer size in the tracheobronchial (TB) and/or alveolar
airways, which facilitates pulmonary retention. As a result, negligible MT and
near 100% lung deposition is possible. Furthermore, regional TB or alveolar
deposition can be engineered allowing for drug targeting by controlling the rate of
size increase. Factors affecting the rate of growth include the initial aerosol size,
drug hygroscopicity, and the gas phase conditions of the humidity and aerosol
delivery streams (i.e., temperature, relative humidity, and flow rate).
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The prediction of aerosol growth in the ECG approach requires accurate
knowledge of the relative humidity (RH) field surrounding the nanoaerosol. To
extend this concept, the following tasks are proposed.
Task 2.1. Determine the size increase of aerosols in a single path model
from the MT region through the TB geometry (~ generation G16).
Task 2.2. Consider the effects of transient inhalation waveforms on the
ECG process in the upper TB airways.
Previous studies have indicated that ECG increases aerosol size from the
submicrometer range to approximately 2 - 3 µm. However, transient inhalation
will affect both aerosol inertia and RH conditions. Furthermore, only delivery in
the upper airways has been explored. Relative humidity and growth conditions
need to be investigated throughout the TB region. Finally, the ECG approach can
potentially be tailored for targeted respiratory drug delivery. Conditions for lung
deposition in the upper, mid, and lower regions of the respiratory tract should be
explored.

Objective 3: Local and Regional Deposition of Pharmaceutical Aerosols.
Previous whole-lung particle deposition models have been used to assess
branch-averaged deposition. However, inaccurate predictions of absorption
associated with using idealized aerosols and neglecting interactions at the patientdevice interface remain significant shortcomings of these models. In contrast,
fully resolved three-dimensional (3-D) models with pharmaceutical delivery
devices can predict local and regional deposition in the TB airways. Furthermore,
local and regional deposition can be extended to predict dissolution and
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absorption into the airways and bloodstream. Therefore, the objective of this
study is to develop a CFD model of orally inhaled drug products that can account
for inhaler attributes (spray or jet momentum), physicochemical properties
(aerodynamic size distribution and dissolution), and physiological parameters
(breathing pattern and airway geometry) in determining local and regional
deposition throughout the TB airways. Specifically, this objective is divided into
the following two tasks.
Task 3.1. Develop a CFD model to evaluate aerosol deposition in a
realistic MT and upper TB model and validate the developed model using new in
vitro results in the geometries considered for specific inhaler devices.
Task 3.2. Characterize deposition within the right lower lung lobe using
the stochastic individual path (SIP) model approach.
For accurate delivery predictions, MDI and DPI inhaler types have been
considered based on (i) the exceedingly large drug losses in the upper airways,
and (ii) the effect of reduced drug aerosol fractions and induced turbulence on
deposition in the lower airways.
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Chapter 2.

Background

Predicting vapor transport and aerosol dynamics in the respiratory airways is
important for analyzing both environmental exposure and respiratory drug
delivery. A large number of analytical models, computational studies, and
experiments on vapor and aerosol transport in the respiratory tract have been
conducted previously. However, a number of critical questions remain
unanswered. For example, the effects of transient vapor absorption into the walls
of the conducting airways have not previously been considered. The delivery of
inhaled medicines to the lungs is known to be highly inefficient due to large
depositional losses in the delivery device and extrathoracic region. In this study,
computational fluid dynamics (CFD) is primarily employed with frequent
comparisons to existing and new experimental data sets to address previously
unanswered issues related to the transport of vapors and aerosol in the respiratory
tract. Background information further motivating the objectives of this study is
provided in this chapter.
2.1

Objective 1: Transient Absorption of Inhaled Vapors.
Determining the transport and absorption of inhaled vapors in the

respiratory tract is an important step in predicting the biological responses and
health effects of exposures (Jarabek 1995). Sources of inhaled vapors may include
potentially toxic environmental pollutants, noxious compounds released in a
chemical terrorist attack, combustion byproducts resulting from fires, and medical
gases.

The dosimetry of these chemical species in the respiratory tract is

controlled by both gas-phase motion in the airways and mass transport through
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the respiratory liquid and tissue layers and into the bloodstream. A number of
studies have considered the gas-phase transport and surface absorption of inhaled
chemical species (Frederick et al. 1998; Kimbell and Subramaniam 2001; Shi et al.
2006; Zhang and Kleinstreuer 2006; Zhang et al. 2006b). Other studies have
more directly focused on the mass transport process through the walls of the
respiratory tract (Aharonson et al. 1974; Anderson et al. 2003; Chang et al. 1983;
Cohen Hubal et al. 1996a; Morris and Blanchard 1992; Morris and Cavanagh
1986; Morris and Cavanagh 1987).
The mass transport of chemical species within the lining of the respiratory
tract is controlled by solubility, diffusion, and wall structure. Motion of the liquid
lining and blood can also create convective transport. Highly and moderately
soluble compounds are largely absorbed in the upper respiratory tract (URT),
which effectively protects the more sensitive alveolar airways. Some highly
soluble compounds like formaldehyde are almost completely absorbed in the
extrathoracic airways during nasal inhalation (Chang et al. 1983; Cohen Hubal et
al. 1997; Kimbell et al. 2001b). Even relatively insoluble compounds like ozone
are largely absorbed in the lower tracheobronchial airways as surface area
increases, thereby significantly reducing the amount reaching the alveolar region.
For species absorbed in the URT, the mucus layer serves as a barrier that reduces
absorption in the tissue and blood components of the wall structure. Therefore, an
accurate view of absorption into the mucus is essential to determine doses
received in the lower layers. Doses of inhaled vapors that reach the respiratory
tract tissue may be associated with a local response such as bronchoconstriction
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and injury in the case of inhaled pollutants. Compounds that reach the blood may
result in systemic uptake and related toxicological effects.

Furthermore, an

accurate prediction of absorption in the URT is important to determine
penetration depth of inhaled vapors traveling down the respiratory tract and into
the highly sensitive alveolar region.
Mass transport through the walls of the URT has been modeled using a
variety of approaches. Cohen Hubal et al. (1996a) summarized previous models
of URT absorption and categorized the existing models as early, lumped
parameter, and distributed parameter approaches. Early models were used to gain
qualitative physical insight regarding the absorption process (LaBelle et al. 1955).
Lumped parameter models assume well-mixed compartments and consider only
time-dependent concentration variables (Chang et al. 1983; Morris and Blanchard
1992; Morris and Cavanagh 1986; Morris and Cavanagh 1987).

Distributed

parameter models consider both spatial and temporal concentrations (Aharonson
et al. 1974; Kimbell et al. 1993). The first distributed parameter model was
reported by Aharonson et al. (1974) to examine the effects of airflow rate on the
uptake of soluble vapors in the nose. In this model, a transient expression for
total uptake was developed based on a local mass transfer coefficient. As with
Aharonson et al. (1974) most of the lumped parameter and distributed parameter
models reviewed by Cohen Hubal et al. (1996a) considered the effect of
absorption time on uptake into the mucus and tissue. However, these models
assumed that a steady state diffusion flux through the respiratory airway wall was
reached instantaneously. This assumption neglects the effects of transient
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diffusion on the absorption and uptake of vapors. To gain a better understanding
of the time scale for absorption in a multilayer system consisting of air, mucus,
tissue, and blood, transient flux boundary conditions were implemented in a
multilayer CFD model of the transport in the upper airways.
Computational fluid dynamics (CFD) modeling provides a distributed
parameter approach that has been used to simulate the transport and uptake of
vapors in the respiratory tract. This approach uses CFD to simulate airflow
dynamics and applies an analytically determined boundary condition to model
absorption in either a mucus or a mucus-tissue representation of the wall. Some
studies assume high reactivity of the inhaled vapor and apply a zero concentration
boundary condition at the wall surface (Shi et al. 2006; Taylor et al. 2007; Zhang
and Kleinstreuer 2003). Studies considering solubility and potential reactions in a
mucus layer include Keyhani et al. (1997), Zhang et al. (2006), and Zhao et al.
(2004). Other studies have considered solubility and reactivity in a mucus-tissue
representation of the URT (Cohen Hubal et al. 1996b; Cohen Hubal et al. 1997;
Frederick et al. 1998; Kimbell et al. 2001a). However, as with previous studies,
all computational models assume that steady state diffusion through the mucus or
mucus and tissue layers is reached instantaneously. That is, the concentration
profiles are immediately linear and a constant flux is assumed through the mucus
and tissue walls into the blood.
In previous mass transport models, the assumption of steady state diffusion
through the mucus and tissue of the URT was based on the observation that these
layers are thin compared with the airway lumen.
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However, this assumption

neglects the fact that diffusion is much slower in liquids than in air. To gain a
better understanding of the time scale for absorption, the mass transfer Fourier
number (Fom) should be considered, which is defined as

Fom =

D
t
H2

(2.1)

In this expression, D is the diffusivity of the chemical species in mucus or tissue,

H is the height of the layer, and t is the absorption time. Values of Fom less than
10 typically indicate that transient effects are significant in the diffusion process.
Considering the mucus layer (Hm ~ 10 μm and Dm ~ 5×10-6 cm2/s) (ICRP 1994)
for a characteristic inhalation time scale of 1 second, the Fourier number is 5. For
a combined mucus and tissue layer (Hmt ~ 60 μm and Dmt ~ 5×10-6 cm2/s) (ICRP
1994), the Fourier number is approximately 0.14. As a result, transient effects in
the diffusion process may significantly influence the uptake of chemical species
through a mucus or mucus-tissue barrier. For example, flux into the mucus may
be faster than predicted with a steady state assumption due to higher initial
concentration differences. In contrast, flux into the blood may be slower than
predicted with steady state conditions based on transient resistance in the higher
layers. However, a more detailed analysis is needed to determine the quantitative
effects of transient diffusion on the absorption and uptake of vapors over a
characteristic time in a multilayer model of the respiratory walls.
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2.2

Objective 2: The Concept of Enhanced Condensational Growth.

Enhanced Condensational Growth (ECG) Concept
Enhanced condensational growth (ECG) applied to respiratory drug delivery
is a recently proposed concept that seeks to combine the advantages of both
submicrometer and micrometer aerosols.

In this approach, a submicrometer

aerosol is delivered to the respiratory airways in conjunction with an airstream
that is saturated or supersaturated with water vapor and above body temperature.
The initially submicrometer particles or droplets, in the approximate size range of
100 – 900 nm, have very low deposition values in the mouth-throat (MT) and
upper tracheobronchial regions (Cheng 2003; Cohen et al. 1990; Xi and Longest
2008a; Xi and Longest 2008b). As a result, aerosol loss in the MT can be largely
eliminated. The inhaled water vapor is used to create supersaturation conditions
within the respiratory airways. Submicrometer droplets in this supersaturated
environment will increase in size at a controlled rate due to condensation. Size
increases to within the range of 2 – 3 μm can be used to ensure full lung retention
of the aerosol. Furthermore, engineering the rate of size increase can be used to
target deposition within specific regions of the lung. Factors influencing the
amount and rate of size increase with the ECG approach include the degree of
supersaturation, temperature, particle or droplet hygroscopicity, initial size, and
aerosol number concentration. However, the effects of these variables on aerosol
size growth have only been investigated on a very limited basis.
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Hygroscopic Aerosol Growth in the Lungs
The relative humidity (RH) of the tracheobronchial airways beyond the first
several bronchi is generally expected to be 99.5% (Ferron 1977). Furthermore,
many inhaled environmental and pharmaceutical aerosols are soluble. As a result,
hygroscopic effects are known to influence the deposition of these inhaled
respiratory aerosols (Ferron 1977; Ferron et al. 1988; Finlay and Stapleton 1995;
Li and Hopke 1993; Martonen et al. 1982; Zhang et al. 2006b). Hygroscopic
particle growth has been investigated experimentally for NaCl particles (Cinkotai
1971), pharmaceutical aerosols (Peng et al. 2000), and combustion droplets (Li
and Hopke 1993). A number of mathematical models have also been formulated
for the hygroscopic growth of respiratory aerosols at RH values below 100%
(Broday and Georgopoulous 2001; Ferron 1977; Ferron et al. 1988; Ferron et al.
1989; Finlay and Stapleton 1995; Robinson and Yu 1998; Varghese and
Gangamma 2009). These studies typically indicate a maximum size increase of
approximately 400% for NaCl particles. The hygroscopic growth of most other
salts and most pharmaceutical aerosols result in size increases less than 100% at
RH values of 99.5% and below (Ferron et al. 1988; Ferron et al. 1989). Recently,
Zhang et al. (2006a) developed a CFD model of hygroscopic growth in the upper
respiratory tract. It was found that saline concentrations of 10% and higher were
required for hygroscopic growth to have a significant impact on deposition.
Finlay and Stapleton (1995) applied a numerical model to show that mass
coupling between aerosol droplets and the continuous phase was significant for
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droplet concentrations above 25,000 part/cm3. However, all of these previous
studies have only considered RH conditions up to 100%.

Supersaturation in the Respiratory Airways
Very little work has been done to evaluate the effects of RH conditions
above 100% (i.e., supersaturated conditions) on the condensational growth of
respiratory aerosols. However, supersaturated conditions can be achieved in the
respiratory tract through the inhalation of warm (T > Tbody) saturated air. Ferron
et al. (1984) has shown that RH above 100% is possible in the upper respiratory
tract under some inhalation conditions. Significant growth of NaCl particles was
observed for very localized supersaturation in the nasal cavity (Ferron et al. 1984).
Longest and Xi (2008) considered the inhalation of warm humidified air during
smoking. Computational fluid dynamics simulations indicated that the inhalation
of warm saturated air approximately 3 oC above body temperature could result in
supersaturation conditions (RH > 100%) through approximately the 6th respiratory
bifurcation. Moreover, submicrometer aerosols exposed to RH conditions in the
range of 101% experienced a large and rapid increase in size.

2.3

Objective 3: Local and Regional Deposition of Pharmaceutical
Aerosols.
Inhalation of aerosol drugs is widely used in the treatment of asthma and

chronic obstructive pulmonary disease (COPD). Predicting the regional and
highly localized deposition of pharmaceutically aerosols from oral drug delivery
devices is a critical component in determining the dose received and the resulting
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local and systemic responses (Isaacs et al. 2005; Martonen et al. 2005a; Martonen
et al. 2005b). Whole-lung and regional models as well as experiments in
respiratory casts have been employed to investigate aerosol dynamics and
deposition in the lung (Balashazy et al. 2003; Comer et al. 2000; Darquenne 2002;
Darquenne and Paiva 1996; Hofmann et al. 2003; Karl et al. 2004; Kimbell and
Subramaniam 2001; Liu et al. 2002; Martonen et al. 2003; Martonen et al. 2001;
Schroeter et al. 2001; Zhang and Kleinstreuer 2002; Zhang et al. 2005; Zhang et
al. 2004). Whole-lung deposition models can predict deposition based on the
branch-averaged correlations (Asgharian et al. 2001; ICRP 1994; Martonen 1993;
NCRP 1997). Additionally, CFD models have been used to determine branchaveraged deposition in whole-lung modeling (Balashazy et al. 2003; Hofmann et
al. 2003; Zhang et al. 2005). These models considered the effects of multiple
physiological, geometric, and particle characteristics on deposition patterns. A
number of these studies have quantitatively validated the resulting aerosol
deposition rates with in vitro data (Liu et al. 2002; Longest and Vinchurkar
2007b; Martonen et al. 2001; Oldham et al. 2000; Zhang and Kleinstreuer 2002).
However, these models neglected the importance of the interface between device
and patient in achieving efficient aerosol drug delivery to the lungs. For this
reason, a validated CFD model is needed which can account for inhaler
characteristics (spray or jet momentum), drug physiochemical properties
(aerodynamic size distribution, dissolution) and physiological parameters
(breathing pattern, geometry) in determining local and regional deposition in the
TB airways. Specifically, pressurized metered dose inhalers (MDIs) and dry
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power inhalers (DPIs) deliver drug while target inflammation control and airway
dilation (Ibsen and Bratton 1999), are considered in this study. These two
representative classes of inhalers are the most common devices for administering
drugs for inhalation. Pharmaceutical aerosols from MDIs are delivered as a spray
droplet by actuation of the canister contains a pressurized propellant drug
formulation, in contrast, DPIs are breath actuated and deliver a power aerosol.
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Chapter 3.

Transient Absorption of Inhaled Vapors into a Multilayer
Mucus-Tissue-Blood System

3.1

Introduction
Individual multilayer models are considered that represent the wall

dimensions of the nasal extrathoracic, upper, and lower tracheobronchial airways.
A constant concentration of vapor species is assumed at the air-mucus interface
and zero concentration is assumed in the blood. The sample vapors considered
are highly or moderately soluble in mucus and tissue. To determine absorption,
mass transport is calculated based on an existing analytical steady state solution, a
new analytical transient solution,

and a numerical transient solution.

Comparisons of results from multiple approaches are used to assess solution
quality. Differences between steady and transient solutions are used to evaluate
the importance of transient effects on the diffusion and uptake process. The
effects of chemical reactions in the mucus and tissue over time are also explored
for a range of first-order reaction rate constants using the numerical model. These
results can be implemented to (i) expand previous estimates of steady state
diffusion to more realistic transient conditions and (ii) lay the foundation for an
analytic boundary condition that accounts for transient diffusion in a CFD model
of respiratory tract absorption and uptake. Furthermore, the solution techniques
developed in this study can be applied to analyze the transport of chemicals in
other multilayer systems such as absorption through mucus in the gastrointestinal
tract and dermal uptake.
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The objective of this study was to evaluate the mass transport of sample
chemical species through a simple multilayer system composed of mucus, tissue,
and blood components on a transient basis and compare with steady state results.

3.2

Methods
In this study, vapor absorption and transport are considered through the

walls of the conducting airways, which are responsible for delivering air to the
alveolar region. Using the notation of Weibel (1963), the conducting airways
originate at the nose or mouth and extend to approximately generation 16. The
walls of the conducting airways are lined with a thin layer of protective mucus
(Yeates et al. 1997). The mucus layer is typically considered to keep the surfaces
of the airways moist, condition incoming air, and trap inhaled particles and
microorganisms. In addition, mucus also serves as a barrier that controls the
absorption of gases and drugs into the walls of the conducting airways. Clearance
of soluble and insoluble compounds trapped in the mucus is accomplished by
ciliary motion, which propels the mucus up the respiratory tract to be expelled or
swallowed (Yeates et al. 1997). The cilia move in a watery substance that lies
under the mucus and is referred to as sol, which also helps lubricate the motion of
the more viscous mucus layer.

Cilia are present throughout the conducting

airways and are secured to an epithelial layer, which is mostly composed of
ciliated, basal, and goblet cells. The epithelial layer is attached to a basement
membrane, which is then followed by a sub-epithelium layer that is highly
vascularized (ICRP 1994).
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To approximate transport within the walls of the conducting airways in this
study, a model system was considered that consists of mucus, tissue, and blood
layers (Fig. 3.1). The liquid mucus and sol regions, which contain the cilia, were
considered to form a single mucus layer. As described below, convection due to
ciliary motion and clearance were neglected in this study. The epithelial region
was approximated as a generalized tissue layer. Finally, the highly vascularized
sub-epithelium region was assumed to form a blood layer.

The resulting

multilayer model is identical to the mucus-tissue-blood airway approximation
considered by Cohen Hubal et al. (1996b; 1997) and adds tissue and blood layers
to the previous approximations considered by Keyhani et al. (1997), Zhang et al.
(2006), and Zhao et al. (2004).
In this study, convection due to mucus motion was neglected and transport
through the multilayer system was assumed to result from pure diffusion. This
assumption was based on the relative rates of convective transport due to mucus
motion compared with diffusive transport through the thin mucus layer. For
example, the average rate of mucus motion in the trachea, which has the fastest
clearance in the tracheobronchial region, is 9.2 × 10-2 mm/s (Foster et al. 1980).
For approximate tracheal conditions (Hm ~ 1×10-3 cm and Dm ~ 5×10-6 cm2/s), the
timescale for diffusive transport through the mucus (Hm2/Dm) is 0.2 s. Based on
mucus velocity, the mucus moves approximately 0.02 mm over the timescale
required for diffusive transport across the boundary. Considering the length of
the trachea is approximately 9 cm (ICRP 1994), it is concluded that convective
mucus motion can be neglected compared with diffusive transport across the
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barrier and into the tissue. Similar results are found for lower lung generations,
arising from the fact that mucus velocity decreases with depth into the lungs
(Foster et al. 1980).
The purpose of this study is to evaluate the time dependent transport of
vapors across a multilayer airway wall system. To facilitate this evaluation,
constant concentrations of vapor species were assumed at the air-mucus and
tissue-blood interfaces (Fig. 3.1). During inhalation in vivo, concentrations of
vapors in the air, mucus, tissue, and blood are all interconnected. For example,
decreasing the solubility of a species in the tissue layer will increase
concentrations in the air and mucus phases. However, it is not necessary to
consider variable air phase concentrations in order to determine the transient
behavior of transport across the airway wall. As a result, to assess transient
effects on diffusional wall uptake in this study, the air phase concentration is
assumed constant and known a priori.

At the tissue-blood interface, zero

concentration of the vapor species is assumed. This approximation is justified for
vapors absorbed in small quantities compared with blood volumes, compounds
with high solubility in blood, or materials that are metabolized in downstream
tissues and organs, such as the liver.
To approximate wall dimension for the conducting airways, multiple regions
were considered. The conducting airways were divided based on the ICRP (1994)
dosimetry model convention into extrathoracic (ET2), bronchial (BB), and
bronchiolar (bb) regions. The ET2 region includes the nasal passages distal to the
nasal valve, pharynx, and larynx.

The BB region consists of the trachea
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(generation 0), main bronchi, and distal bronchi ending with approximately
generation 8. Finally, the conducting airways conclude with the bb region, which
extends from generation 9 to approximately generation 16. Dimensions of each
region are reported in Table 3.1, based on ICRP (1994) estimates. Considering
the relative thicknesses of each layer, diffusive transport in the ET2 and BB
regions is expected to be similar. In contrast, the thin layers of the bb region will
likely result in much faster absorption compared with the other models.

Vapor Species and Properties
Representative environmental pollutants considered in this study are
acetaldehyde and benzene, which are highly soluble and moderately soluble in
mucus, respectively. Substances with relatively low solubilities were neglected
because they are already considered to be dependent on transient effects during
the absorption process. Benzene is a known human carcinogen that may also
cause nervous system disorders, immune system suppression, and anemia
(ATSDR 2007b). Benzene is considered a hazardous air pollutant by the United
States Environmental Protection Agency (US EPA) (1999) and is also found in
mainstream and sidestream cigarette smoke (Sakuma et al. 1984). Acetaldehyde
is also classified as a hazardous air pollutant (EPA 1999) that is a potential
carcinogen in humans and may cause respiratory tract irritation and lesion
formation at sufficient concentrations (ATSDR 2007a). Recently, acetaldehyde in
cigarette smoke was linked to the formation of MAO-inhibitors, which may play a
role in reinforcing tobacco smoke dependence and addiction (Talhout et al. 2007).
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Transport through the airway wall is controlled by absorption into the mucus,
diffusion across the mucus barrier, partitioning into the tissue, diffusion within the
tissue, and partitioning into the blood. Therefore, two diffusional coefficients and
three partition coefficients are needed to describe uptake in the multilayer system.
Considering diffusion, the transport of a vapor species in mucus was assumed to
be equivalent to diffusion in water at the same temperature (Cohen Hubal et al.
1996a). The diffusivity of a species in tissue was assumed to be approximately
one-third of the value in water (George et al. 1996; Hlastala and Robertson 1998).
The resulting diffusivities in mucus (Dm) and in tissue (Dt) are reported in Table
3.2 for a body temperature of 37 oC.
The mucus-air partition coefficient is defined in nondimensional form as

λma =

Cm
Ca

(3.1)

where the concentration of a species on the mucus side of the mucus-air interface,

Cm (g/cm3), is in equilibrium with the concentration on the air side Ca (g/cm3).
Considering that mucus is primarily composed of water (Yeates et al. 1997), the
mucus-air partition coefficients were assumed to be equal to well known water-air
coefficients. Species with λma >> 1 are considered to be highly soluble in mucus,
and coefficients in the range of 1 are assumed to be moderately soluble. Specific
values of mucus-air partition coefficients are reported in Table 3.2 for
acetaldehyde and benzene.
For most vapor species, the blood-tissue partition coefficient, λbt, is assumed
to be equal to one (Anderson et al. 2003). The tissue-mucus partition coefficient,
λtm, can be approximated as (Anderson et al. 2003)
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λtm =

1 λba

(3.2)

λbt λma

where λba is the frequently reported blood-air partition coefficient. Values of both
λba and λtm are reported in Table 3.2 for the compounds of interest.
Governing Equations and Boundary Conditions
The transient diffusion equations governing absorption into the mucus and
tissue can be expressed as
∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
,
∂t
∂y 2

y ∈ [0, H m ]

(3.3a)

∂Ct ( y, t )
∂ 2Ct ( y, t )
= Dt
,
∂t
∂y 2

y ∈[H m , H m + Ht ]

(3.3b)

where y is the spatial coordinate defining the depth into the mucus and tissue.
Heights of the mucus and tissue layers are denoted Hm and Ht, respectively.
Concentrations Cm(y,t) and Ct(y,t) are the bulk densities of chemical species in
mucus and tissue with units of g/cm3. These concentrations are spatially and time
dependent in each material. In the equations above, the left-hand-side accounts
for temporal variations in concentration at a fixed location and the right-hand-side
accounts for net diffusive transport through a control volume. Initially, zero
concentration is assumed in the mucus and tissue. The boundary conditions of the
multilayer system are

Cm ( y, t ) | y =0 = λma Cair ,

(3.4a)

Ct ( y, t ) | y = H m = λtmCm ( y, t ) | y = H m ,

(3.4b)
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− Dm

∂Cm ( y, t )
∂C ( y, t )
| y = H m = − Dt t
| y= Hm ,
∂y
∂y

Ct ( y, t ) | y = H m + Ht = 0 ,

(3.4c)
(3.4d)

where Cair is the concentration on the air side of the mucus-air interface (assumed
to be constant). Equations (3.4a and 3.4b) imply that equilibrium occurs on each
side of the thin mucus-air and mucus-tissue interfaces. Equation (3.4c) implies
that the vapor species mass flux (mass flow rate of a compound per unit area with
units of g/s-cm2) leaving the mucus is equal to the flux entering the tissue. As
indicated above, zero concentration of the vapor species was assumed in the blood.
A summary of the multilayer system considered with the appropriate governing
equations and boundary conditions is shown in Fig. 3.2.
Constant air-phase boundary conditions of acetaldehyde and benzene are
taken to be 100 ppm (1.83×10-7 g/cm3) and 1 ppm (3.19×10-9 g/cm3), respectively,
which are below OSHA short term exposure limits. Breathing frequencies for
sedentary, light, and heavy activity conditions are 14, 21, and 33 breaths per
minute, respectively (ICRP 1994). Assuming that inhalation occurs for one-half
of the breathing cycle, the associated inhalation times are 2.2, 1.4, and 0.9 s. As a
result, inhalation can be characterized as occurring for a period of approximately
1 to 2 s. Based on these estimates, transient effects that are significantly less than
1 s can be considered negligible. However, transient effects on the order of 1 s
may significantly affect absorption over the inhalation period. In this study,
transient absorption is considered for periods of 2 s and beyond to evaluate a
range of potential breathing conditions and the time required to reach steady state.
Furthermore, some simulations are conducted in which a 2 s inhalation period is
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followed by a 2 s exhalation period with zero air phase concentration to evaluate
the potential for species buildup in the mucus over multiple breath cycles.
Solution Techniques
In this study, the governing equations were solved using three different
solution approaches with the goals of (i) evaluating the influence of transient
effects on absorption and (ii) developing the form of an analytic solution that can
be used as a boundary condition in a CFD model. First, a common steady state
analytical solution was performed for comparison with transient solutions over
time. An analytical transient solution was then developed by splitting the steady
and time-dependent components of the governing equations and performing a
Fourier series solution. To verify the transient analytical results, a numerical
solution of the equations was then conducted with the Transient Absorption of
Chemical Species (TAOCS) 1.0 program. Each of these solution techniques is
described in more detail below.
Analytical Steady State Solution
For steady state conditions, the time derivative is not present in Equations
(3.3a and b), and the resulting coupled ordinary differential equations have the
solution
C% m ( y ) = λma Cair −

C% t ( y ) =

λma Cair − C% m ( y ) | y = H

λtmC% m ( y ) | y = H
Ht

Hm
m

(H m + Ht ) −
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m

y ∈ [0, H m ]

y,

λtmC% m ( y ) | y = H
Ht

m

(3.5a)

y , y ∈[H m , H m + Ht ]

(3.5b)
In the expressions above, C% m and C% t represent concentrations in the mucus and
tissue at steady state. The concentration on the mucus side at the mucus-tissue
interface is obtained by substituting Equations (3.5a and 3.5b) into the flux
condition provided by Equation (3.4c), resulting in

C% m ( y ) | y = H m =

H t Dm λma Cair
H m λtm Dt + H t Dm

(3.5c)

Analytical Transient Solution
An analytical solution to the coupled transient set of partial differential
equations is presented in Appendix A. Briefly, the transient ( Cˆ m ) and steady state
( C% m ) components of the solution can be separated. A substitution approach can
then be used to evaluate the transient components of the equations. The resulting
combined Fourier series and linear solution is expressed
Cm ( y, t ) = Cˆ m ( y, t ) + C% m ( y )
∞

= ∑ Wn sin( μn
n =1

μ y − μn
Dm H t
) sin( n )e
Dt H m
Hm

2

Dm
H m2

t

+ λma Cair −

λma Cair − C% m ( y ) | y = H
Hm

m

y,

(3.6a)
and
Ct ( y, t ) = Cˆ t ( y, t ) + C% t ( y )
∞

= λtm ∑ Wn sin( μn ) sin( μn
n =1

Dm H m + H t − y − μn
)e
Dt
Hm

2

Dm
H m2

t

+

λtmC% m ( y ) | y = H
Ht

m

( H m + H t − y)
(3.6b)

In these equations, the eigenvalues μn were determined by solving a
transcendental equation using Brent’s method (Brent 1973), as described in
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Appendix A. The Fourier series coefficients were determined by utilizing the
orthogonal relation and zero concentration initial conditions. Compared with the
steady solution (Eqs. 3.5a and 3.5b), the transient solution is observed to include a
series expression, that decreases exponentially as a function of the transient mass
Fourier number presented as Eq. (2.1).
Numerical Transient Solution
Equations (3.3a and 3.3b) and (3.4a-d) were also solved as a coupled set
using the TAOCS 1.0 program. Zero initial concentration was assumed in the
mucus and tissue layers as with the analytical solution. A finite volume method
was used for the spatial discretization of the well-posed set of equations. Time
integration was performed with a stiff implicit multi-step solver. The relative
tolerance for numerically evaluating the equations was set to 1×10-12. Decreasing
the relative tolerance by an order of magnitude had a minimal impact (less than
1% difference) on concentration and uptake values throughout the system.

3.3

Results

Concentration Values
Concentration values for acetaldehyde and benzene within the model
systems considered are shown in Fig. 3.3 based on the analytical transient and
steady state solutions. In each case, the transient results are shown to approach
the steady state solution over time. In the ET2 region (Fig. 3.3a), significant
differences between the transient and steady state solutions are observed at both 1
and 2 s. Again, a typical inhalation period is expected to last for approximately 2
26

s or less. These differences in concentration values over time will result in a
variable flux and rate of absorption into the multilayer system.

Temporal

differences from steady state conditions appear more significant for benzene,
which is less soluble in mucus but more soluble in tissue compared with
acetaldehyde. for both compounds, the transient solution is shown to agree with
the steady state conditions after 10 s.
Considering the BB region (Fig. 3.3b), concentrations over time are nearly
identical to those found in the ET2 region. This similarity is expected because
there is little difference in layer heights between the ET2 and BB models (Table
3.1). As a result, transient effects are also shown to be highly significant in the
BB region over a timescale of approximately 2 seconds.
In the bb region (Fig. 3.3c), concentrations evolve approximately one order
of magnitude faster in time compared with the upper airway models. Significant
differences in mucus and tissue concentrations are observed to remain at 0.2 s.
However, the analytical steady state and transient solutions are nearly identical at
1 s.
A comparison of analytical and numerical transient solutions of
concentration over time is provided in Fig. 3.4 for acetaldehyde and benzene.
Concentrations are only reported in the BB region to illustrate the close match
between the analytical and numerical results. In each case, a point by point
comparison of concentration values indicates that the analytical and transient
solutions were on average within 0.1%. Similar results were found for the ET2
and bb regions.

Agreement between the approaches considered provides
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confidence that the analytical solution includes a sufficient number of terms in the
series summation (cf. Eqs. 3.6a and 3.6b) and is correct. The close match also
indicates that numerical errors are small and controlled in the simulations.
Concentration values of acetaldehyde and benzene at the mucus-tissue
interface are displayed in Fig. 3.5 over time. These results indicate the timeframe
for establishing steady state transport through the mucus. The relative values of
concentrations on the mucus and tissue sides of the interface also illustrate the
effects of the mucus-tissue partition coefficients. For example, benzene is more
soluble in tissue than in mucus (λtm > 1). Therefore, concentrations of benzene
are higher in the tissue compared with the mucus. In each case, the concentration
curves become flat over time as steady state conditions are approached.
Considering the BB region (Fig. 3.5a), temporal effects for acetaldehyde and
benzene appear relatively small after approximately 2 and 4 s, respectively.
Results are similar for the ET2 region (not shown). In the bb region, where the
individual layers are significantly thinner, temporal effects for acetaldehyde and
benzene are diminished after approximately 0.2 and 0.4 s, respectively (Fig. 3.5b).
Flux and Uptake
Flux values (g/s-cm2) into the tissue and blood phases are reported in Fig.
3.6 for acetaldehyde and benzene in the BB and bb regions. Under steady state
conditions, the fluxes into the tissue and blood are equal and are constant over
time. However, results in Fig. 3.6 indicate that the transient flux values are highly
variable over time. Flux into the tissue spikes just after t = 0 due to zero initial
concentrations and the thin mucus layer.
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In contrast, flux into the blood

experiences a gradual increase as concentrations cross the thick tissue region and
reach the lower boundary. In the BB region, fluxes of acetaldehyde and benzene
reach constant steady state conditions in approximately 6 and 8 s, respectively
(Fig. 3.6a). In contrast, fluxes of acetaldehyde and benzene in the bb region reach
steady state conditions approximately one order of magnitude faster (Fig. 3.6b).
However, transient effects appear potentially significant compared to an
inhalation period of 1 s for all cases considered.
Uptake of chemical species in each layer is calculated as the time integral of
the difference between the inlet and outlet fluxes, i.e.,
Uptakei = ∫ ( Fluxi ,in − Fluxi ,out ) dt
t

0

(3.7)

In the expression above, uptake is calculated for layer i in units of g/cm2 based on
the flux values presented in Fig. 3.6. No outlet flux is assumed for the blood, so
the blood uptake is simply the time integral of the inlet flux. Under steady state
conditions, fluxes into and out of the mucus and tissue are equal at all times.
Therefore, steady state uptake in these layers is zero. The resulting uptake values
in the BB and bb regions for acetaldehyde and benzene are presented in Fig. 3.7.
For steady state conditions, the constant flux values in the blood result in a liner
estimate of uptake. In contrast, transient flux values produce non-linear uptake
profiles, as shown in Fig. 3.7. Uptake differences between transient and steady
state conditions are highly significant in the BB region (Fig. 3.7a). Again, steady
state predictions of tissue uptake are zero compared with the nonzero transient
tissue uptake values. At 1 s, the transient blood uptake of acetaldehyde and
benzene is lower than steady state conditions by a factor of approximately 30 in
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the BB model. In contrast, differences between transient and steady state blood
uptake values are significantly less in the bb region (Fig. 3.7b). Specifically,
transient and steady state predictions of blood uptake differ by factors ranging
from 1.2 to 1.3 at 1 s.
Comparisons of steady state and transient uptake in the BB and bb regions
over time are presented in Fig. 3.8 as percent differences. The percent difference
values are calculated as the absolute difference between steady and transient
results divided by the transient value. As shown in Fig. 3.8, percent differences in
tissue uptake are 100% for all times considered because the steady state tissue
uptake value is zero. In the BB region, percent differences for blood uptake of
acetaldehyde and benzene range from approximately 1×105 % to 100% through 4
s (Fig. 3.8a). At 1 s, the percent differences in BB blood uptake for acetaldehyde
and benzene are 2,900% and 2,500%, respectively. In the bb region, differences
in steady vs. transient blood uptake range from approximately 100% to below
10% (Fig. 3.8b). After 1 s, the bb percent differences for acetaldehyde and
benzene are 23% and 27%, respectively. These percent differences between
steady and transient uptake values are also presented in Tables 3.3 and 3.4.
Multiple Breath Cycles

The previous results considered zero initial vapor concentrations in the
mucus and tissue and a single inhalation period. However, vapor concentrations
may build up over time in the mucus and tissue regions during multiple inhalation
and exhalation cycles. Transient effects may be dimensioned if the concentrations
of vapor in the mucus and tissue are near steady state conditions at the start of an
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inhalation cycle. To test for the buildup of vapor species, a case was considered
in which the system was exposed to a constant concentration for 2 s (inhalation
period). The concentration was then removed for 2 s (exhalation period). This
model assumes that the vapor species is completely absorbed into the blood and
removed in the deeper alveolar region, which is reasonable for highly and
moderately soluble components. As a result, zero concentrations are applied
during the exhalation phase.
Concentrations at the mucus-tissue interface over 2 breathing cycles in the
BB region are illustrated in Fig. 3.9. Minimum differences are observed in the
quantitative concentration values between cycles 1 and 2 at the end of inhalation
and exhalation (< 10% difference).

Subsequent breathing cycles resulted in

negligible differences of concentration values (< 1%).

Based on these

observations, it is concluded that the effects of transient absorption are not
diminished by multiple breaths, provided that full downstream blood absorption
can be assumed.
Effects of Chemical Reactions

Chemical reactions of some absorbed species are known to occur in the
mucus and tissue layers of the upper respiratory tract (Cohen Hubal et al. 1996a).
For reactive species, these conversions may significantly alter the transient uptake
characteristics. However, reactivity levels that may influence transient absorption
have not been previously considered. To better evaluate the effects of chemical
reactions on mucus and tissue uptake, acetaldehyde and benzene were considered
over a range of first order reaction rate constants extending from 0.01 – 1×104
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min-1 (1.67×10-4 – 167 s-1). First order reaction rate constants are presented in
Table 3.5 for a range of compounds considered to be non-reactive through highly
reactive in mucus and tissue. As shown in the table, benzene was reported as
non-reactive and a representative first-order reaction rate constant of 0.01 min-1
was assumed. Acetaldehyde may be reactive with a first order reaction rate
constant in tissue of approximately 0.1 min-1, which is approximately equal to that
of S02. In comparison, formaldehyde and ozone are typically considered to be
highly reactive with first order reaction rate coefficients ranging from 1 – 300,000
min-1.
Evaluation of chemical reactions requires that the governing diffusional
equation in mucus, Equation (4a), be written as
∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
− K m Cm ( y , t ) ,
∂t
∂y 2

y ∈ [0, H m ]

(3.8)

where Km is the first-order reaction rate coefficient in mucus. The governing
equation for diffusion in tissue contains a similar reaction term for Kt. The
boundary conditions expressed as Equations (3.4a-d) remain unchanged for the
reactive case. Solutions to the coupled reaction equations were obtained using the
TAOCS 1.0 program in a manner identical to the non-reactive equations. The
resulting transient uptake values in tissue and blood are shown in Figures. 3.10
and 3.11, respectively, for acetaldehyde and benzene across a range of K values.
In the numerical simulations, K values were assumed equal in mucus and tissue to
maximize the effects of reactivity.
Considering transport in the tissue (Fig. 3.10), reactivity appears to only
begin influencing uptake for K values greater than 100 min-1 in both the BB and
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bb regions. This reaction rate coefficient is three orders of magnitude greater than
the reported value of 0.1 min-1 for acetaldehyde and four orders of magnitude
greater than the value assumed for benzene. Therefore, it can be concluded that
reactions do not influence the transient uptake of acetaldehyde and benzene at the
concentrations considered in this study. Moreover, a K value of 100 min-1 is two
orders of magnitude greater than the reaction rate coefficient reported for
formaldehyde (Table 3.5). In contrast, K values of approximately 10,000 min-1
eliminate nearly all of the acetaldehyde in the BB tissue region and reduce
concentrations in the bb model by an order of magnitude, resulting in greatly
reduced uptake values (Fig. 3.10). While not shown in Fig. 3.10, it is clear that
the K value of ozone (K ≈ 300,000 min-1) will result in nearly 100% removal in
both the BB and bb regions. Results are similar for uptake in the blood (Fig.
3.11), with K values of 100 min-1 and below having a minimal impact on transient
uptake. As a result, it can be concluded that chemical reactions have a negligible
impact on the transient uptake of both benzene and acetaldehyde. Moreover, of
the species shown in Table 3.5 only ozone has a sufficiently large K value to
influence the transient uptake values.

3.4

Discussion

This study considered the transient absorption and uptake of representative
vapor species in a model multilayer system representing the walls of the
conducting airways.

Three models of the wall were evaluated based on

dimensions for the ET2, BB, and bb regions (ICRP 1994). No previous study of
which the authors are aware has considered the effects of time-dependence on the
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transport and absorption of vapors into the walls of the respiratory tract. Results
indicated that concentrations within the mucus and tissue layers were highly time
dependent in the ET2 and BB regions and moderately time dependent in the bb
model over the timescale of an inhalation cycle, which is approximately 1 – 2 s.
Fluxes of vapors into the tissue and blood varied with time for approximately 6 –
8 seconds in the BB region and 0.6 – 0.8 s in the bb model. The associated
transient blood uptake of acetaldehyde and benzene in the upper ET2 and BB
regions varied from steady state values by a factor of approximately 30 after 1 s.
Under similar conditions, transient blood uptake in the bb model varied from
steady state conditions by a factor of approximately 1.3 after 1 s. For all cases
considered, transient uptake in the tissue was greater and transient uptake in the
blood was less than predicted under steady state conditions. As a result, it was
concluded that the absorption and uptake of moderately and highly soluble vapors
in the conducting airways are time-dependent over a period consistent with one
inhalation cycle. This time dependence is highly significant for the ET2 and BB
regions, which extend through respiratory generation 8, and less significant for
the remainder of the conducting airways.
A primary implication of this study is that transient absorption effects
should be considered when evaluating the uptake of moderately and highly
soluble compounds in the upper respiratory tract. Based on this analysis, both
mucus and lung tissue serve as effective “temporal” barriers that prevent the entry
of inhaled vapors into the blood stream. Studies that ignore this temporal effect
over predict blood uptake by a factor of approximately 30 in the ET2 and BB
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regions. As described, differences are significantly less in the bb region, due to
the thinner mucus and tissue layers.

These results can be used to improve

absorption and uptake predictions made in previous studies. Furthermore, future
studies of vapor absorption and uptake should consider transient absorption
effects or at least correct estimates made for steady state flux conditions based on
the results of this study.
Both analytical and numerical transient solutions were considered in this
study. This approach provided the advantage of ensuring correctness of the
analytical solution and accuracy of the numerical simulation. In addition, an
analytical solution of wall conditions is needed to formulate a transient absorption
boundary condition for CFD simulations of gas phase transport and uptake. To
derive the appropriate CFD boundary condition, the existing analytical solution
needs to be extended to account for air phase resistance and a variable air phase
vapor concentration. The resulting air-mucus-tissue-blood analytical expression
can then be used to develop a transient flux boundary condition at the air-mucus
interface.
Chemical reactions are typically considered to influence the mucus and
tissue absorption of some vapor species (Cohen Hubal et al. 1996a; ICRP 1994).
Mucus contains enzymes to break down foreign substances (Yeates et al. 1997).
Tissue reactions are also frequent for inhaled vapors (Cohen Hubal et al. 1997;
Miller et al. 1985). Benzene is generally considered to have a low reactivity once
absorbed. In contrast, acetaldehyde is typically expected to have some reactivity
in the tissue under steady state conditions (Morris and Blanchard 1992).
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Interestingly, results of this study showed that chemical reactions had a negligible
effect on the transient absorption of both acetaldehyde and benzene. A reaction
rate constant of approximately 100 min-1 was required for chemical reactions to
influence transient absorption at 2 s, which is three orders of magnitude greater
than the reported K value of acetaldehyde.

Furthermore, the K value of

formaldehyde did not result in significant reactions through 2 s. Based on steady
state analysis, chemical reactions in the upper airways for SO2, acetaldehyde,
formaldehyde, and ozone are generally thought to be significant (Cohen Hubal et
al. 1997; Franks 2005; ICRP 1994; Morris and Blanchard 1992). In comparison,
the results of this study imply that transient effects may diminish the influence of
chemical reactions. When transient absorption is considered, initial flux values
into the mucus and tissue are higher and concentrations are lower compared with
steady state. Both of these factors serve to reduce the relative contribution of
chemical reactivity. As time proceeds, transient effects decrease and reactivity
contributions increase to a steady state level. Increases in reactivity effects over
time are observed in Fig 10a as the curve for K = 100 min-1 increasingly separates
from the other cases. This separation eventually reaches a steady state, as shown
in Fig. 3.10b for the bb region. As a result, it appears critical to consider transient
absorption effects when evaluating the influence of reaction on vapor uptake.
Moreover, including transient absorption may practically eliminate the effect of
chemical reactions for many compounds over the timescale of one inhalation
cycle. These estimates of reactivity may be a function of air phase concentration
values. However, significant increases in air phase concentration will be required
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to overcome the observed three order of magnitude deficit in the K value required
for reactivity to become important. Future studies are needed to further explore
the effects of reaction coefficients and air phase concentrations on transient
absorption.
Limitations of the current study include the assumptions of a constant air
phase concentration, isothermal conditions, thermodynamic equilibrium at the
interfaces, and a lack of data for some material properties. A constant air phase
concentration was assumed to simplify the evaluation of transient absorption in
the mucus, tissue, and blood layers. In the body, air phase concentrations vary
with both space and time. However, spatial and temporal variations of air phase
concentrations are expected to enhance temporal variations in the wall layers.
Future analyses are required to extend the analytical solution of this study to
variable air phase concentrations. Nevertheless, modifying the constant air phase
concentration does not alter the reported uptake differences between the transient
and steady state solutions shown in Fig. 3.8. Similarly, the assumption of zero
concentration during exhalation is only a first order approximation for species that
are fully absorbed in the deeper lung.

Considering isothermal conditions,

inhalation and exhalation may result in significant changes in the mucus and
tissue temperatures, as a function of environmental conditions. These temperature
variations will influence the species vapor pressures on the mucus surface, the
partition coefficients, and the diffusion coefficients. Thermodynamic equilibrium
was assumed at each interface to allow for the implementation of standard
partition coefficients. This assumption requires that the interfaces are infinitely
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thin and that the mass transfer coefficients are not too high, which is typically the
case in biological systems (Bird et al. 1960). Transient effects are then controlled
by diffusion in the much thicker mucus, tissue, and blood layers. Finally, the
transport properties in mucus, tissue, and blood are not fully known. For example,
the diffusion coefficients of the chemical species in tissue were set to be one-third
their values in water, as reported by George et al (George et al. 1996). Additional
simulations (not shown) indicated that setting the diffusion coefficients in tissue
equal to the corresponding water values decreased the time to steady state
conditions by a factor of approximately two.
In conclusion, this study has demonstrated that transient absorption can
significantly influence the transport and uptake of vapors in the walls of the
conducting airways.

The importance of transient effects was observed for

multiple regional models, moderately and highly soluble compounds, and over
multiple breathing cycles. The quantitative results presented in this study can be
used to improve previous estimates of vapor absorption and uptake in the mucus,
tissue, and blood layers. Furthermore, the analytical solution developed in this
study provides the basis for a boundary condition in future CFD simulations of
coupled air-phase transport and wall absorption. Future studies are needed to
evaluation the effects of air-phase resistance, variable air-phase concentrations,
chemical reactions at multiple concentrations, and non-zero blood concentration
levels.
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Table 3.1.

Thickness of mucus and tissue in each region.

Region

Mucus (μm)

Tissue (μm)

Nasal-extrathoracic region (ET2)

15

50

Bronchial region (BB) G0 – G8

11

55

Bronchiolar region (bb) G9 – G16

6

15
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Table 3.2.

Values of transport parameters.

Model parameter

Acetaldehyde

Benzene

8×10-2 a

8.8×10-2 a

Dm (cm2/s)

8×10-6 a

9.8×10-6 a

λma

3.2×102 b

4.4 b

Dt (cm2/s)

2.64×10-6 c

3.23×10-6 c

λtm

5.9×10-1 d

4.1 d

Air
Da (cm2/s)

Mucus

Tissue

Blood
Db (cm2/s)

2.31×10-6

λbt

1d

λba

1.9×102

e

2.84×10-6
1d

f

1.8×101

a

US Department of Environmental Quality (1994)

b

NIST Chemistry WebBook (2008)

c

Calculated as one-third value of mucus
(George et al. 1996; Hlastala and Robertson 1998)

d

Anderson et al. (2003)

e

Estimated using the Stokes–Einstein–Sutherland equation

f

Karch and Peat (2007)

g

McClellan and Henderson (1995)
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g

e

Table 3.3.

Blood uptake difference (%) between steady state and transient
conditions for acetaldehyde.

Time

ET2

BB

bb

t=0.5 s

6.1×104

1.1×105

5.8×101

t=0.75 s

6.6×103

1.0×104

3.3×101

t=1 s

2.1×103

2.9×103

2.3×101

t=2 s

3.1×102

3.9×102

1.0×101

t=3 s

1.4×102

1.7×102

6.0×100

t=4 s

8.4×101

1.0×102

4.9×100

Table 3.4.

Blood uptake difference (%) between steady state and transient
conditions for benzene.

Time

ET2

BB

bb

t=0.5 s

3.3×104

5.8×104

7.0×101

t=0.75 s

5.1×103

7.5×103

3.9×101

t=1 s

1.9×103

2.5×103

2.7×101

t=2 s

3.4×102

4.0×102

1.2×101

t=3 s

1.6×102

1.8×102

7.6×100

t=4 s

9.8×101

1.1×102

5.6×100
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Table 3.5.

Reactivity constants of common chemicals in mucus and tissue.

Compound

K in mucus (min-1)

K in tissue (min-1)

Reported values

Non-reactivec

Non-reactivec

This study

0.01a

0.01

Reported values

0.1020c

0.1020c

Reported values

Non-reactive d

0.0921d

This study

0.1b

0.1

Reported values

Non-reactive e

1.08 e

Reported values

71,880 f

300,000 f

Benzene

SO2

Acetaldehyde

Formaldehyde

Ozone
a

Assumed to be a non-reactive baseline value.

b

Reactivity was set equal in the mucus and tissue to estimate a maximum possible
effect.

c

Hlastala and Robertson (1998)

d

Goswami and Banerji (1970)

e

Franks (2005)

f

Miller et al. (1985)
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Air

Gas/ Vapor

Diffusion and
Convection

Mucus

Gas/ Vapor

Diffusion

Tissue

Gas/ Vapor

Diffusion

Blood

Gas/ Vapor

Figure 3.1.

Diffusion and
Convection

Multilayer system representing the absorption and transport of
respiratory vapors into the walls of the conducting airways.
Adapted from ICRP.
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Air
Cm ( y, t ) | y =0 = λma Cair

Mucus

∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
∂t
∂y 2
∂C ( y, t )
∂C ( y, t )
− Dm m
| y = H m = − Dt t
| y=H m
∂y
∂y

Hm

y

Ct ( y, t ) | y = H m = λtmCm ( y, t ) | y = H m

Tissue

∂Ct ( y, t )
∂ 2Ct ( y, t )
= Dt
∂t
∂y 2

Ht

Ct ( y, t ) | y = H m + Ht = 0

Blood
Figure 3.2.

Approximate wall model consisting of mucus, tissue, and blood
regions with governing equations and boundary conditions.
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Chapter 4.

Development of a CFD Boundary Condition to Model

Transient Vapor Absorption in the Respiratory Airways
4.1

Introduction

We employ both numerical methods and analytical methods to investigate
transport and absorption of acetaldehyde and benzene over time in an air-mucustissue-blood (AMTB) system. Air phase resistance is considered, and the model
allows air phase concentration to change with time. Both analytical and numerical
solutions are considered and compared in a simple multilayer AMTB system. The
transient analytical solutions of the partial differential equations describing
diffusion result a complicated task involving calculation of Fourier series,
eigenvalues, and orthogonal eigenfunctions. We also develop a boundary
condition at the air-mucus interface that includes the effects of solubility,
diffusivity, medium thickness, and duration of exposure. This boundary condition
was then used to calculate transient absorption in a realistic nasal-laryngeal model.
To our knowledge, no other study has reported the solution of this multiphase
system on a transient basis.

4.2

Methods

Models of the Conducting Airway Walls and Nasal-Laryngeal Airway

To approximate transport within the walls of the conducing airway in this
study, a multilayer system was considered. As Fig. 4.1a shows, the model is
divided into four compartments: i) the air layer, ii) the mucus layer, iii) the tissue
layer, and iv) the blood layer. Ha, Hm, and Ht are the thicknesses of the air, mucus,
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and tissue in specific regions of the respiratory tract, respectively. In this study,
the extrathoracic nasal region was considered, which includes the posterior nasal
passages, larynx, pharynx, and mouth. Evaluation of this region is critical
considering that it serves as a primary conduit for all vapors entering the lungs. In
this region, Hm and Ht are commonly reported to be approximately 1.5×10-3 cm
and 5×10-3 cm, respectively (ICRP 1994). As shown in Fig. 4.1b, the nasallaryngeal airway model consists of four parts: the nasal cavity, including the
vestibule, valve region (VR), turbinate region (TR), and olfactory region (OR);
nasopharynx, pharynx, and larynx. Xi and Longest (2009) constructed the airway
model, and generated a computational mesh composed of approximately two
million unstructured tetrahedral elements and a very fine near-wall pentahedral
grid, which was employed in this study.
Governing Equations in the Mucus and Tissue with Boundary Conditions

We assume that there are no chemical reactions or convection (caused by an
imposed mucus flow) occurring in the mucus and tissue layers. The rate at which
mass concentration is absorbed into the mucus and tissue is determined by solving
a system of transient diffusion equations:
∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
,
∂t
∂y 2

y ∈ [0, H m ]

(4.1a)

∂Ct ( y, t )
∂ 2Ct ( y, t )
= Dt
,
∂t
∂y 2

y ∈[H m , H m + Ht ]

(4.1b)

where y є [0, Hm+Ht] is the spatial coordinate defining the depth into the mucus
and tissue (Fig. 4.2). The variable t is the time dimension, where the period t > 0.
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Cm(y,t) and Ct(y,t) are the concentrations (bulk densities) of a chemical species in

the mucus and tissue with units of g/cm3. These concentrations are spatially and
time dependent in each material. Dm and Dt are the species diffusivities in mucus
and tissue, respectively. The diffusivity of each species in each material is
constant. Initially, zero concentration is assumed in the mucus and tissue. The
boundary conditions are:
Cm ( y, t ) | y =0 = λma Ca ( y, t ) | y =0 ,

(4.2a)

Ct ( y, t ) | y = H m = λtmCm ( y, t ) | y = H m ,

(4.2b)

− Dm

∂Cm ( y, t )
∂C ( y, t )
| y = H m = − Dt t
|y= Hm ,
∂y
∂y

Ct ( y, t ) | y = H m + Ht = 0 ,

(4.2c)
(4.2d)

where Ca ( y, t ) | y =0 is not known and depends on the air layer concentration at the
air-mucus interface. Equations (4.2a and 4.2b) imply that equilibrium occurs on
each side of the air-mucus and mucus-tissue interfaces, where λma and λtm are the
mucus-air and tissue-mucus partition coefficients, respectively. Equation (4.2c)
implies that the vapor species mass flux (mass flow rate of a compound per unit
area with units of g/s-cm2) leaving the mucus is equal to the flux entering the
tissue. The system is shown in Fig. 4.2.
Analytical Transient Solution

An analytical solution to the coupled transient set of partial differential
equations is presented in Appendix A. Briefly, the transient ( Cˆ m ) and steady state
( C% m ) components of the solution can be separated. A substitution approach can
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then be used to evaluate the transient components of the equations. The resulting
combined Fourier series and linear solution is expressed
Cm ( y, t ) = Cˆ m ( y, t ) + f (t )C% m ( y )
∞

= ∑ Wn sin( μn
n =1

− μn
μ y
Dm H t
) sin( n ) ∫ e
Dt H m
H m τ =0
t

2

Dm
H m2

( t −τ )

⎛ 1 − C% m ( y ) | y = H m ⎞
df (τ )
dτ + f (t ) ⎜ 1 −
y ⎟,
⎜
⎟
dτ
H
m
⎝
⎠
(4.3a)

and
Ct ( y, t ) = Cˆ t ( y, t ) + f (t )C% t ( y )
∞

= λtm ∑ Wn sin( μn ) sin( μn
n =1

t

− μn
Dm H m + H t − y
)∫ e
Dt
Hm
τ =0

2

Dm
H m2

( t −τ )

df (τ )
dτ +
dτ

(4.3b)

⎛ λtmC% m ( y ) | y = H m
⎞
f (t ) ⎜
( H m + H t − y) ⎟
⎜
⎟
Ht
⎝
⎠

where f (t ) = Cm ( y, t ) | y =0 , and C% m ( y ) | y = H m =

H t Dm
.
H m λtm Dt + H t Dm

In these equations, the eigenvalues μn were determined by solving a
transcendental equation using Brent’s method (Brent 1973), as described in
Appendix A. The Fourier series coefficients Wn were determined by utilizing the
orthogonal relation and zero concentration initial conditions.
Flux Boundary Conditions at the Air-Mucus Interface

As Fig. 4.3 shows, there are two boundary conditions at the air-mucus
interface; one is Equation (4.2a), and the other boundary condition is:
− Da

∂Ca ( y, t )
∂C ( y, t )
| y =0 = − Dm m
| y =0 ,
∂y
∂y
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(4.4)

where Ca(y,t) is the concentration (bulk density) of a chemical species in air with
units of g/cm3. The concentration is spatially and time dependent in each material.
Da is the constant species diffusivity in air.

The analytical solution in the mucus (Eq. 4.3a) and the two boundary
conditions (Eqs. 4.2a and 4.4) at the air-mucus interface can combined into a
desired transient flux boundary condition at the air-mucus interface.
Differentiating Cm ( y, t ) with respect to y , then substituting

∂Cm ( y, t )
| y =0 into
∂y

Equation (4.4), the transient flux boundary condition at the air-mucus interface
becomes
∂Ca ( y, t )
| y =0 =
∂y
2 Dm
⎛ 1 ∞
⎞
Dm H t t − μn H m2 ( t −τ ) dCa ( y,τ ) | y =0
⎜
⎟
W
sin(
)
e
d
−
μn n
μn
τ
∑
Dt H m τ ∫=0
dτ
Dm λma ⎜ H m n =1
⎟
⎜
⎟,
% ( y) |
Da
1
C
−
m
y
H
=
⎜ C ( y, t ) |
⎟
m
y =0
⎜ a
⎟
H
m
⎝
⎠

(4.5)

Equation (4.5) is the transient flux boundary condition which accounts for the
effects of diffusivity, solubility, medium thickness, and duration of exposure. For
steady state conditions where t → ∞ , this boundary condition (4.5) simplifies to
dC% a′ ( y )
| y =0 + KC% a′ ( y ) | y =0 = 0,
dy

where K =

Dm λma (1 − C% m ( y ) | y = H m )
Da H m

(4.6)

(4.7)

,

In this expression, C% a′ ( y ) is the steady-state concentration in the air layer.

58

The Air-phase Transport

The concentration in the air layer satisfies the diffusion equation given by
∂Ca ( y, t )
∂ 2 Ca ( y , t )
, y ∈ [− H a , 0]
= Da
∂t
∂y 2

(4.8)

Initially, zero concentration is assumed in the mucus and tissue. The boundary
conditions are:
Ca ( y, t ) | y =− H a = Cair ,

(4.9)

The transient flux boundary condition at the air-mucus interface can be found in
Eq. (4.5).
In order to develop a model system to test the importance of transient
effects, the height of the air layer is set equal to a constant and small value, which
was selected to be Hm. This distance is selected to be small in order to focus the
analysis on transport in the mucus, tissue, and blood layers. In part of this study,
numerical predictions are used to determine Ca in a simple AMTB model. The
concentrations of acetaldehyde and benzene (Cair) at the top of the air layer are
taken to be 100 ppm (1.83×10-7 g/cm3) and 1 ppm (3.19×10-9 g/cm3),
respectively, which are below OSHA short term exposure limits. Values of
transport parameters are reported in Table 3.2 for acetaldehyde and benzene.
Solution Techniques in the AMTB Model

In this study, the governing equations for the air-mucus-tissue-blood model
were solved using two different solution approaches. First, a numerical solution of
the system of Equations (4.1a), (4.1b), and (4.8), and boundary conditions (4.2ad), (4.4) and (4.9) was found in Transient Absorption of Chemical Species
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(TAOCS) 1.0 program using a finite volume method for spatial discretization and
an implicit backward Euler method for time stepping. Figure 4.4a shows the
system setup for the numerical solutions in the multilayer system. For the second
solution technique, a hybrid numerical-analytical method was employed. In the air
layer, Equation (4.8) with boundary condition (4.9) and the analytical transient
flux boundary condition (4.5) was solved using a finite difference method for
spatial discretization and an implicit backward Euler method for time stepping.
Analytical solutions in the mucus and tissue, which are dependent on the solution
in the air layer, were then solved using Equations (4.3a and 4.3b). Figure 4.4b
shows the system setup for the hybrid solution in the multilayer system. The cgs
system of units was used for all simulations. Comparison of the two solution
techniques is used to verify the hybrid numerical-analytical solution. This
approach is then applied as a boundary condition in a CFD simulation of vapor
absorption in the nasal-laryngeal geometry, as described below.
Transport Equations in the Nasal-Laryngeal Airway Model

The low-Reynolds-number (LRN) k − ω model of Wilcox (1998)

was

selected for simulating the air flow in the nasal-laryngeal model because it has
been shown to provide an accurate and numerically efficient solution for
transitional and turbulent flows. Furthermore, this model was found to accurately
predict laminar flow as the turbulent viscosity approaches zero. The transport
equations governing the turbulent kinetic energy ( k ) and the specific dissipation
rate ( ω ) were provided by Wilcox (1998) and were previously reported in
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(Longest and Xi 2007b; Xi and Longest 2007a; Xi and Longest 2008b; Zhang and
Kleinstreuer 2004; Zhang and Kleinstreuer 2006).
The turbulent vapor mass transfer equation in turbulent flow can be written on
a mass fraction basis as
∂Ca ∂ (u j Ca )
∂
+
=
∂t
∂x j
∂x j

⎡⎛
ν T ⎞ ∂Ca ⎤
⎢⎜ Da +
⎥,
⎟
σ C ⎠ ∂x j ⎦⎥
⎣⎢⎝

(4.10)

where Ca is the mass fraction of a chemical species in air, Da is the species
diffusivity in air, and νT is the turbulent viscosity. Vectors uj and xj are the fluid
velocity vector and position, respectively, and σC is the turbulence Prandtl number,
taken to be 0.9.
Deposition Factors
For the transport model, the total or regional deposition fraction at steady
state can be expressed as
DFi =

m& w,i
,
m& in

(4.11)

where m& w,i is the total mass absorption into the wall surface and m& in is the inlet
mass flow rate. The transient regional deposition fraction can be expressed as
T

∫ m&

w ,i

DFi =

dt

0
T

,

∫ m&

in

(4.12)

dt

0

where T is the time period of the simulation. In this study, transient absorption is
considered for periods of 2 s.
The total mass absorption rate into the wall surface can be expressed as
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N

m& w,i = ∑ − ρ m A j ( Da +
j =1

ν T ∂Ca
)
|
σ C ∂n w, j ,

(4.13)

where Aj is the local area, and the summation is performed over the total or

i − region of interest. The mixture density is ρm. The vector n is the wall normal
coordinate pointing out of the geometry.
The inlet mass flow rate can be determined as
m& in = ρ mQCin ,

(4.14)

where Q is the inlet inhalation flow rate. Cin is the inlet mass fraction, taken to be
0.05.
A deposition enhancement factor (DEF), similar to that suggested by Xi and
Longest (2007b), was defined in order to quantify local deposition in region Aj
with respect to the total deposition rate as follows.
DEFj =

DFj / Aj
DFi / Ai

(4.15)

,

where Ai is the total area.
Flow Rates and Boundary Conditions
Steady inhalation was assumed for all simulations. An inhalation flow rate
of 20 L/min was considered, which is consistent with resting conditions (ICRP
1994). During inhalation, airflow enters the nasal cavity, travels through the
nostrils, nasal turbinates, pharynx, and exits the larynx. The transient flux
boundary condition (Eq. 4.5) and steady flux boundary condition (Eq. 4.6) were
considered for transient and steady absorption into the wall, respectively.
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Two cases were considered in the nasal-laryngeal airway model, as outlined
in Table 4.1. Case 1 (S:S) and Case 2 (S:T) are intended to quantify the effects of
transient absorption compared with steady state absorption. A steady state flow
field and mass species profile were considered in both cases. Steady absorption
versus transient absorption into the wall are then evaluated over a timescale
consistent with one inhalation cycle.
To solve the governing conservation equations, the CFD package Fluent
6.2.16 (Ansys Inc.) was employed. User-supplied C programs were implemented
for the calculation of the transient boundary condition, vapor absorption, and
deposition enhancement factors.

4.3

Results

Validation of the Transient Analytical Solution in the Air-Mucus-Tissue-Blood
System
A comparison between the transient numerical and hybrid solutions of
concentration over time are shown in Fig. 4.5 for acetaldehyde and benzene. A
point by point comparison of concentration values indicates that the transient
numerical and hybrid solutions were on average within 0.1%. Agreement between
the approaches considered provides confidence that the analytical flux boundary
condition at the air-mucus interface and analytical solutions in the mucus and
tissue are correct. The relative values of concentrations in the air, mucus and
tissue sides of the interface also illustrate the effects of the air-mucus and mucustissue partition coefficients. For example, acetaldehyde is more soluble in mucus
than in air at the air-mucus interface (λma > 1) and less soluble in tissue than in
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mucus at the mucus-tissue interface (λtm < 1). Therefore, concentrations (g/cm3)
of acetaldehyde are higher in the mucus compared with the air and lower in the
tissue compared with the mucus. As a result, transient effects are also shown to be
highly significant in the mucus and tissue layers over a timescale of
approximately 2 seconds.
Concentration Values
Concentration values of acetaldehyde and benzene at the air-mucus and
mucus-tissue interfaces are displayed in Fig. 4.6 over time based on the numerical
solution.

These results indicate the timeframe for establishing steady state

transport through the air and mucus. The concentration curves become flat over
time as steady state conditions are approached. As observed, it is much faster to
reach steady state in the air than in the mucus. Considering the mucus and tissue
layers, temporal effects for acetaldehyde and benzene appear relatively small after
approximately 2 and 4 s, respectively. In the air layer, where the diffusion process
is significantly faster, temporal effects for acetaldehyde and benzene are
diminished after approximately 0.1 and 0.05 s, respectively.
Flux and Uptake
The fluxes of acetaldehyde and benzene into the mucus, tissue, and blood
layers are reported in Fig. 4.7. Results in Fig. 4.7 indicate that the transient flux
values for acetaldehyde and benzene are highly variable over approximately 4 and
6 s, respectively. The fluxes into the mucus, tissue and the blood layers are equal
and constant when steady state is reached quantitatively. The fluxes of
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acetaldehyde and benzene reach constant steady state conditions (within 99%) in
approximately 6 and 8 s, respectively. Since the concentrations at the air-mucus
and mucus-tissue interfaces increase rapidly from zero initially, it is seen that the
fluxes of each species into the mucus and tissue initially spike. Due to the zero
concentration at the blood-tissue interface, the flux of each species into the blood
is initially delayed and then approaches a steady state. Uptake within the mucus,
tissue, and blood layers was estimated by time integrating the difference between
the inlet and outlet flux values. The resulting uptake values for acetaldehyde and
benzene are presented in Fig. 4.8. It is observed that transient absorption is
significantly different from the steady state conditions. For acetaldehyde, uptake
values in the mucus and tissue are higher than in the blood over a transient
exposure. Based on these observations, the uptake in the blood is lower for a
transient exposure compared with steady state conditions. It is observed that the
transient blood uptake for acetaldehyde and benzene varied from steady state
values by a factor of approximately 4 after 2 s.
A comparison of steady state and transient blood uptake over time is
presented in Fig. 4.9 as percent differences. The percent difference values are
calculated as the absolute difference between steady and transient results divided
by the transient value. As shown in Fig. 4.9, percent differences for blood uptake
range from approximately 100% to 1×105 % through 4 seconds. These percent
differences between steady and transient uptake are also presented in Table 4.2.
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Effects of Chemical Reactions
To better evaluate the effects of chemical reactions on mucus, tissue, and
blood uptake, acetaldehyde and benzene were considered over a range of first
order reaction rate constants extending from 0.01 – 1×103 min-1. First order
reaction rate constants are presented in Table 3.5 for a range of compounds
considered to be non-reactive through highly reactive in mucus and tissue.
Evaluation of chemical reactions requires that the governing diffusion
equation in mucus, Equation (4.1a), be written as
∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
− K mCm ( y, t ) , y ∈ [0, H m ]
∂t
∂y 2

(4.16)

where Km is the first-order reaction rate coefficient in mucus. The governing
equation for diffusion in tissue contains a similar reaction term for Kt. The
boundary conditions expressed as Eqs. (4.2a-d) remain unchanged for the reactive
case. The resulting transient uptake values in mucus, tissue, and blood are shown
in Fig. 4.10 for acetaldehyde and benzene across a range of K values. In the
numerical simulations, K values were assumed equal in mucus and tissue to
maximize the effects of reactivity.
It is observed that reactivity appears to only begin influencing uptake for K
values greater than 100 min-1. This reaction rate coefficient is three orders of
magnitude greater than the reported value of 0.1 min-1 for acetaldehyde and four
orders of magnitude greater than the value assumed for benzene. Therefore, it can
be concluded that reactions do not influence the transient uptake of acetaldehyde
and benzene at the concentrations considered in this study.
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Deposition Fractions in the Nasal-Laryngeal Model
Deposition fractions (DF) for acetaldehyde and benzene vapors in mucus,
tissue, and blood in the nasal-laryngeal airway model for Case 1 (S:S) and Case 2
(S:T) are shown in Fig. 4.11 for a 2 seconds inhalation. The DF values of
acetaldehyde and benzene for both cases considered are also tabulated in Table
4.3. It is observed that DF values for transient absorption (Case 2) are
significantly different from steady state absorption (Case 1). Furthermore, DF
values of acetaldehyde in mucus are approximately 8 times greater for transient
absorption compared with steady state absorption. DF values of benzene in mucus
are approximately 3 times greater for transient absorption compared with the
steady absorption condition. For Case 1, the DF values are equal in mucus, tissue,
and blood. For Case 2, the DF values of acetaldehyde in mucus are approximately
6 times higher than in tissue and 40 times higher than in blood. The DF values of
benzene in mucus are approximately 2 times higher than in tissue and 16 times
higher than in blood. The higher absorption of acetaldehyde vapor may be
attributed to its higher solubility in the mucus layer.
Local Deposition
DEF contours of acetaldehyde and benzene vapors are shown in Figures
4.12 and 4.13, respectively, at an inhalation flow rate of 20 L/min. High DEF
values were observed in the TR and VR regions, and low DEF values were
observed in the OR region. Differences of the DEF distribution for Cases 1 and 2
are significant. The DEF values for Case 1 were distributed more uniformly,
whereas DEF values for Case 2 were highly heterogeneous and localized.
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4.4

Discussion

This study has considered the transient absorption of highly and moderately
soluble vapors into a simple multilayer AMTB model of the conducting airway
walls. Based on an analytic solution of absorption, a transient boundary condition
for CFD simulations of vapor transport was developed for the first time and tested
in comparison with the typically applied steady state approach. Considering the
AMTB model, results indicated that absorption was highly time dependent over
the timescale of one inhalation cycle. At 1 s, transient conditions resulted in
approximately 2 – 3 times more uptake in tissue and 20 – 25 times less uptake in
blood than at steady state for both acetaldehyde and benzene. These results are
consistent with the previous study of Tian and Longest (2010b), which neglected
the air phase and only considered a mucus-tissue-blood wall model.
Consideration of an AMTB wall representation in the current study allowed for
the development of a novel transient flux boundary condition. Application of this
boundary condition to CFD simulations of a nasal-laryngeal geometry showed, as
expected, that transient absorption significantly affected total deposition fractions
in the mucus, tissue, and blood. Moreover, transient absorption was also shown
to significantly affect the local deposition pattern of acetaldehyde and benzene
based on the DEF parameter. As a result, local tissue doses predicted using the
transient absorption model will be significantly higher than when a steady
absorption assumption is made. Based on these findings, previous studies that
have assumed steady state absorption of vapors into the respiratory walls may
have significantly under predicted mucus and tissue absorption, over predicted
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blood absorption, and under predicted local vapor absorption in cases where
transient uptake is important.
In this study, transient vs. steady state absorption was compared for both the
AMTB wall model and the nasal-laryngeal geometry. The resulting difference
ratios were calculated as the transient uptake divided by the steady state uptake
value. From a dosimetry perspective, uptake in the tissue and blood are most
important. Interestingly, difference ratios at 2 s for tissue and blood uptake were
nearly identical between the AMTB and nasal-laryngeal models. For both models
at 2 s and both species considered, the difference ratios in tissue were
approximately 1.5 – 2 and the difference ratios in blood were approximately 0.17
– 0.24. As shown in Tables 4.2 and 4.3, these values are significantly diminished
from the differences predicted at 1 s. Similarity in the difference ratio values
between the two models indicates that the AMTB model may be used to predict
potential errors in CFD calculations using a steady state absorption approximation.
Moreover, the application of a steady state absorption model may be considered
in future CFD studies in conjunction with corrections predicted by the much
simpler AMTB wall model.
Limitations of the current study include the assumption of steady state flow
field conditions (air and vapor transport), the consideration of one inhalation
cycle, neglecting reactions, selecting an arbitrary height of the air layer, and zero
vapor concentration in the blood. The assumption of steady state air flow is not
consistent with transient inhalation and exhalation.

However, both transient

inhalation in the air phase and transient absorption in the wall will affect uptake.
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The assumption of a steady state air phase was made in this study to isolate the
effect of transient wall absorption. Considering the AMTB model, the timescale
of one inhalation cycle was considered.
exposure over multiple inhalations.

Vapor exposures often consist of

For highly and moderately soluble

compounds, it is reasonable that full lung absorption occurs. Furthermore, Tian
and Longest (2010b) previously showed that concentrations did not accumulate in
the mucus, tissue, and blood layers over multiple inhalations, provided that the
species was fully absorbed by the lungs.

Chemical reactions are generally

considered significant for most of the reaction rate values considered, which
ranged from 0.01 to 100 min-1. However, by considering transient absorption,
reactivity only occurred for K values of approximately 100 min-1, which is
significantly greater than the first order reaction constant of acetaldehyde and
benzene. As described, a small arbitrary value was used to define the height of
the air layer in the AMTB model. By selecting a small value, diffusion through
the air had a negligible impact on the transient absorption rates into the mucus,
tissue, and blood components. Finally, zero concentration of inhaled vapor was
assumed in the blood, which is most accurate for short exposures or compounds
that are highly metabolized in the circulation.
In conclusion, transient absorption was found to be significant compared
with steady state predictions for highly and moderately soluble compounds in the
upper airways. The influence of transient absorption was observed in both a
multilayer AMTB wall model and a CFD model of the nasal-laryngeal region.
Findings from the CFD model indicated that transient effects influenced both total
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absorption as well as local tissue doses. The complex transient flux boundary
condition developed and tested in this study may be very useful in future more
accurate simulations of vapor uptake in the respiratory airways. Results also
indicated that the much simpler AMTB model could be applied to predict the
effect of transient absorption compared with steady state conditions in the CFD
model of the nasal-laryngeal geometry. Therefore, the AMTB model may be
implemented to simplify future simulations of transient vapor uptake. Future
studies are needed to evaluate the effects of transient air flow, multiple breathing
cycles, blood absorption and concentration levels, and chemical reactions.
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Table 4.1.

Two cases considered.
Air phase and mass

Absorption

Designation

species
Case 1

Steady

Steady flux

S:S

Case 2

Steady

Transient flux

S:T

Table 4.2.

Blood uptake difference (%) between steady state and transient
conditions for acetaldehyde and benzene.

Time

Acetaldehyde

Benzene

t=0.5 s

7.1×104

3.5×104

t=0.75 s

7.1×103

5.2×103

t=1 s

2.2×103

1.9×103

t=2 s

3.1×102

3.4×102

t=3 s

1.4×102

1.6×102

t=4 s

8.5×101

9.9×101
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Table 4.3.

Deposition fraction (%) in mucus, tissue, and blood for Cases 1
and 2 considered during a 2 seconds inhalation.
Acetaldehyde

Benzene

in mucus

in tissue

in blood

in mucus

in tissue

in blood

Case 1

6.22

6.22

6.22

0.58

0.58

0.58

Case 2

53.68

9.71

1.46

1.64

1.07

0.10
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a)

Air

b)
Gas/ Vapor

Diffusion and
Convection

Mucus

Gas/ Vapor

Diffusion

Tissue

Gas/ Vapor

Diffusion

Blood

Gas/ Vapor

Figure 4.1.

Diffusion and
Convection

(a) The AMTB system and (b) the nasal-laryngeal airway model.
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Air
Cm ( y, t ) | y =0 = λmaCa ( y, t ) | y =0

Mucus

∂Cm ( y, t )
∂C ( y, t )
| y = H m = − Dt t
| y=Hm
∂y
∂y

Ct ( y, t ) | y = H m = λtmCm ( y , t ) | y = H m

y = Hm

∂Ct ( y , t )
∂ 2Ct ( y, t )
= Dt
∂t
∂y 2

Ct ( y, t ) | y = H m + Ht = 0

y = H m + Ht

Blood
Figure 4.2.

y

∂Cm ( y, t )
∂ 2 Cm ( y , t )
= Dm
∂t
∂y 2
− Dm

Tissue

y=0

System setup for analytic solutions in the mucus and tissue layers.
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Air

− Da

∂Ca ( y, t )
∂C ( y, t )
| y =0 = − Dm m
| y =0
∂y
∂y

Cm ( y, t ) | y =0 = λmaCa ( y, t ) | y =0

Mucus

y=0
y

Cm ( y , t )

y = Hm
Figure 4.3.

Boundary conditions at the air-mucus interface.
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a)

b)
Ca ( y , t ) | y =− H a

Air

Ca ( y , t ) | y =− H a

y = −Ha

∂Ca ( y , t )
∂ 2Ca ( y , t )
= Da
∂t
∂y 2
∂C ( y , t )
∂C ( y , t )
− Da a
| y =0 = − Dm m
| y =0
∂y
∂y
Cm ( y , t ) | y =0 = λmaCa ( y, t ) | y =0

Air

y=0

∂C a ( y , t )
∂ 2C a ( y , t )
= Da
∂t
∂y 2
∂Ca ( y, t )
| y =0
∂y

y = −Ha

y=0

y

∂Cm ( y, t )
∂ Cm ( y, t )
= Dm
∂t
∂y 2

y

2

Mucus

− Dm

∂Cm ( y, t )
∂C ( y, t )
| y = H m = − Dt t
|y=Hm
∂y
∂y

Ct ( y, t ) | y = H m = λtmCm ( y, t ) | y = H m

Tissue

Figure 4.4.

Cm ( y , t ) from Eq. (12a)

y = Hm

∂Ct ( y , t )
∂ 2Ct ( y, t )
= Dt
∂t
∂y 2

Ct ( y, t ) | y = H m + Ht = 0

Blood

Mucus

y = Hm

Tissue

y = Hm + Ht

Ct ( y , t ) from Eq. (12b)

Blood

System setup for (a) the numerical solutions and (b) the hybrid
solutions in the multilayer system.
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y = Hm + Ht

5E-08

Tissue

Mucus
t=1 s (numerical solution)
t=2 s (numerical solution)
t=10 s (numerical solution)
t=1 s (hybrid solution)
t=2 s (hybrid solution)
t=10 s (hybrid solution)

3

Acetaldehyde concentration (g/cm )

6E-05

5E-05

4E-05

3E-05

2E-05

Tissue
t=1 s (numerical solution)
t=2 s (numerical solution)
t=10 s (numerical solution)
t=1 s (hybrid solution)
t=2 s (hybrid solution)
t=10 s (hybrid solution)

4E-08
3

Mucus

Benzene concentration (g/cm )

7E-05

3E-08

2E-08

1E-08
1E-05

Interface

Interface

0

0
0

0.001

0.002

0.003

0.004

0.005

0.006

0.007

y (cm)

Figure 4.5.

0

0.001

0.002

0.003

0.004

0.005

0.006

y (cm)

Comparison of numerical transient and hybrid solutions for
acetaldehyde and benzene concentrations in the mucus and tissue.
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0.007

Air side (air-mucus interface)
Mucus side (air-mucus interface)
Mucus side (mucus-tissue interface)
Tissue side (mucus-tissue interface)

6E-05

5E-05

4E-05

3E-05

2E-05

1E-05

0
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2

3

4

Time (s)

Figure 4.6.

5E-08

Benzene concentration at the interfaces (g/cm3)

Acetaldehyde concentration at the interfaces (g/cm3)

7E-05

Air side (air-mucus interface)
Mucus side (air-mucus interface)
Mucus side (mucus-tissue interface)
Tissue side (mucus-tissue interface)
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3E-08

2E-08

1E-08

0
0

1

2

3

Time (s)

Acetaldehyde and benzene concentrations at the air-mucus and
mucus-tissue interfaces.
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4

Flux into the mucus
Flux into the tissue
Flux into the blood

3E-07

1E-10

8E-11
2

Flux of benzene (g/s.cm )

2

Flux of acetaldehyde (g/s.cm )

2.5E-07

Flux into the mucus
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Flux into the blood
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2

4

6

8

10

0
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Figure 4.7.

2

4

6

8

Time (s)

Flux of acetaldehyde and benzene into the mucus, tissue and blood
layers.
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2E-10
Uptake in the mucus (transient)
Uptake in the tissue (transient)
Uptake in the blood (transient)
Uptake in the blood (steady state)
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Figure 4.8.

Uptake in the mucus (transient)
Uptake in the tissue (transient)
Uptake in the blood (transient)
Uptake in the blood (steady state)
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Uptake of acetaldehyde and benzene for transient and steady state
conditions.
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Tissue
Blood
Difference in Benzene uptake (%)

Difference in Acetaldehyde uptake (%)
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Figure 4.9.
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Percent differences between steady state vs. transient predictions
of uptake for acetaldehyde and benzene.
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Uptake of acetaldehyde and benzene for transient conditions
including reactivity.
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2.0
Case 1 (S:S)
Case 2 (S:T)
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Deposition fraction of benzene (%)

Deposition fraction of acetaldehyde (%)

60.0

0.0

Case 1 (S:S)
Case 2 (S:T)
1.5

1.0

0.5

0.0
Mucus

Figure 4.11.

Tissue

Blood

Mucus

Tissue

Blood

Deposition fraction of acetaldehyde and benzene vapors in mucus,
tissue, and blood in the nasal-laryngeal airway model for Cases 1
and 2 over a 2 seconds inhalation.
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Figure 4.12.

DEF contours of acetaldehyde for both cases considered.
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Figure 4.13.

DEF contours of benzene for both cases considered.
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Chapter 5.

Transient Absorption of Inhaled Vapors in the Mouth-Throat

Region with an Air-Mucus-Tissue-Blood Wall Boundary Condition
5.1

Introduction

The objective of this study is to predict transient vapor mass absorption of
acetaldehyde and benzene in a model of the extrathoracic oral airways with an airmucus-tissue-blood boundary representation. CFD simulations of air phase
transport were coupled with an analytically based boundary condition that
accounted for transient absorption into the mucus, tissue, and blood layers of a
previously developed mouth-throat (MT) geometry. A well tested low Reynolds
number (LRN) k − ω turbulence model was employed to simulate the flow field.
Results of this study indicate that transient absorption can significantly influence
the transport and mass absorption of vapors onto the walls of the conducting
airways.

5.2

Methods

Upper Airway Geometry
As shown in Fig. 5.1, the upper respiratory tract model considered includes
the oral cavity, pharynx, larynx, and upper trachea. This model was originally
developed in Xi and Longest (2007b) based on a cast of the oral cavity combined
with CT images of the pharyngeal and laryngeal regions. The geometry was then
simplified using elliptical cross sections, which maintained the flow area and
hydraulic diameter of the original model (Xi and Longest 2007b). The geometry
was modified for this study by including an elliptical mouth opening, which is
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consistent with relaxed oral inhalation. This model is referred to as the mouththroat (MT) geometry.
Flow Rates
In this study, transient and steady state airflow fields are considered. Both
cases are based on one inhalation cycle with a breathing frequency ( f ) of 15
breaths/minute and a tidal volume (VT) of 1000 cm3/breath. For steady airflow,
the steady state inhalation flow rate QS (500 cm3/s or 30 L/min) is obtained using
the equation
QS = 2f VT ,

(5.1)

For transient airflow, the transient inhalation flow rate Q(t) was approximated as a
sinusoidal function with the form
Q(t ) = Qm sin(ωt ) ,

(5.2)

where ω = 0.5π radians / s . The mean cyclic flow rate Qm (785.40 cm3/s) in Eq.
(5.2) can be obtained by solving the equation
T /2

∫Q

m

sin(ωt )dt = VT ,

(5.3)

0

where T = 4 s/breath. In this manner, the tidal volume and breathing frequency
are consistently applied to find both the steady and transient inhalation flow rates.
It is noted that setting Qs to 500 cm3/s and satisfying Eq. (5.1) would require
artificially modifying the reference inhalation frequency value (f = 15
breaths/min) selected. The resulting inlet Reynolds number (based on the inlet
hydraulic diameter) for the steady flow rate and mean cyclic flow rate are 2320
and 3645, respectively.
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Transport Equations
The low-Reynolds-number (LRN) k − ω model of Wilcox (1998) was
selected for simulating the airflow in the MT model because it has been shown to
provide an accurate and numerically efficient solution for transitional and
turbulent flows. Furthermore, this model was found to accurately predict laminar
flow as the turbulent viscosity approaches zero. The transport equations for the
(LRN) k − ω model, including those governing the turbulent kinetic energy ( k )
and the specific dissipation rate ( ω ), were provided by Wilcox (1998) and were
previously reported in Xi and Longest (2007b).
The vapor mass transport equation for turbulent flow can be written on a
mass fraction basis as
∂Ca ∂ (u j Ca )
∂
+
=
∂t
∂x j
∂x j

⎡⎛
ν T ⎞ ∂Ca ⎤
⎢⎜ Da +
⎥,
⎟
σ C ⎠ ∂x j ⎦⎥
⎣⎢⎝

(5.4)

where Ca is the mass fraction of a chemical species in air, Da is the species
diffusivity in air, and νT is the turbulent viscosity. Vectors uj and xj are the fluid
velocity and position, respectively, and σC is the turbulent Prandtl number, taken
to be 0.9.
Analytical Solution for Mass Transport in Mucus and Tissue Layers
In this study, vapor absorption and transport are considered in both the
airflow field and through the walls of the conducting airways. To approximate
transport within the walls of the conducting airways, a model system was
considered that consists of air, mucus, tissue, and blood layers. The wall model
along with governing equations in each layer are illustrated in Figure 5.2.
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Assumptions made in the wall model are that convection is negligible compared
with diffusion and that zero concentration of the absorbed chemical species exists
in the blood. Zero blood concentration over short term exposures is appropriate
due to high convective transport rates in blood relative to diffusion through the
wall.

However, 1-D models and experiments clearly show that blood

concentrations increase over longer timescales (Kumagai and Matsunaga 1995).
An analytical solution of this system was previously developed in Chapter 3 and
extended to formulate a CFD boundary condition including the air phase in
Chapter 4. The analytical solution for the concentration of an absorbed species in
the mucus and tissue layers is briefly reviewed below. Flux-based boundary
conditions for absorption are then provided for both transient and steady state
conditions.
The analytical solution for the transient absorption of a chemical species
into a multilayer air-mucus-tissue-blood wall model was previously (Chapter 4)
obtained using the Fourier series expansion as
D
t
− μn 2 m2 ( t −τ ) dC |
⎛ ∞
a y =0
Hm
ˆ
Cm = λma ⎜ ∑ WnYm ∫ e
dτ + Ca | y =0
⎜ n =1
dτ
0
=
τ
⎝

D
t
− μn 2 m2 ( t −τ ) dC |
⎛ ∞
a y =0
Hm
ˆ
Ct = λma ⎜ ∑ WnYt ∫ e
dτ + Ca | y =0
⎜ n =1
dτ
τ
0
=
⎝

⎛ 1 − C% m | y = H m ⎞ ⎞
y ⎟ ⎟ , (5.5)
⎜1 −
⎜
⎟⎟
H
m
⎝
⎠⎠

⎛ λtmC% m | y = H m
⎞⎞
(H m + H t − y) ⎟ ⎟ ,
⎜
⎜
⎟⎟
Ht
⎝
⎠⎠

(5.6)
where C% m | y = H m =

H t Dm
,
H m λtm Dt + H t Dm

(5.7)

90

In these expressions, Cm and Ct are the time-dependent mass fractions of a
chemical species in mucus and tissue, respectively. Dm and Dt are the species
diffusivities in mucus and tissue, respectively, which are assumed to be constant.
λma and λtm are the mucus-air and tissue-mucus partition coefficients. Hm and Ht
are the thicknesses of the mucus and tissue in a specific region of the respiratory
tract, respectively, as shown in Fig. 5.2. Based on ICRP (1994) estimates for the
extrathoracic region, values of Hm and Ht in this study were 1.5×10-3 cm and
5×10-3 cm. The values of transport parameters for two model compounds,
acetaldehyde and benzene, are reported in Table 3.1. Based on the reported
mucus-air partition coefficients, acetaldehyde can be considered highly soluble in
mucus and benzene can be considered moderately soluble. In Equations (5.5) and
(5.6), the coefficient Wn can be determined by utilizing the orthogonal relation.
Hm

Wn = −

∫

λtm

0

where C% m = 1 −

C% t =

1
C% mYˆm dy +

H m + Ht

∫

C% tYˆt dy

Hm

,

N
1 − C% m | y = H m
Hm

λtmC% m ( y ) | y = H
Ht

m

y , y ∈ [0, H m ]

( H m + Ht − y) , y ∈[ H m , H m + H t ]

(5.8)

(5.9)

(5.10)

Dm H t
μ y
Yˆm = sin( μn
) sin( n ) ,
Dt H m
Hm

(5.11)

Dm H m + H t − y
Yˆt = λtm sin( μ n ) sin( μ n
),
Dt
Hm

(5.12)
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N=

Hm

∫
0

2
1
⎡Yˆm ⎤ dy +
⎣ ⎦
λtm

H m + Ht

∫

Hm

2

⎡Yˆt ⎤ dy ,
⎣ ⎦

(5.13)

The eigenvalues, µn, are the sequential positive roots of the transcendental
equation

λtm

Dt
Dm H t
tan( μn ) + tan( μn
) = 0,
Dm
Dt H m

(5.14)

and were determined using Brent’s method (Press et al. 1996). The coefficients
Wn were determined by utilizing the orthogonal relation and zero concentration
initial conditions. The first five values in the eigenvalue and constant series are
provided in Table 5.1, which are accurate to four digits.
Transient Flux Boundary Conditions
The analytical solution in the mucus ( Cm ), the value of the mucus-air
partition coefficient, and an assumption of flux ( g / s − cm 2 ) conservation can be
combined into the transient flux boundary condition at the air-mucus interface.
This boundary condition has the following form, which was developed in Chapter
4
D λ
∂Ca
| y =0 = m ma
Da
∂y

⎛ 1
⎜
⎜ Hm
⎝

∞

∑ μnWn sin(μn
n =1

t

− μn
Dm H t
)∫ e
Dt H m τ =0

2

Dm
H m2

( t −τ )

dCa | y =0
dτ

dτ −Ca | y =0

1 − C% m | y = H m ⎞
⎟
⎟
Hm
⎠

(5.15)
To determine uptake in the tissue and blood layers, flux boundary conditions into
these phases are also needed. The transient flux wall boundary condition at the
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mucus-tissue interface can be found by differentiating Cm with respect to y , and
has the form
⎛ 1
∂Cm
| y = H m = λma ⎜
⎜H
∂y
⎝ m

∞

∑ μnWn sin(μn
n =1

t

− μn
Dm H t
) cos( μn ) ∫ e
Dt H m
τ =0

2

Dm
H m2

( t −τ )

dCa | y =0
dτ

dτ −Ca | y =0

1 − C% m | y = H m ⎞
⎟
⎟
Hm
⎠

(5.16)
The transient flux wall boundary condition at the tissue-blood interface can be
found by differentiating Ct with respect to y , and has the form
⎛ 1
∂Ct
| y = H m + Ht = λma λtm ⎜ −
⎜ Hm
∂y
⎝

t

− μn
Dm ∞
μnWn sin( μn ) ∫ e
∑
Dt n =1
τ =0

2

Dm
H m2

( t −τ )

dCa | y =0
dτ

dτ −Ca | y =0

C% m | y = H m ⎞
⎟
Ht ⎟
⎠

(5.17)

Steady State Flux Boundary Conditions
The transient boundary conditions developed above can be simplified to
steady state conditions by removing the transient terms.

The steady flux

boundary condition at the air-mucus interface results in
dC% a′
| y =0 + K a C% a′ | y =0 = 0,
dy

where K a =

Dm λma (1 − C% m | y = H m )
Da H m

(5.18)

(5.19)

.

In these expressions, C% a′ is the steady-state mass fraction of a chemical species in
air.
The steady flux boundary condition at the mucus-tissue interface reduces to
dC% m′
| y = H m + K mC% a′ | y =0 = 0,
dy

(5.20)
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λma (1 − C% m | y = H )

where K m =

m

Hm

(5.21)

.

In these expressions, C% m′ is the steady-state mass fraction of a chemical species in
mucus.
The steady flux boundary condition at the tissue-blood interface results in
dC% t′
| y = H m + Ht + Kt C% a′ | y =0 = 0,
dy

where K t =

λma λtmC% m | y = H
Ht

m

=

(5.22)

Dm λma (1 − C% m | y = H m )
Dt H m

.

(5.23)

In these expressions, C% t′ is the steady-state mass fraction of a chemical species in
tissue. Furthermore, it can be shown that the steady state fluxes into the mucus,
tissue and blood layers are equal and constant, i.e.,
− ρ m Da

dC% a′
dC% ′
dC% t′
| y =0 = − ρ m Dm m | y = H m = − ρ m Dt
| y = H m + Ht ,
dy
dy
dy

(5.24)

where the mixture density ρ m is assumed constant. As a result, uptake in the
mucus, tissue, and blood layers are equal and constant for steady state conditions.

Deposition Factors
For the transport model, the total deposition fraction at steady state can be
expressed as
DFi =

m& w,i
,
m& in

(5.25)
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where m& w,i is the total mass absorption rate into the wall surface and m& in is the
inlet mass flow rate of the chemical species. The transient total deposition fraction
can be expressed as
T /2

∫ m&

w ,i

DFi =

dt

0
T /2

,

∫ m&

in

(5.26)

dt

0

The breathing period (T) is divided by two in order to account for only one
inhalation cycle (T/2 = 2 s) in most cases considered. For turbulent flow, the total
mass absorption rate into the wall surface can be expressed as
N

m& w,i = ∑ − ρ m Aj ( Da +
j =1

ν T ∂Ca
)
|
σ C ∂n w, j

(5.27)

where Aj is the local area, and the summation is performed over the total or

i − region of interest. The mixture density is ρm. The vector n is the wall normal
coordinate pointing out of the geometry. The inlet mass flow rate of the chemical
species can be determined as

m& in = ρ mQCin ,

(5.28)

where Q is the inlet inhalation flow rate and Cin is the inlet mass fraction, taken to
be 0.05.
A deposition enhancement factor (DEF), similar to that suggested by
Longest and Xi (2007a), was defined in order to quantify local deposition in local
area Aj with respect to the total deposition rate, i.e.,

DEFj =

DFj / Aj
DFi / Ai

(5.29)

,
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where Ai is the total area of the model. Deposition enhancement factors represent
the ratio of a compound depositing in a local area (taken to be a control volume
surface with an area of approximately 0.5 mm x 0.5 mm) to the total deposition
within the geometry.

Numerical Method
While effective, implementation of the transient absorption, or even the
steady state absorption, boundary conditions can be complex. For the transient
case, the flux-based boundary conditions contain a series summation and require
the evaluation of an integral term.

Eigenvalues μn and coefficients Wn are

included in the summation term and must be determined from a transcendental
equation and integral expression, respectively.

Application of this complex

boundary condition in a CFD solution of the airflow phase can be difficult. To
facilitate implementation of the transient absorption boundary conditions, a new
user-friendly program titled Transient Absorption of Chemical Species (TAOCS)
1.0 was developed. The TAOCS 1.0 program is based on the AMTB wall model
and equations shown in Fig. 5.2. The TAOCS graphical user interface (GUI)
along with several input windows for specifying transport properties and
determining the eigenvalues are shown in Fig. 5.3. The user inputs the transport
properties of the chemical species (from Table 3.1), wall conditions, and initial
surface concentrations. Based on the previous work in Chapters 3 and 4, and the
boundary conditions presented in this study, the TAOCS program provides:
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1. Ready to implement user-defined functions (UDFs) for use with a
commercial CFD program (Fluent 6.3), which specify the transient
flux boundary conditions, i.e., Eqs. (15) – (17).
2. The μn and Wn coefficients through any order needed to evaluate the
flux expressions (cf. Table 5.1).
3. The analytical solution of transport into an air-mucus-tissue-blood
system based on both steady and transient absorption.
4. The numerical solution of transport into an air-mucus-tissue-blood
system based on both steady and transient conditions for
comparisons with the analytical solution and CFD results.
In this study, the TAOCS program was used to calculate the μn and Wn
coefficients for use in the transient boundary conditions (Table 5.1) and to
generate the UDFs needed for implementation of the boundary conditions in the
CFD code.
To solve the governing conservation equations, the CFD package Fluent 6.3
(Ansys Inc.) was employed. User-supplied C programs were implemented for the
calculation of the transient boundary condition, vapor absorption, and deposition
enhancement factors.

All transport equations were discretized to be at least

second order accurate in space. For the convective terms, a third order QUICK
scheme was used to interpolate values from cell centers to nodes. The diffusion
terms were discretized using central differences. A segregated implicit solver was
employed to evaluate the resulting linear system of equations. This solver uses
the Gauss-Seidel method in conjunction with an algebraic multigrid approach.
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The PISO algorithm was employed to evaluate pressure-velocity coupling in the
transient solutions. The outer iteration procedure was stopped when the global
mass residual had been reduced from its original value by five orders of
magnitude and when the residual-reduction-rates for both mass and momentum
were sufficiently small. To ensure that a converged solution had been reached,
residual and reduction rate factors were decreased by an order of magnitude and
the results were compared.

The stricter convergence criteria produced a

negligible effect on both velocity and vapor absorption predictions. To improve
accuracy, cgs units were employed, and all calculations were performed in double
precision. Grid converged results based on negligible change in the velocity and
concentration fields (< 1%) as well as negligible differences in the total deposition
fractions (< 3%) were established for a mesh consisting of 1×106 hexahedral
control volumes. The size of the first control volume next to the wall surfaces
was found to strongly affect mesh convergence. A value of 0.05 mm was needed
to produce negligible (< 3%) changes in the absorption predictions.

Cases Considered
Six cases were considered in the MT airway model, as outlined in Table 5.2.
Each case is represented by a combination of steady (S) vs. transient (T) airflow
conditions and steady vs. transient vs. perfect (P) wall absorption. Perfect wall
absorption is defined as a concentration of zero on the wall boundary, which may
be appropriate for very high absorption or reactivity rates. These conditions are
abbreviated for each case in terms of (flow field condition : wall absorption). For
Case 1 (S:S) and Case 3 (S:T), steady state flow fields and mass concentration
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fields were assumed. For Case 2 (T:S) and Case 4 (T:T), transient flow fields and
mass concentration fields were simulated. Absorption was then modeled based on
either the steady state or transient boundary condition over a timescale consistent
with one inhalation cycle (2 s). For Case 5 (S:P) and Case 6 (T:P), perfect
absorption was assumed, which can be mathematically expressed as C% a′ ( y ) | y =0 = 0
at the wall. The focus of the results is then to identify differences between the
most complex case (Case 4 (T:T)) and the other commonly used approximations.

5.3

Results

Mass Fraction
Effects of airflow and wall absorption conditions on vapor mass fraction
distributions of acetaldehyde and benzene in the MT model are shown in Figures
4 and 5, respectively. For the transient conditions shown, a 2 second inhalation
period was applied. Beginning with acetaldehyde, the concentration profiles for
Case 4 (T:T) are highly complex (Fig. 5.4). Considering airflow effects, steady
state conditions appear to significantly change the concentration profiles (Case 3
(S:T) vs. Case 4 (T:T)). Considering absorption, steady state again appears to
have a major impact on the concentration profiles (Case 2 (T:S)) vs. Case 4 (T:T)).
Of the cases considered, transient airflow and perfect absorption (Case 6) appear
to best match the transient conditions of Case 4. However, similar mass fraction
concentrations in the flow field do not necessarily imply that absorption into the
walls will be similar between Cases 4 and 6.
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Considering benzene, the lower solubility coefficient results in nearly
constant concentrations for Case 4 (T:T) conditions (Fig. 5.5) at the selected
contour levels.

Steady airflow is again observed to significantly impact the

concentration profile (Case 3 (S:T) vs. Case 4 (T:T)). With respect to absorption,
steady state conditions Case 2 (T:S) appear to provide a reasonable approximation
to the transient wall conditions of Case 4. As expected, perfect absorption (Case
6 (T:P)) provides very different contours from the transient absorption case.

Deposition Fraction Values of Acetaldehyde and Benzene
Deposition fractions (DF) for acetaldehyde and benzene vapors in mucus,
tissue, and blood in the human upper airway model for Cases 1-4 are shown in Fig.
5.6. The DF values of acetaldehyde and benzene for all cases considered are also
tabulated in Table 5.3. The DF is defined as the amount of inhaled vapor mass
that enters each wall layer normalized by the amount of inhaled mass (cf. Eq.
(26)). As such, the DF provides a relative estimate of the amount of the species
that reaches each level of the wall over a defined time period. It is observed that
DF values for transient absorption (Cases 3 and 4) are significantly different from
steady state absorption (Cases 1 and 2). Specifically, DF values of acetaldehyde in
the mucus are approximately 10 to 15 times greater for transient absorption
compared with steady state absorption. Deposition fraction values of benzene in
the mucus are approximately 4 to 6 times greater for transient absorption
compared with the steady absorption condition. For Case 1 (S:S), the DF values
are equal in mucus, tissue, and blood. For Case 2, the transient flow effects cause
little difference in DF values for mucus, tissue, and blood. For Cases 3 and 4, the
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DF values of acetaldehyde in mucus are approximately 6 times higher than in
tissue and 40 times higher than in blood. The DF values of benzene in mucus are
approximately 2 times higher than in tissue and 20 times higher than in blood.
The higher deposition of acetaldehyde vapor may be attributed to its higher
solubility in the mucus layer compared with benzene. Under the same absorption
conditions, the differences of DF values in mucus between Case 1 and Case 2,
Case 3 and Case 4, Case 5 and Case 6, are 11.3%, 28.1%, and 27.0% for
acetaldehyde and 10.0%, 26.8%, and 27.1% for benzene, respectively. Therefore,
it is concluded that the transient flow field also influences the deposition fraction,
but to a much lesser extent than the transient absorption condition.
Comparisons of DF values in mucus for the human upper airway model
between Case 3 (S:T) and Case 5 (S:P), and between Case 4 (T:T) and Case 6
(T:P) are shown in Fig. 5.7. Case 5 (S:P) and Case 6 (T:P) assume that the airway
wall is a perfect sink for vapors, i.e., the boundary condition on the wall is

C% a′ ( y ) | y =0 = 0 . However, this assumption is only reasonable for vapors of high
solubility, or for estimating the maximum deposition of vapors in the airways.
Compared with Case 3, the DF values of Case 5 are approximately 1.5 times
greater for acetaldehyde and 40 times greater for benzene. Similarly, compared
with Case 4, the DF values of Case 6 are approximately 1.5 times greater for
acetaldehyde and 40 times greater for benzene. Therefore, the perfect absorption
boundary condition is accurate to within approximately 50% (calculated as a
relative percent error) compared with transient absorption for the highly soluble
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compound acetaldehyde and should not be applied for compounds with lower
solubilities.

Local Deposition
Contours of local deposition enhancement factors (DEFs) for acetaldehyde
and benzene vapors are shown in Figures 8 and 9, respectively. As described, the
DEF contours represent the locally absorbed mass divided by the area-averaged
total absorption to give a normalized representation of local uptake. Similarities
in local deposition based on DEF patterns and maximum values were consistent
with observations of total deposition fractions. For acetaldehyde, Case 4 (T:T)
local deposition values were most similar to Case 3 (S:T) indicating that the
absorption condition is most significant. Case 6 (T:P) DEF patterns were also
similar with Case 4 (T:T), but with a much higher maximum (8.81 vs. 2.72) as
expected for perfect absorption. Considering benzene, Case 4 (T:T) local DEF
values were found to be similar with Case 3 (S:T) and Case 2 (T:S). The
similarity with Case 3 was expected based on observations made with the total
deposition fractions.

However, similarity between Cases 4 and 2 was not

expected considering the order of magnitude difference in the total deposition
fractions.

Mass Absorption into the Wall Layers
Mass absorption into the wall layers for acetaldehyde and benzene under
Cases 1 (S:S) and 3 (S:T) conditions are presented in Fig. 5.10. Steady airflow
fields are considered to isolate the effects of transient vs. steady state absorption
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over time. The mass absorption differences between Case 1 and Case 3 are highly
significant. At 2 s, transient mass absorption into the mucus layer for
acetaldehyde and benzene is approximately 15 times and 6 times higher than
predicted with the steady state solution, respectively. Transient mass absorption
into the tissue layer for acetaldehyde and benzene is approximately 3 times higher
than predicted with the steady state solution. Similarly, the mass absorption into
the blood for acetaldehyde and benzene is lower than with steady state conditions
by a factor of approximately 4.

Mass Absorption over Multiple Breaths
The results presented in the previous figures are for one inhalation cycle.
However, buildup of species concentrations in the wall layer over multiple
breathing cycles may diminish transient absorption effects.

To evaluate the

buildup of concentrations in the wall layers, three breath cycles (2 s inhalation and
2 s exhalation) were simulated for Case 4 (T:T) and compared with the Case 1
(S:S) results. The species concentrations entering the model at the larynx during
exhalation were estimated based on expected lung uptake values. Considering the
high and moderate solubilities of acetaldehyde and benzene, the estimated
concentrations entering the larynx during expiration were assumed to be 0 and
30% of the inhaled mass concentrations, respectively, which assumes 100 and
70% lung absorption. These values are only intended to explore the potential for
buildup in the wall layers during absorption and desorption and may not provide
quantitative estimates of acetaldehyde and benzene uptake in vivo. It is noted that
an accurate prediction of the concentration entering the geometry during

103

exhalation will require a linked CFD and 1-D model, as performed in other
studies (Frederick et al. 1998; Kimbell et al. 2001a; Overton et al. 2001).
Multiple breath simulation results are shown in Fig. 5.11 in terms of
absorption rate (g/s). To allow a direct comparison between the steady state Case
1 and transient Case 4 estimates, a time average was taken of the transient mass
absorption rate (time-averaged transient rate). During the first inhalation cycle for
acetaldehyde and benzene, a rise is observed in the transient absorption rate.
However, after the first inhalation cycle the transient absorption rate appears to
repeat for subsequent breaths without significant change.

Specifically,

differences in the maximum transient absorption value between breaths 2 and 3
are less than 0.2% for both compounds. This implies that some buildup of the
species occurs in the wall after the first breath due to incomplete desorption.
Thereafter, a cyclic pattern emerges that is repeated for subsequent breaths. This
first breath buildup has a relatively minimal effect on the absorption rate of
acetaldehyde. In contrast, a more visible effect is observed for benzene arising
from the non-zero concentration entering the model during exhalation. While
concentration buildup in the wall layer is expected to reduce transient effects, the
transient fluctuations still clearly influence mass absorption. Specifically, the
transient mass absorption rate averaged over breaths 2 and 3 (once a repeating
pattern occurs) is 7 times greater than the steady state prediction for acetaldehyde
and 3.5 times greater than the steady state prediction for benzene. Absorption
results evaluated in the tissue and blood layers were similar to those found in the
mucus.
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5.4

Discussion

This study has considered transient absorption of inhaled vapors into a
multilayer air-mucus-tissue-blood system in a human upper airway model. The
transient flux boundary condition at the air-mucus interface was employed for
CFD simulations of gas phase transport and mass transfer. Six cases were
intended to quantify the effects of transient absorption compared with steady state
conditions. A new dosimetry program TAOCS 1.0 was used in conjunction with a
CFD model to apply and evaluate both steady state and transient wall absorption
conditions.
Conclusions of the model results can be summarized as described below.
These conclusions are based on the single inhalation cycle simulations performed
in this study, which neglect reactions in the airway wall, and assume zero species
concentration in the blood.

•

For both highly and moderately soluble compounds:
o Steady state absorption cannot capture transient absorption

conditions. After 2 seconds, differences were at least one order
of magnitude.
o Steady state airflow produces significant changes in the

concentration field compared with transient airflow. However,
steady state airflow conditions only influence total deposition
fractions by approximately 10 – 30%.
o Steady airflow also produced reasonable approximates of local

DEF values compared with transient airflow conditions.
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•

For highly soluble compounds (λma ≥ 320)
o Perfect absorption provides a reasonable estimate (within

~50%) of total deposition compared with the transient boundary
condition.
o Considering local deposition, perfect absorption significantly

over predicts maximum DEF values.

•

For moderately soluble compounds (λma ~ 4)
o Total deposition fractions cannot be approximated with either

steady state or perfect absorption boundary conditions.
Therefore, consideration of transient wall absorption is required.
o Based on total absorption findings, local absorption should not

be approximated with steady or perfect absorption conditions.
To summarize these observations, steady state airflow provides a reasonable
approximately to transient airflow conditions (within 10 – 30%) in terms of total
and local deposition. However, the simulation of transient wall absorption is
critical unless the compound is highly soluble (λma ≥ 320) and a perfect absorption
boundary condition can be applied.

Still, the perfect absorption boundary

condition does not adequately model local DEF values.
A primary limitation of this study is the omission of chemical reactivity in
the mucus, tissue, and blood.

Other studies have shown that reactivity can

significantly influence uptake under steady state absorption conditions (Cohen
Hubal et al. 1996b; Cohen Hubal et al. 1997; Keyhani et al. 1997; Kimbell et al.
2001a; Zhang and Kleinstreuer 2006). However, the previous studies of Tian and
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Longest (2010a; 2010b) have shown that when transient absorption is considered,
the effects of chemical reactions are significantly diminished. This is because of
finite reaction rate times over 1 – 2 s with transient absorption vs. infinite reaction
rate times associated with a steady absorption model. The results of Tian and
Longest (2010a; 2010b) indicated that reactions were not significant compared
with transient absorption for both acetaldehyde and benzene at typical inhalation
concentrations and short term exposures with zero blood concentrations. However,
for highly reactive compounds like ozone, reactions cannot be neglected. Future
work is needed to extend the current transient absorption boundary condition
developed by our group to account for chemical reactions in a time-dependent
manner. Because reactions were neglected in this study, the quantitative values
reported for acetaldehyde and benzene should be examined further and interpreted
as representative of general highly and moderately soluble compounds.
A second limitation of the current study is the focus on a single breath or a
small number of breaths. Buildup of concentrations in the tissue and blood are
known to have an effect on absorption (Kumagai and Matsunaga 1995) and are
expected to reduce the overall importance of time dependence. To evaluate
concentration buildup in the wall under the assumption of zero blood
concentration, a multiple breath simulation was conducted (Fig. 5.11). While
exact values of concentrations entering the larynx are not known, results of these
multiple breath simulations were informative. In summary, it was found that
buildup in the wall influences transient flux values between the first and second
breaths. Thereafter, a cyclic repeating transient absorption pattern was observed.
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Despite an expected reduction in transient absorption effects, the time-averaged
transient absorption rate remained 3.5 to 7 times greater than the corresponding
steady state estimate. Therefore, it can be concluded that buildup in the wall
layers does not significantly diminish transient absorption effects, even if 30% (or
potentially more) of the inspired concentration is exhaled.
Similar to buildup in the wall layers, absorption and buildup of chemicals in
the blood may diminish transient differences from steady state values. Previous
1-D models have shown that blood concentrations of species can increase over
long exposure timescales on the order of hours (Kumagai and Matsunaga 1995).
It is expected that until saturated blood levels are reached, transient absorption
and desorption from the wall layer into the air will produce absorption rate values
different from steady state estimates. However, this analysis is beyond the scope
of the current study.
It is stressed that the results of this study are for zero concentration of the
absorbed species in the blood, which may be referred to as the initial wash-in
phase of vapor exposure. During this period, it is expected that absorption rates
will be elevated, potentially heightening the effects of cyclic inhalation and
transient wall absorption. In comparison, it is noted that previous experimental
and numerical results have indicted that steady and transient exposures produce
similar absorption rates. For example, Morris and Blanchard (1992) showed that
the fractional upper respiratory tract absorption in a rodent model was similar
between steady state and cyclic experimental conditions at equivalent flow rates
for an exposure period of 40 minutes.
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Both steady state and cyclic total

absorption results were reasonably well predicted by the model of Aharonson et al.
(1974). Using a CFD-PBPK model that updated blood concentration and exhaled
fraction with time, Frederick et al. (1998) showed that transient and steady state
predictions of acrylic acid concentration in tissue varied by a factor of 2 over an
exposure period of three minutes.

As indicated earlier, this study included

transient flow field and inlet concentration effects, but the CFD model most likely
applied steady state flux equations to describe transport through the walls of the
nasal cavity model. Furthermore, previous experimental studies have highlighted
the importance of chemical reactions in the airways (Morris and Blanchard 1992;
Morris and Cavanagh 1987). One potential reason that the results of the current
study differ from previous experimental and numerical results is the time scale
considered. It is suggested that during the initial wash-in phase, when zero blood
concentrations can be assumed, transient effects are highly significant as
suggested in the current study. As blood concentrations increase, absorption is
reduced, and the effects of cyclic breathing and transient absorption are
diminished. Therefore, long-term exposures to environmental type pollutants
may be appropriately modeled using a steady state approach. In contrast, shorter
exposures described by the wash-in phase of airway kinetics (and zero or near
zero blood concentrations) may need to consider the transient effects described in
this study. Examples of short term exposures where transient effects will likely
be most important include smoking, the delivery of vaporized pharmaceuticals,
and the inhalation of high concentrations of noxious chemicals that may be
released during an environmental accident, fire, or chemical weapons attack.
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The model presented in this study is a first step toward better estimating
transient absorption using CFD predictions, which can provide highly localized
uptake values.

The simulations clearly show that the implementation of a

transient flux boundary condition appears critical to predict total and local
deposition characteristics for even highly soluble compounds. However, future
work is needed to make toxicologically relevant predictions in many cases. First,
the transient absorption boundary condition currently neglects reactions in the
airway wall.

While Tian and Longest (2010a; 2010b) clearly showed that

transient effects diminished the influence of reactivity, future work is needed to
confirm this finding over a range of exposure concentrations and times. The
transient absorption model is most appropriate for predicting uptake over short
term exposures before significant buildup in blood concentrations occurs.
Examples of these types of exposures include smoking and inhalation of noxious
compounds. Simulations of multiple breaths showed that a cyclic pattern of
mucus absorption and desorption is quickly reached. However, buildup of species
in the blood and the effect on subsequent absorption needs to be considered in
future studies. To address longer term exposures, a combination of the proposed
CFD model with a lumped parameter or 1-D whole-body model is suggested
which can accurately predict both local transient absorption and blood
concentrations over time. Still, the results as presented provide a valuable next
step toward time-resolved CFD predictions of vapor absorption in the respiratory
airways.
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In conclusion, the effects of transient airflow and absorption vs. steady state
conditions were considered for highly and moderately soluble compounds in an
upper airway model. The use of the TAOCS program in conjunction with CFD
simulations resulted in a new dosimetry approach to effectively simulate steady
state and transient absorption on a regional and highly localized basis. Findings
highlighted the need for considering transient wall absorption.

However,

differences associated with steady state flow fields may be acceptable. Future
studies are needed to consider chemical reactions, the buildup of concentrations in
the blood, absorption throughout the respiratory tract and over longer time periods,
and to validate the model with experimental results.
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Table 5.1.

The first five eigenvalues µn and coefficients Wn.

Acetaldehyde

Benzene

µ1= 0.5092

W 1=-1.4549

µ1=0.4050

W 1=-1.3355

µ2=0.9992

W 2=0.5802

µ2=0.8708

W 2=0.2435

µ3=1.4243

W 3=-0.4656

µ3=1.3677

W 3=-0.1033

µ4=1.7934

W 4=0.3618

µ4=1.8712

W 4=0.0787

µ5=2.2359

W 5=-0.2578

µ5=2.3646

W 5=-0.1027
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Table 5.2.

Definition of steady and transient cases considered.
Airflow (Air and mass species)

Absorption

Designation

Case 1

Steady

Steady flux

S:S

Case 2

Transient

Steady flux

T:S

Case 3

Steady

Transient flux

S:T

Case 4

Transient

Transient flux

T:T

Case 5

Steady

C% a′ | y =0 = 0

S:P

Case 6

Transient

C% a′ | y =0 = 0

T:P
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Table 5.3.

Total deposition fractions (DF) as percentages in mucus, tissue,
and blood.
Acetaldehyde

Benzene

in mucus

in tissue

in blood

in mucus

in tissue

in blood

Case 1

2.13

2.13

2.13

0.20

0.20

0.20

Case 2

1.89

1.87

1.87

0.18

0.17

0.17

Case 3

29.87

4.75

0.71

1.12

0.51

0.05

Case 4

21.49

3.66

0.55

0.82

0.45

0.04

Case 5

44.13

0

0

46.14

0

0

Case 6

32.21

0

0

33.66

0

0
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Figure 5.1.

Surface model of the mouth-throat region including the oral cavity,
pharynx, larynx, and a portion of the upper trachea.
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Air
Cm ( y, t ) | y =0 = λma Ca ( y, t ) | y =0
∂Cm ( y, t )
∂ 2 Cm ( y , t )
=
D
Mucus
m
∂t
∂y 2
∂C ( y, t )
∂C ( y, t )
− Dm m
| y = H m = − Dt t
| y=Hm
∂y
∂y

Ct ( y, t ) | y= H m = λtmCm ( y, t ) | y= H m

Tissue

y
y = Hm

∂Ct ( y, t )
∂ 2Ct ( y, t )
= Dt
∂t
∂y 2

Ct ( y, t ) | y = H m + Ht = 0

Blood
Figure 5.2.

y=0

y = Hm + Ht

Submodel of the airway wall including air, mucus, tissue, and
blood (AMTB) layers.

Equations governing transport in this

multilayer system are also shown.
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Figure 5.3.

Graphical user interface (GUI) of the Transient Absorption of
Chemical Species (TAOCS) 1.0 model. Windows shown include
the main GUI and input panels for transport properties and finding
the eigenvalues.
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Figure 5.4.

Contours of acetaldehyde mass fractions in the air phase (Ca) for
all cases considered. For cases with either transient airflow or wall
absorption, conditions at 2 seconds are shown. The inlet mass
fraction of each chemical species considered was 5% for all cases.
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Figure 5.5.

Contours of benzene mass fractions in the air phase (Ca) for all
cases considered. For cases with either transient airflow or wall
absorption, conditions at 2 seconds are shown.
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Case 1 (S:S)
Case 2 (T:S)
Case 3 (S:T)
Case 4 (T:T)
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20.0
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Figure 5.6.

Deposition fraction of benzene (%)

Deposition fraction of acetaldehyde (%)

35.0

Tissue

Blood

Mucus

Tissue

Blood

Total deposition fractions of acetaldehyde and benzene vapors in
mucus, tissue, and blood in the MT model for Cases 1 – 4 after 2
seconds.
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60.0

60.0

Case 4 (T:T)
Case 6 (T:P)

50.0

Deposition fraction in mucus (%)

Deposition fraction in mucus (%)

Case 3 (S:T)
Case 5 (S:P)

40.0
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0.0

50.0
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20.0

10.0
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Acetaldehyde

Figure 5.7.

Benzene

Acetaldehyde

Benzene

Total mucus deposition fraction of acetaldehyde and benzene for
the evaluation of the perfect absorption condition.
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Figure 5.8.

Deposition enhancement factors (DEFs) and total deposition
fractions (DFs) for acetaldehyde and all cases considered after 2 s.
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Figure 5.9.

Deposition enhancement factors (DEFs) and total deposition
fractions (DFs) for benzene and all cases considered after 2 s.
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Figure 5.10.
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Mass absorption of acetaldehyde and benzene in individual wall
layers under steady airflow conditions over time.
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2

Figure 5.11.

Mass absorption rate (g/s) of acetaldehyde and benzene into the
mucus based on Case 1 (S:S) and Case 4 (T:T) conditions
considered over multiple breaths.
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Chapter 6.

Evaluation of Enhanced Condensational Growth (ECG) for

Respiratory Drug Delivery in a Realistic Mouth-Throat and
Tracheobronchial Single Path Model
6.1

Introduction

The feasibility of improving respiratory drug delivery using enhanced
condensational growth (ECG) has previously been demonstrated using both in

vitro and CFD models of the upper respiratory airways. Previous studies have
indicated that ECG is an effective approach for significantly reducing MT aerosol
deposition and increasing aerosol size from the submicrometer range to
approximately 2-4 µm, which is expected to produce nearly 100% lung retention.
However, condensational growth and deposition in the tracheobronchial (TB)
region beyond approximately generation G4 was not considered. It is currently
not clear how far into the lungs condensational growth will continue. It is also
conceivable that some evaporation may occur in the deep lung once subsaturated
conditions are reached for non-hygroscopic aerosols. To verify full lung retention
of the aerosol under ECG conditions, the aerosol size change and deposition
needs to be characterized throughout the TB airways. To address these issues, a
model of ECG delivery within the medium and small TB airways is needed.
The objective of this study is to evaluate the ECG delivery of respiratory
submicrometer pharmaceutical aerosols in a single path model extending from the
mouth-throat (MT) to the end of the TB region. This single path model is
constructed by continuing only one branch of each bifurcation through generation
G16. Separate streams of nebulized submicrometer aerosol and saturated
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humidified air are combined as they are introduced into a realistic MT-TB single
path geometry. Initially monodisperse aerosol sizes of 560 and 900 nm are
delivered in conjunction with control subsaturated air and ECG conditions with
saturated air at temperatures of 39 and 42 ◦C, consistent with previous
experimental studies of ECG (Longest et al. 2010). A previously validated CFD
model of aerosol transport and deposition during ECG delivery in the respiratory
airways is applied.

6.2

Methods

MT-TB Geometry
A physical model of the MT-TB geometry was considered as shown in Fig.
6.1. The geometry consists of the MT region, the upper TB airways extending
from the trachea to the third respiratory bifurcation (B3), and an individual path
model of the medium and small TB airways extending to the terminal bronchioles
(B15). The trachea and the initial part of the main bronchi constitute bifurcation
B1. The MT geometry includes the oral cavity, pharynx, and larynx. The MT
model was originally developed in Xi and Longest (2007b) based on a cast of the
oral cavity (Cheng et al. 1997) combined with CT images of the pharyngeal and
laryngeal regions. The geometry was then simplified using elliptical cross
sections which maintained the flow area and hydraulic diameter of the original
model.
The upper TB airways are considered extending from the trachea to the third
bifurcation (B3). This asymmetrical model was generated using the anatomical
cast dimensions reported by Yeh and Schum (1980) and scaled to a functional
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residual capacity (FRC) of 3.5 L, which is consistent with an adult male (ICRP
1994). The individual bifurcation units were based on the physiological realistic
bifurcation (PRB) parameters reported by Heistracher and Hofmann (1995).
Surface properties of the bifurcations such as carinal ridge and curvature radius of
branches were based on the measurement reported by Horsfield et al. (1971) and
Hammersley and Olson (1992). These bifurcation parameters such as branch
diameter, length, bifurcation angle, and gravity angle were taken from Yeh and
Schum (1980). In the TB model, B2 of the right lung braches into the right upper
lobe directly, whereas the lower third bifurcation branches into the right middle
and right lower lobes. In the left lung, B2 branches into the left upper and left
lower lobes.
The upper TB model is asymmetrical and includes out-of-plane rotations of
individual bifurcations. The asymmetrical model is considered to be sufficiently
accurate to characterize aerosol growth and deposition in the upper airways,
which will be verified with comparisons to the upper TB deposition data of Zhou
and Cheng (2005).
Beyond the third bifurcation, an individual path model was considered by
continuing from the trachea to the end of the TB region (B15) of the right lower
lung lobe. Bifurcations within the model were based on PRB units with the airway
dimensions reported by Yeh and Schum (1980). Use of the individual path model
based on PRB units allows for the application of a hexahedral mesh, which
improves solution accuracy, and an adequate number of computational cells to
fully resolve the flow domain (Longest and Vinchurkar 2007a; Vinchurkar and
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Longest 2008). Based on available data, the bifurcations in the individual path
model section (B4-B15) were symmetric and included a symmetric outflow
assumption at each bifurcation level. At each bifurcation, continuation of the left
or right branch was selected at random. Consecutive branches were rotated at 90◦
to approximate physiological conditions (Phalen et al. 1978). This individual path
model is not intended to exactly mimic a specific connection of bronchi as with a
patient specific model. Instead, it is intended to provide and effective 3-D
representation of transport and deposition in the medium and small TB airways.
Branch 15 was assumed to end with the terminal bronchioles, based on the
existing anatomical data (Yeh and Schum 1980).

Boundary and Delivery Conditions
Separated streams of aerosol and humidified air are delivered to the mouth
inlet for both control and ECG growth conditions. As illustrated in Fig. 6.1, the
humidified air is delivered through an outer circle whereas the aerosol stream is
delivered through an inner ring at the mouth inlet. To allow separate streams of
aerosol and humidified air to be introduced into the MT, Hindle and Longest
(2010) developed and presented a dual flow mouthpiece. As reported by Hindle
and Longest (2010), the inlet areas of the aerosol and humidity streams are
balanced to maintain a constant velocity. The total inlet flow rate considered in
this study is approximately 30 L/min under steady state conditions.
The airway walls were assumed to be at body temperature. As a result, the
RH of the airway wall was set at 99.5%. Previous studies have reported variable
wall temperatures from the mouth to core body temperature downstream.
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However, correlations describing this change are based on the inhalation of
ambient environmental conditions. During ECG delivery, which is via a nebulizer
and requires multiple inhalations (Hindle and Longest 2010), it is expected that
the inhalation of warm air will significantly decrease any airway wall temperature
gradients. The walls of the airway model are assumed fixed and rigid.
Outflow conditions from the upper TB model into each lung lobe were
based on the estimates of Horsfield et al. (1971). Beyond the lobar bronchi,
symmetric outflow conditions were assumed at each bifurcation level (B4-B15).
This assumption is not expected to largely influence the growth and regional
deposition characteristics of interest in this study.
Aerosol and humidified air inlet conditions are shown in Table 6.1 for the
delivery of 560 and 900 nm droplets. Both control and ECG delivery cases were
considered. For the control scenarios, the aerosol was delivered with ambient air
(25 ◦C) and assumed to be a non-evaporating particle (Case 1) or a droplet
experiencing either evaporation or condensation (Case 2). The humidified air inlet
condition for Case 1 is identical to Case 2. Considering the one-way coupled
results, continuous field variables such as temperature and RH conditions for Case
1 are the same as for Case 2. ECG conditions were evaluated as the remaining two
cases. Under these conditions, the aerosol and humidified air were delivered at
either 39 ◦C (Case 3) or 42 ◦C (Case 4). Increasing the aerosol and humidity
stream temperatures allows for more water vapor mass to be delivered to the
airways, which is expected to increase the final aerosol size and alter the
deposition profile. Albuterol sulfate (AS) was considered as a model drug in the
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aerosol. The mass fractions of drug in the initial 560 and 900 nm droplets were
assumed to be 31% and 49%, respectively, based on a previous experimental
study in which these aerosols were formed using a small particle aerosol generator
(Longest et al. 2010). At these mass fractions, the hygroscopic effects of AS are
expected to enhance size increase initially for RH values below 100%. However,
hygroscopic effects are expected to significantly diminish once the aerosol
increases in size above approximately 1 μm (Longest et al. 2010).

Deposition Factors
Deposition within regions of the respiratory tract can be reported as either
a fraction or efficiency. The deposition fraction (DF) for the ith region is
calculated as
DFi =

number of particles depositing in region i
number of particles entering the mouth

(6.1)

In contrast, the corresponding deposition efficiency (DE) for region i is
calculated as
DE i =

number of particles depositing in region i
number of particles entering region i

(6.2)

To determine a total deposition fraction, DFi values in individual regions
can be directly summed. Deposition efficiency values are an effective method to
report the characteristics of an individual section of the respiratory tract without
the influence of upstream aerosol losses. In this study, DE values are calculated
for each bifurcation. Sectional DE values are then computed by combining the
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individual bifurcation values (ICRP 1994). For example, the DE in region B4 to
B7 is calculated as
DE B 4−7 = 1 − (1 − DE B 4 )(1 − DE B 5 )(1 − DE B 6 )(1 − DE B 7 )

(6.3)

The total DF for the entire MT-TB network is then calculated as
I

DFMT −TB = 1 − ∏ (1 − DE i )

(6.4)

i =1

which includes all regions (i=1 to I) from the MT to B15. It is noted that the total
DE of the model is equal to the total DF.

CFD Simulations
The low-Reynolds-number (LRN) k − ω model of Wilcox (Longest and
Hindle 2009a; Longest et al. 2009) was selected for simulating mixing of the
delivery streams and flow in the MT-TB model because it has been shown to
provide an accurate and numerically efficient solution for laminar, transitional
and turbulent flows. Furthermore, this model was found to accurately predict
aerosol transport and deposition in upper airway models (Longest and Xi 2008).
The coupled governing equations of heat and mass transport were considered to
evaluate the variable temperature and RH fields in the MT-TB model. These
transport equations were previously reported in Longest and Xi (2007) and
Longest et al. (2007). The Lagrangian transport equations interconnected with
user defined functions were employed to calculate droplet trajectories,
condensation, evaporation, deposition, near-wall anisotropic turbulence correction
(Longest and Xi 2007b), near-wall particle interpolation (Longest and Xi 2007b),
and Brownian motion (Longest and Vinchurkar 2007a; Vinchurkar and Longest
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2008) in the complex three-dimensional temperature and humidity fields. The
discrete phase transport model includes the Kelvin effect, drug hygroscopicity,
and the effect of droplet temperature on surface vapor pressure. In simulating
aerosol evaporation and growth, the effect of the droplets on the continuous phase
was typically neglected, resulting in a one-way coupled approach. One-way
coupled simulations are expected to be accurate in this study due to the presence
of wetted walls. However, to assess the validity of this assumption, the effect of
the discrete aerosol phase on the continuous heat and water vapor fields was also
included in some simulations, which is referred to as two-way coupling. An
experimentally measured concentration of 2.8×105 particles/cm3 for the 900 nm
aerosol (after mixing with the humidity stream) was employed to assess the twoway coupling effects.
To solve the governing equations, the CFD package Fluent 6.3, (ANSYS
Inc.) coupled with user defined functions was employed. All transport equations
were discretized to be at least second order accurate in space. For the convective
terms, a third order QUICK scheme was used to interpolate values from cell
centers to nodes. The diffusion terms were discretized using central differences.
A segregated implicit solver was employed to evaluate the resulting linear system
of equations. This solver uses the Gauss-Seidel method in conjunction with an
algebraic multigrid approach. The SIMPLEC algorithm was employed to evaluate
pressure-velocity coupling. The outer iteration procedure was stopped when the
global mass residual had been reduced from its original value by five orders of
magnitude and when the residual-reduction-rates for both mass and momentum
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were sufficiently small. To ensure that a converged solution had been reached,
residual and reduction rate factors were decreased by an order of magnitude and
the results were compared.

The stricter convergence criteria produced a

negligible effect on both velocity and particle deposition fields. To improve
accuracy, all calculations were performed in double precision. As shown in Fig.
6.2, the computational mesh was composed of approximately 2×106 hexahedral
elements and a very fine near-wall grid. Hexahedral meshing has been shown to
provide a better quality solution in aerosol deposition studies compared with
tetrahedral and hybrid grids (Vinchurkar and Longest 2008). Grid converged
results based on negligible change in the velocity and concentration fields (< 1%)
as well as negligible differences in the total deposition fractions (< 3%) were
established for a mesh consisting of 2.4 million control volumes. In order to
produce convergent aerosol deposition results, 1.2×105 monodisperse droplets
were injected at the aerosol inlet stream for each aerosol size and inlet case
considered. MMAD values after growth were calculated based on the midpoint
diameters of a standard Andersen cascade impactor (Vinchurkar et al. 2009).
Doubling the number of droplets considered had a negligible impact on both total
and sectional deposition results.

Model Validation
The CFD model employed in this study has previously been extensively
tested in comparison with experimental deposition results. For both constant-sized
particles and evaporating droplets, the CFD model was shown to accurately
predict local and sectional deposition profiles in comparison with in vitro
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experiments (Longest and Hindle 2009a; Longest et al. 2009b; Longest and
Vinchurkar 2007b). Longest and Hindle (2010) recently presented a CFD model
of ECG aerosol delivery in detail. In this study, excellent agreement was found
between experimental measurements of final particle size after condensational
growth and CFD predictions. Hindle and Longest (2010) compared in vitro results
and numerical predictions of aerosol drug deposition in a MT–TB geometry
extending to the fifth respiratory generation. Good agreement was found between
the experimental and numerical predictions of deposition for both control and
ECG conditions on a sectional basis and for the entire MT–TB geometry.

Comparison of Upper TB Deposition to Previous Studies
As discussed, some differences are observed between the upper TB model
considered in this study and previously reported models. An advantage of the
current model is the use of a standard well described bifurcation unit (the PRB)
that can be reproduced by other researchers. Furthermore, the characteristic TB
model considered can accommodate a hexahedral mesh. However, differences in
deposition from potentially more realistic models may be a concern. To address
this issue, deposition in the current upper TB model was compared to the
experimental results of Zhou and Cheng (2005) on a regional basis. Particles in
the range of 0.93- 30 µm were considered at an inhalation flow rate of 30 L/min.
Particle deposition efficiency in the upper tracheobronchial airway as a function
of Stokes number are compared with the correlation by Zhou and Cheng (2005).
The Stokes number is defined as St=ρpdp2U/18μDp, where ρp is the particle
density, dp is the particle diameter, U is the mean velocity, μ is the air viscosity,
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and D is the parent diameter of each bifurcation. As shown in Fig. 6.3, deposition
efficiencies in the trachea, first bifurcation, second bifurcation, and third
bifurcation provide an excellent match to the experimental data. As a result, it is
concluded that the current model is sufficiently detailed to capture regional
deposition characteristics in the upper TB airways. Furthermore, this comparison
provides an additional validation study indicating that our CFD model is accurate.

6.3

Results

Temperature Fields
Contours of temperature are shown for the MT, upper TB airways, and
selected medium and small TB airways in Fig. 6.4 for Cases 1-4. Temperature
contours are presented as mid-plane slices within each of the airway regions
shown. For Cases 1 and 2, the initially cool 25 ◦C airstream is rapidly warmed by
effective mixing in the MT and reaches approximately 30-34 ◦C in the trachea.
Temperatures are generally above 34 ◦C in B4-B7 and near 37 ◦C in B12-B15.
However, some areas below 36.5 ◦C are observed in the distal airway branches.
For the inlet conditions of Cases 3 and 4, rapid cooling is observed in the MT
with temperatures in the range of 37-39 ◦C in the trachea for Case 3, and in the
range of 39-41 ◦C for Case 4. Temperatures of approximately 37 ◦C are observed
in B4-B7 for Case 3, and approximately 38 ◦C for Case 4. Temperature is nearly
uniform at 37◦C in the B12-B15 region for Case 3 and 37.5 ◦C for Case 4.
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Relative Humidity
Contours of RH for Cases 1-4, presented as midplane slices, are illustrated
in Fig. 6.5. As expected, the cool subsaturated inlet conditions of Cases 1 and 2
result in low RH values through a majority of the upper TB airways. Due to mass
transfer from the wet walls, RH values of 95% and greater are observed in
bifurcations B4-B7. In the distal bifurcations B12-B15, RH values are
predominately equal to the wall value of 99.5%. However, contour levels below
walls conditions are also observed even in the most distal airways considered. For
inlet conditions of Cases 3 and 4, rapid cooling of the saturated airstream results
in a rapid progression to supersaturation, with values as high as 101% observed in
the pharynx for Case 3, and as high as 103% for Case 4. RH values remain in the
range of 100-101% for Case 3 and 101-103% for Case 4 through a majority of the
upper TB geometry and bifurcations B4-B7. In B12-B15, RH values are near wall
conditions of approximately 99.5% for Case 3 and in the range of 99.5-101% for
Case 4.

Droplet Trajectories
Trajectories of initially monodisperse 900 nm droplets in the full MT–TB
geometry are illustrated in Fig. 6.6 for Cases 2–4. Considering Case 2, rapid
droplet evaporation occurs in the oral cavity until only a solid drug particle
remains. As RH increases due to the warm and wet walls, some hygroscopic
growth of the aerosol is observed with B15 trajectories in the range of 0.9–1.0 μm.
For ECG delivery (Cases 3 and 4), rapid aerosol growth is observed throughout
the MT and first bifurcation. In the medium and small TB branches, growth slows
137

due to reduced RH values and a decreased hygroscopic effect associated with
higher droplet mass fractions of water. However, slower droplet velocities in the
more distal airways allow more time for growth to occur. The net result is
observed to be continued growth without visible evaporation throughout the
airways. For Cases 3 and 4, individual trajectories passing through bifurcation
B15 are found to have increased in size from 900 nm to ranges of 2 to >2.5 μm
and 2.5 to >3 μm, respectively.

Exit Size Distribution
Droplet size distributions sampled at specific cross-sectional locations in
the model are presented in Fig. 6.7 in terms of mass fraction per micrometer of
sampling bin size. MMAD values are also presented for each aerosol size
distribution. Considering Case 2, MMAD values change little from the initial
sizes of 560 and 900 nm. However, mixed evaporation and hygroscopic growth
result in a spreading of the size distribution from the initial monodisperse
condition. In contrast with Case 2, ECG conditions result in a definite shift in the
distribution profile to larger sizes. Considering Case 3 and initial sizes of 560 and
900 nm, both the MMAD and size distribution indicate significant and successive
growth at the tracheal inlet and B5 outlet. However, some decrease in MMAD
size is observed between the B5 outlet and B15 outlet for the 560 (~0.4 μm
reduction) and 900 nm (~0.2 μm reduction) aerosols. This decrease in MMAD
may arise from (i) deposition of the larger particles and (ii) minor evaporation as
RH approaches 99.5%. Considering that only a small size decrease is observed for
the 900 nm aerosol under Case 3 conditions, the decrease of the 560 nm aerosol is
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likely due to minor evaporation arising from a lower drug concentration in the
droplet and a reduced hygroscopic effect. Under Case 4 delivery conditions, size
decreases between the B5 and B15 outlets of approximately 0.2 μm are observed
for both aerosol sizes. Size distribution profiles indicate that 20–40% of the
aerosol mass is associated with droplets of 4 μm and above. Furthermore, RH
values shown in Fig. 6.5 were generally above 100% for Case 4 delivery
conditions. As a result, this minor decrease in aerosol size may be primarily due
to the deposition of larger droplets in the bifurcating airways.
MMADs of the polydisperse aerosol entering each bifurcation (B1–B15)
are presented in Fig. 6.8 for the various delivery conditions. For Case 2, results
indicate sudden evaporation followed by very slow growth, as expected.
Considering the ECG conditions, rapid growth is observed from the mouth to the
tracheal (B1) inlet. It is noted that the reported MMADs are calculated over all
droplets entering each bifurcation, i.e., as they cross the inlet plane. However,
details of growth for the aerosol ensemble are not resolved within each model
segment due to the number of droplets considered. In the figure, significant
growth is observed to occur through approximately B3. Thereafter, minor growth
is observed through approximately B8, and some size decrease occurs between B8
and B15. As described above, this size decrease is generally in the range of 0.2–
0.4 μm and likely arises from both deposition and minor evaporation; however,
deposition appears to be the primary cause.
To evaluate the validity of the one-way coupled assumption, two-way
coupled simulations were also considered. In two-way coupling, heat and mass
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transfer from the droplets are accounted for as source terms in the continuous
phase equations and influence subsequent droplet size change. The 900 nm
aerosol was considered under Case 3 and 4 conditions, where the effects of twoway coupling are expected to be the strongest (Longest et al. 2010). An aerosol
concentration of 2.8 × 105 particles/cm3 was considered, based on the
experimental study of Longest et al. (2010), in which the 900 nm aerosol was
formed. In general, two-way coupling is expected to slow both size decrease and
increase as changes in air phase RH damp evaporation and condensation.
However, the simulation results indicate that two-way coupling has a minimum
effect on aerosol size change, likely because of the wet-wall boundary conditions.
Specifically, relative percent differences were calculated as |MMADone-way MMADtwo-way|/MMADtwo-way × 100. The comparisons of one-way and two-way
coupling on MMADs of the polydisperse aerosol entering each bifurcation (B1–
B15) are presented in Fig. 6.9 for Cases 3 and 4. Percent differences in MMADs
for aerosols entering each bifurcation were less than approximately 10%.

Aerosol Deposition
Particle deposition locations of individual droplets are illustrated for the
900 nm aerosol with Cases 1-4 delivery conditions in Fig. 6.10. The droplets are
colored based on their size at the time of deposition. Deposition efficiencies were
calculated for each bifurcation and then combined (e.g., Eq. (6.3)) to represent the
total deposition efficiencies for the sections reported along the individual path.
Considering Cases 1 and 2, very little deposition is observed with a maximum of
only 7.1% in the airways B8–B15. For ECG delivery conditions of Cases 3 and 4,
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the MT deposition efficiency remains very small (~1%) as observed by Hindle
and Longest (2010). In contrast with this low MT value, deposition efficiencies in
B4–B7 and B8–B15 are increased by an order of magnitude compared with the
evaporating control case (Case 2). Furthermore, deposited particles beyond B4 are
2 μm and above, which provides evidence that the observed minor reduction in
MMAD is due to the loss of the larger aerosols in the polydisperse size
distribution.
The results of two-way coupling on particle deposition locations and
regional deposition efficiencies (DE) of drug mass for an initially 900 nm aerosol
in Cases 3 and 4 are presented in Fig. 6.11. Two-way coupling is observed to
slightly increase the DE with relative percent differences less than approximately
10%.
To support the accuracy of transport and deposition within the bifurcations
of each lung lobe, two additional individual paths were randomly generated.
Particle deposition locations and regional deposition efficiencies of drug mass for
an initially 900 nm aerosol of the individual paths 2 and 3 for Case 4 are shown in
Fig. 6.12. It is observed that MT and upper TB deposition values are slightly
different than previous results. Considering similarities in these results, it appears
that use of the stochastic individual path approach provides a reasonable estimate
of deposition within an individual lung lobe.
A complete description of deposition efficiencies for each inhalation case
considered is presented in Fig. 6.13 and Table 6.2. Deposition efficiencies are
again calculated as the combination of the values determined for each bifurcation.
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For all cases, MT and upper TB deposition remained extremely low
(approximately <2%). Deposition in the more distal airways is then observed to
increase by an order of magnitude for the ECG conditions (Cases 3 and 4) vs. the
controls (Cases 1 and 2). For both initial sizes, Case 4 conditions approximately
double deposition in B4–B7 and increase deposition in B8–B15 by a relative
difference of approximately 25% compared with Case 3. Considering the ECG
growth cases, minor differences in regional deposition efficiencies are observed
for the initial 560 nm aerosol vs. the 900 nm aerosol. As a result, it appears that
overall deposition is more influenced by inlet conditions than initial aerosol size.
Deposition efficiencies of Case 4 with an initially 900 nm aerosol are reported for
multiple paths in Table 6.3. The averages of these deposition efficiencies are also
reported and the small standard deviation values provide evidence that the
individual path approach is accurate.
Predicted total DEs of the TB airways are compared with the in vivobased correlations of Stahlhofen et al. (1989) and Chan and Lippmann (1980) in
Table 6.4. To calculate the total DE of the TB region from the CFD predictions,
the deposition efficiencies of each bifurcation were combined using an expression
similar to Eq. (6.3) from B1 to B15. The major assumption here is that the DEs of
each bifurcation in the right lower lobe single path are representative of
conditions in the other four lung lobes. For comparison, the TB correlations based
on in vivo deposition data from Stahlhofen et al. (1989) (Eq. 15) and Chan and
Lippmann (1980) (Eq. 3) were employed. The single characteristic aerosol size
required in these correlations was assumed to be the calculated MMAD exiting
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B5, as shown in Table 6.4. The tracheal inlet flow rate of 30 L/min used in the
CFD simulation was approximated in the correlations as an inhalation flow rate of
500 cm3/s with an inhalation volume of 1500 cm3 to represent deep inspiration,
which is characteristic of pharmaceutical aerosol delivery. As shown in Table 6.4,
the predicted DEs from this study are in general agreement with the in vivo data,
but the CFD predictions are somewhat higher. Considering the in vivo variability
reported by Stahlhofen et al. (1989), it is observed that the CFD predictions are
well within the range of the experimental data. The CFD predictions are likely
higher than the mean experimental data because of the use of a single lobe and
single path model to represent the remainder of the TB airways, a larger CFD
lung volume than in the experiments (3.5 vs. ~3.0 L), and the use of a single
droplet diameter to account for the deposition of a polydisperse aerosol that is
increasing in size.
To approximate whole lung retention of the aerosol, the MT–TB
deposition fractions predicted with Eq. (6.4) are reported in Table 6.5. These
values are combined with the alveolar deposition efficiency correlation of
Stahlhofen et al. (1989) to provide estimates of total lung deposition (DFtotal).
Again, an inhalation rate of 500 cm3/s was employed along with a volume of 1500
cm3. As observed from Table 6.5, total lung deposition fractions for the ECG
conditions are 90% and above, except for Case 3 and the 560 nm aerosol, where
the DFtotal is 83%. These whole lung deposition values could be increased further
with the inclusion of a breath pause. In contrast, for both controls (Cases 1 and 2),
the total lung deposition fraction was between approximately 23–38%.
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6.4

Discussion

In this study, the concept of ECG applied to respiratory drug delivery was
tested in a representative airway model extending from the oral cavity to the end
of the TB airways. Droplet transport, size change, and deposition were simulated
using a previously well-tested and experimentally validated CFD model.
Simulations were conducted in a previously developed MT-TB model whereas
deposition throughout the TB region was approximated using an individual path
approach. Results indicate that both control and ECG delivery conditions produce
very little deposition and aerosol loss in the MT and upper TB airways. With
ECG delivery, significant size increases of the initially submicrometer aerosols
were observed to occur, resulting in MMADs of 2–3 μm in the medium and small
TB airways. This increase in aerosol size was shown to produce an order of
magnitude increase in drug deposition in the TB airways, with TB deposition
efficiencies of approximately 32–46% for ECG conditions. Estimates of
downstream pulmonary deposition indicted near full lung retention of the aerosols
during ECG delivery.
As previously demonstrated by Hindle and Longest (2010) delivering
pharmaceutical aerosols using the ECG approach resulted in very low MT
deposition (~1%). In contrast, MT depositional losses are currently reported as
~60% for a typical MDI with a HFA propellant (Cheng et al. 2001), ~70% for a
typical DPI (Zhang et al. 2007) , and 30–40% for state-of-the-art breath-actuated
nebulizers (Newman 2009; Nikander et al. 2010). For the same MT and similar
upper TB geometry as considered in this study, Hindle and Longest (2010)
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reported experimental values of drug deposition using a Proventil HFA MDI. The
mean (and standard deviation) AS deposition in the MT–TB model was found to
be 49.7 (7.2)% of the dose. The majority of the dose from the MDI was deposited
in the MT region (46.0%), with only 3.6% deposited in the B1–B5 airways. Minor
differences between this study and that of Hindle and Longest (2010) include the
use of an initially monodisperse aerosol and an upper TB model that is complete
through B3 in the current study. Equivalent aerosol and humidity inlet
temperatures are also employed for ECG conditions in the current study, which
were only considered for one case in Hindle and Longest (2010). As a result, MT
and upper TB deposition values are slightly different than previously reported.
However, the primary motivation behind the current study was to investigate
conditions throughout an individual path model of the entire TB region.
Prior to this study, airway conditions and aerosol behavior in the medium
and small TB bifurcations was unknown for ECG delivery. Previous results of
aerosol size change during the inhalation of cool saturated air in the upper airways
indicated that aerosol size increase may be temporary and some evaporation may
occur (Ferron et al. 1984; Zhang et al. 2006b). However, results of this study
indicate that with the inhalation of warm saturated air, several degrees above body
temperature, supersaturated conditions extend well into the respiratory tract. This
increased region of supersaturation likely occurs due to the larger mass of water
vapor that enters the airways with the inhalation of warm vs. cool saturated air. As
a result of extensive supersaturation in the flow field, aerosol growth was
observed to occur throughout a majority of the TB airways without visible
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evaporation of individual trajectories under ECG conditions. Minor decreases in
the aerosol MMAD were observed beginning with B8 (Fig. 6.8). However, this
decrease in MMAD can be largely explained as resulting from the higher
deposition fraction of the larger droplets in the medium and small TB bifurcations
(Fig. 6.9). With ECG, deposition within the TB airways beginning with B4 was
increased by an order of magnitude compared to the evaporating control case
resulting in single path deposition efficiencies of 32–46%. Aerosols exiting B15
had MMADs ranging from 2.00 to 2.95 μm. As a result of these observations, it is
concluded that the advantages of ECG delivery are maintained throughout the TB
region and that negligible evaporation of individual droplets occurs. Furthermore,
estimates indicate that alveolar deposition will result in near full lung retention of
the aerosol (Table 6.4). Based on the aerosol behavior observed in the medium
and small TB airways, only negligible evaporation is expected in the alveolar
region.
For the prescribed inhalation flow conditions (Q = 500 cm3/s and VT =
1500 cm3), application of the Stahlhofen et al. (1989) equation for alveolar
deposition in combination with the TB deposition values predicted in this study
indicated near full lung retention of the aerosol with ECG delivery. The alveolar
estimates are based on the aerosol size exiting B5, which is approximately 3 μm
for ECG conditions. It is noted that full lung retention of an aerosol is
significantly influenced by both particle size and inhalation parameters. In vivo
studies of the full lung deposition of monodisperse stable 3 μm particles indicate
that retention may be less than 100% for different breathing parameters. For

146

example, the review article of Kim (2009) shows that the in vivo total lung
deposition fraction of a 3 μm aerosol with Q = 500 cm3/s and VT = 1000 cm3 is
approximately 60% based on a bolus delivery technique. One factor that may
contribute to the predicted high lung deposition values compared with previous in
vivo studies is that the approximate aerosol size of 3 μm is based on droplets
which have not deposited and exit B15. It is difficult to determine a representative
droplet size for predicting full lung deposition with ECG due to the combination
of both active growth and deposition in the airways. Figure 6.9 clearly shows that
the majority of deposited particles are greater than 3 μm and further analysis of
the data indicates a number of deposited 4 μm particles. Table 6.3 also shows that
the CFD predicted values for TB deposition are representative of, but greater than,
the corresponding correlation-based values using an average static inlet diameter.
Therefore, 3 μm may be a small approximate static size for comparing the
predictions of the current study with previously reported whole lung deposition
data. Further investigation is needed to better predict deposition in the alveolar
region and to approximate the total lung doses delivered with ECG. However, the
CFD predictions of TB deposition presented in this study are expected to be
accurate based on the extensive validations that have previously been performed
in terms of both aerosol size increase and deposition (Hindle and Longest 2010;
Longest and Hindle 2010).
In addition to significantly reducing MT deposition and enabling full lung
retention, results also illustrate the ability of ECG to target deposition within
regions of the TB airways. Specifically, increasing the ECG delivery temperature

147

from 37 to 39 ◦C approximately doubled the amount of drug mass deposited in
region B4–B7 (e.g., 4.7–9.2%). This increase was observed for both aerosol sizes.
Increasing both the delivery temperature and initial size increased deposition in
B8– B15 by a factor of 1.25 (e.g., 28.6–37.0%). In general, the initial size of the
aerosol (560 vs. 900 nm) had a minor influence on the final size and deposition
fraction. As observed by Longest et al. (2010), surrounding temperature and RH
conditions and not initial size generally control the final aerosol size achieved
with ECG delivery. However, the initial size may become a more significant
factor if hygroscopic effects are larger, for high number concentration aerosols,
and if shorter times are available for growth as may occur with targeted upper
airway delivery. The observed variations in TB deposition associated with ECG
initial conditions may be reduced in vivo due to variations in patient anatomy and
inhalation profiles. Furthermore, ECG does not provide a means to produce
highly localized targeted deposition, as may potentially be achieved with
magnetic aerosols (Xie et al. 2010).
In this study, an individual path model was used for the first time to
characterize flow field conditions and aerosol transport from the fourth
bifurcation to the end of the TB region. As indicated above, this approach is not
intended to fully resolve all pathways throughout the conducting airways. Instead,
it serves as a representative model for assessing transport and deposition. In future
analyses, it is proposed to use individual paths to stochastically characterize
transport and deposition within the bifurcations of each lung lobe. Randomly
generated individual path models can be simulated to create an ensemble of
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deposition efficiencies. Averages of these ensemble results can then be used to
quantify transport conditions and deposition fractions (branch-averaged and
highly localized) on a stochastic basis. However, a full characterization of the
entire TB tree was not necessary to achieve the objective of this study. In this
study, deposition efficiencies calculated from each branch of the individual path
model were used to estimate total deposition in the TB region. The fact that these
estimates were in general agreement with existing correlations for TB deposition
in vivo provided evidence that the individual path model approach is reasonable
and also supports the accuracy of the CFD predictions.
The predicted MT deposition of approximately 1–2% may initially appear
low considering that the typical aerosol size entering the trachea is 2 μm with
ECG conditions. Furthermore, the elliptical MT model is known to be a
representation of a more realistic geometry (Xi and Longest 2007b). The previous
study of Longest et al. (2008b) showed that 2 μm particles at a steady flow rate of
30 L/min resulted in a MT deposition of approximately 5%. Xi and Longest
(2007b) reported that the deposition of a 2 μm aerosol in the MT model at 30
L/min was approximately 10%. Several factors contributed to the observed
reduction in MT deposition in this study. First, droplet growth occurs
continuously, so the actual deposition is expected to be smaller than would occur
for the final aerosol size at the MT outlet. Second, the dual flow mouthpiece
centralized the aerosol and surrounded it with a layer of clean air. The previous
study of Longest and Oldham (2006) showed that reducing the aerosol inlet crosssectional area could significantly reduce aerosol deposition. The deposition results
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of Xi and Longest (2007b) are likely high for particles in the 1–2 μm size range,
because of the use of the k–ω turbulence model without an anisotropic correction,
as employed in the current study. However, the results of Xi and Longest (2007b)
did show very little difference in the MT total deposition values between a more
realistic geometry and the current elliptical model at 30 L/min, which provides a
justification for the use of the elliptical model. The low MT deposition values of
the current study are in good agreement with the experimental upper airway
results of Hindle and Longest (2010), which further supports the validity of the
current simulations. However, some differences between the in vitro data and
current results likely arise due to the factors described above, such as the
implementation of an initially monodisperse aerosol distribution with the CFD
model of this study.
Limitations of the current study are associated with the geometry
employed, simulation conditions, and numerical model. As previously discussed,
the MT and upper TB models implemented some simplifications to facilitate a
mathematically described geometry and allow for the use of more accurate
hexahedral meshes (Vinchurkar et al. 2009). Furthermore, wall motion of the
airways, particularly in the range of B15, may influence aerosol deposition. The
assumed rotation angle of 90◦ for successive bifurcations may also be an
overestimation of physiological conditions. The current model assumed steady
state flow, which may impact the transport and deposition of some near-wall
particles in the distal branches. The lobar ventilation rates were based on the
volume estimates of Horsfield et al (1971). More accurate representations may be
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available from numerical models (Asgharian and Price 2006; Asgharian et al.
2006), or for supine individual patients (Yin et al. 2010). Higher accuracy
representations of the turbulent laryngeal jet can be computed with more time
intensive models, such as direct numerical simulation and large eddy simulation
(Lin et al. 2007; Matida et al. 2006). However, our previous results indicate good
agreement between the LRN k–ω approximation with near-wall corrections and
experimental predictions of growth and deposition. In conclusion, ECG delivery
resulted in supersaturated RH fields throughout large portions of the TB airways.
Initial submicrometer aerosols were observed to increase in size to a target range
of 2–4 μm and evaporation of individual droplets was not evident. As a result,
ECG provides an effective method to virtually eliminate MT depositional losses,
and the associated intersubject variability, while providing for high TB deposition
and near full lung retention of the aerosol. Targeting drug deposition within
specific lung regions was also demonstrated. Future studies are needed to consider
the effects of unsteady flow, drug concentrations in the droplets, additional
individual path models for full TB characterization, and deposition in the alveolar
region with moving boundaries.
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Table 6.1.

All cases considered.
Aerosol inlet

Humidified air inlet

Case 1: control

Q: 9 L/min

Q: 20 L/min

non-evaporating

(150 cm3/s)

(333.3 cm3/s)

560 and 900 nm

T: 25 OC

T: 25 OC

RH: 97.5%

RH: 50%

Case 2: control

Q: 9 L/min

Q: 20 L/min

evaporating

(150 cm3/s)

(333.3 cm3/s)

560 and 900 nm

T: 25 OC

T: 25 OC

RH: 97.5%

RH: 50%

Case 3: ECG 1

Q: 9 L/min (150 cm3/s)

Q: 20 L/min (333.3 cm3/s)

560 and 900 nm

T: 39 OC

T: 39 OC

RH: 97.5%

RH: 100%

Case 4: ECG 2

Q: 9 L/min (150 cm3/s)

Q: 20 L/min (333.3 cm3/s)

560 and 900 nm

T: 42 OC

T: 42 OC

RH: 97.5%

RH: 100%
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Table 6.2.

Deposition efficiency (%) for each case.

Case 1: 560 nm

MT
1.65

Trachea-B3
0.44

B4-B7
1.46

B8-B15
2.49

900 nm

2.26

0.57

1.73

6.98

Case 2: 560 nm

1.35

0.46

1.45

2.47

900 nm

2.18

0.73

1.85

7.09

Case 3: 560 nm

0.92

0.69

4.70

28.57

900 nm

1.31

0.80

7.08

33.00

Case 4: 560 nm

0.90

0.81

9.19

35.36

900 nm

0.92

0.83

13.35

36.97

Table 6.3.

Stochastic analysis of deposition efficiency (%) for Case 4.

Case 4: 900 nm

MT

Trachea-B3

B4-B7

B8-B15

Path 1

0.92

0.83

13.35

36.97

Path 2

0.93

0.79

12.06

34.29

Path 3

0.91

0.80

14.46

34.72

Average

0.92

0.81

13.29

35.54

SD

0.0001

0.0002

0.0098

0.0119
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Table 6.4.

Comparison with existing TB correlations (DE).
Predicted DE TB

DE TB (Chan
and Lippmann
1980; Eq. 3)

0.04

DE TB
(Stahlhofen
et al. 1989;
Eq. 15)
0.01

0.01

0.09

0.03

0.03

Case 2: 560 nm 0.47

0.04

0.01

0.01

900 nm 0.74

0.09

0.02

0.02

Case 3: 560 nm 2.39

0.32

0.17

0.19

900 nm 2.58

0.38

0.20

0.22

Case 4: 560 nm 3.13

0.42

0.27

0.30

900 nm 3.28

0.46

0.30

0.32

MMAD at
the B5
outlet (µm)
Case 1: 560 nm 0.56
900 nm 0.9
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Table 6.5.

Predicted pulmonary and total deposition fractions.
DFtotal

0.06

DFalveolar
(Stahlhofen et
al.,1989; Eq. 19)
0.17

0.11

0.27

0.38

Case 2: 560 nm 0.57

0.06

0.17

0.23

900 nm 0.84

0.11

0.26

0.37

Case 3: 560 nm 2.00

0.33

0.50

0.83

900 nm 2.23

0.39

0.52

0.91

Case 4: 560 nm 2.89

0.42

0.54

0.96

900 nm 2.95

0.46

0.54

1

MMAD at the
B15 outlet (µm)
Case 1: 560 nm 0.56
900 nm 0.9

Predicted
DFMT-TB
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0.23

Figure 6.1.

Geometry used to evaluate the enhanced condensational growth
(ECG) delivery of submicrometer aerosol in the mouth-throat
(MT) and tracheaobronchial (TB) regions extending down a single
path to bifurcation 15 (B15) of the right lower lung lobe.
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Figure 6.2.

Computational mesh of the MT-TB airway model.
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Figure 6.3.

Comparison of aerosol deposition efficiency in the upper TB
airways between CFD predictions with the MT-TB geometry
considered in this study and the experimental results Zhou and
Cheng (2005) for a cast-based replica model.
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Figure 6.4.

Predicted temperature conditions for (a) Cases 1 and 2, (b) Case 3,
and (c) Case 4 conditions.
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Figure 6.5.

Predicted relative humidity (RH) conditions for (a) Cases 1 and 2,
(b) Case 3, and (c) Case 4 conditions.
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Figure 6.6.

Predicted droplet trajectories for initially 900 nm monodisperse
aerosols and (a) Case 2, (b) Case 3, and (c) Case 4 conditions.
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Figure 6.7.

CFD predictions of exiting polydisperse size distributions for
initially 560 nm and 900 nm monodisperse aerosols under Case 2-4
conditions.

162

Figure 6.8.

Comparisons of the mass median aerodynamic diameters (MMAD)
with the aerosol entering one branch of each bifurcation through
bifurcation 15 (B15) for Cases 2-4.
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Figure 6.9.

Comparisons of the mass median aerodynamic diameters (MMAD)
with the aerosol entering one branch of each bifurcation through
bifurcation 15 (B15) for Cases 3 and 4 with one-way and two-way
coupling.
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Figure 6.10.

Particle deposition locations and regional deposition efficiencies
(DE) of drug mass for an initially 900 nm aerosol and (a) Case 1,
(b) Case 2, (c) Case 3, and (d) Case 4 conditions.
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Figure 6.11.

Particle deposition locations and regional deposition efficiencies
(DE) of drug mass for an initially 900 nm aerosol with (a) Case 3
and two-way coupling and (b) Case 4 and two- way coupling.
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Figure 6.12.

Particle deposition locations and regional deposition efficiencies
(DE) of drug mass for an initially 900 nm aerosol and (a) Case 4
down path 2 vs. (b) Case 4 down path 3.
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Figure 6.13.

Comparison of deposition efficiencies (DE) for initially (a) 560
and (b) 900 nm droplets.
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Chapter 7.

Effects of Transient Inhalation on Enhanced Condensational

Growth (ECG) in a Realistic Mouth-Throat and Tracheobronchial
Single Path Model
7.1

Introduction

Previous results indicate the enhanced condensational growth (ECG) can
improve the delivery of pharmaceutical aerosols to the lungs based on steady
inhalation conditions in a realistic mouth-throat (MT) and tracheobronchial (TB)
single path model. However, transient inhalation will influence the transport,
growth, and deposition of droplet aerosols by modifying the (i) inertia of the
particles, (ii) the time available for growth, and (iii) the relative humidity (RH)
field. A more complete picture of aerosol growth and deposition in the MT-TB
single path model is needed.
The objective of this study is to evaluate the effect of a transient inhalation
waveform on the ECG delivery of respiratory aerosols, using the realistic MT-TB
single path model previously described in Chapter 6. CFD methods will be
employed to evaluate aerosol deposition and outlet particle sizes under transient
inhalation conditions. The CFD results will then be compared with steady
inhalation conditions to determine if steady state approximations are adequate, or
if more detailed transient simulations are needed.
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7.2

Methods

Transient Inhalation Waveform
The steady state inhalation flow rate considered in Chapter 6 is
approximately 30 L/min. In this chapter, one inhalation cycle (2 s inhalation and 2
s exhalation) with a breathing frequency (f) of 15 breaths/minute and a tidal
volume (VT) of 1 L/breath is considered. Using the format from the Chapter 3, the
transient inhalation waveform Q(t) (L/min) was approximated as the sinusoidal
function shown in Fig. 7.1 and represented as

Q(t)=47sin(0.5πt)

(7.1)

This waveform is equivalent to a steady state inhalation flow rate of 30 L/min
based on the Eqs. (5.1) and (5.3).

Boundary and Delivery Conditions
As in Chapter 6, a wall temperature of approximately 37 oC with a surface
RH of 99.5% was considered. The airflow and droplet inlet boundary conditions
employed in the CFD simulations are presented in Table 7.1. As shown in the
table, Case 3 from the Chapter 6 was considered under transient inhalation
conditions. In this case, an inlet temperature condition of 39 oC was selected for
both the aerosol and humidity streams. Monodisperse nebulized aerosol droplets
with initial diameters of 900 nm were simulated with a surrounding air phase RH
condition of 97.5% at a total flow rate of 9 L/min. The humidified air inlet stream
was generated with RH conditions of 100% at 20 L/min. The outlet flow
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distribution in the MT-TB model was consistent with the values reported by
Horsfield et al. (1971) at the exit of the third bifurcations.

Transport Equations in MT-TB Single Path Model
The low-Reynolds-number (LRN) k − ω model of Wilcox (1998) was
selected for simulating mixing of the delivery streams in the MT-TB single path
model because it has been shown to provide an accurate and numerically efficient
solution for laminar, transitional and turbulent flows. Furthermore, this model was
found to accurately predict aerosol transport and deposition in upper airway
models (Longest and Hindle 2009a; Longest et al. 2009). The coupled governing
equations of heat and mass transport were considered to evaluate the variable
temperature and RH fields in the MT-TB model. These transport equations were
previously reported in Longest and Xi (2008) and Longest et al. (2007). The
Lagrangian transport equations interconnected with user defined functions were
employed to calculate droplet trajectories, condensation, evaporation, deposition,
near-wall anisotropic turbulence correction (Longest et al. 2007), near-wall
particle interpolation (Longest and Xi 2007b), and Brownian motion (Longest and
Xi 2007b) in the complex three-dimensional temperature and humidity fields. The
discrete phase transport model includes the Kelvin effect, drug hygroscopicity,
and the effect of droplet temperature on surface vapor pressure.

Numerical Methods
To solve the transport governing equations, the CFD package Fluent 6.3,
(ANSYS Inc.) coupled with user defined functions was employed. All transport
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equations were discretized to be at least second order accurate in space. For the
convective terms, a third order QUICK scheme was used to interpolate values
from cell centers to nodes. The diffusion terms were discretized using central
differences. A segregated implicit solver was employed to evaluate the resulting
linear system of equations.

This solver uses the Gauss-Seidel method in

conjunction with an algebraic multigrid approach. The PISO algorithm was
employed to evaluate pressure-velocity coupling in the transient solutions. The
outer iteration procedure was stopped when the global mass residual had been
reduced from its original value by five orders of magnitude and when the
residual-reduction-rates for both mass and momentum were sufficiently small. To
ensure that a converged solution had been reached, residual and reduction rate
factors were decreased by an order of magnitude and the results were compared.
The stricter convergence criteria produced a negligible effect on both velocity and
particle deposition fields. To improve accuracy, all calculations were performed
in double precision. The computational mesh developed from the Chapter 6
composed of approximately 2.4×106 unstructured hexahedral elements and a very
fine near-wall grid and was constructed in Gambit 2.3.16 (ANSYS, Inc.).
Hexahedral meshing has been shown to provide a better quality solution in
aerosol deposition studies compared with tetrahedral and hybrid grids (Longest
and Vinchurkar 2007a; Vinchurkar and Longest 2008). Grid converged results
based on negligible change in the velocity and concentration fields (< 1%) as well
as negligible differences in the total deposition fractions (< 3%) were established
for a mesh consisting of 2.4×106 control volumes. In order to produce convergent
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aerosol deposition results, 1.2×105 initially 900 nm monodisperse droplets were
released at the aerosol inlet stream from 0-1 s during inhalation.

7.3

Results

Temperature Fields
Contours of temperature are shown for the MT, upper TB airways, and
selected medium and small TB airways in Fig. 7.2 for steady and transient
inhalation conditions. Temperature contours are presented as mid-plane slices
within each of the airway regions shown. For steady state conditions, rapid
cooling is observed in the MT with temperatures in the range of 37-39 ◦C in the
trachea. Temperatures of approximately 37 ◦C are observed in the B4-B7 and
B12-B15 regions. Temperature values at t=0.5 s were found to be similar with
steady state conditions. This similarity is likely because the inhalation flow rate at
t=0.5 s is near 30 L/min. Temperature values at t=2 s in the MT are less than the
values at t=0.5 s and steady state due to an decreased inhalation rate.

Relative Humidity
Predicted contours of RH for steady and transient conditions (t=0.5 and 2
s) are displayed for midplane and cross-sectional slices in Fig. 7.3. For steady
state conditions, rapid cooling of the saturated airstream results in a rapid
progression to supersaturation, with values as high as 101% observed in the
pharynx. RH values remain in the range of 100-101% through a majority of the
upper TB geometry and bifurcations B4-B7. In B12-B15, RH values are near wall
conditions of approximately 99.5%. Again, RH values at t=0.5 s were similar to
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those values found under steady state conditions. The increased RH values in the
MT from t=0.5 s to t= 2 s are likely because of the decreased temperature values
already discussed and can be expected to enhance aerosol growth.

Aerosol Transport and Growth
Comparisons of droplet size distributions at specific cross-sectional
locations for initially 900 nm monodisperse aerosols in the model between steady
and transient inhalation conditions are presented in Fig. 7.4 in terms of mass
fraction per micrometer of sampling bin size. Mass median aerodynamic
diameters (MMAD) values are also presented for each aerosol size distribution.
For steady state conditions, the MMADs of an initially 900 nm aerosol increased
to 1.88 µm at the trachea inlet and continued condensational growth was observed
with the aerosol exiting B5 with a predicted size of 2.58 µm. The MMAD of the
aerosol exiting B15 had decreased to 2.23 µm. This decrease in MMAD likely
arises from deposition of the larger particles as discussed in Chapter 6. For the
transient case, size increase was based on all particles crossing the planes of
interest from particle release at t = 0 s through t=2 s. For the transient simulation,
condensational growth was observed as droplets enter the trachea with a predicted
MMAD of 1.76 µm and continued with a predicted size of 2.42 µm at the exit of
B5. The MMAD of the aerosol exiting B15 had decreased to 2.23 µm. Size
distribution profiles indicate that 75-85% of the aerosol mass is associated with
droplets of approximately 3 μm exiting B5 and B15 under steady inhalation
conditions, but this has decreased to 55-60% in the same locations after 2s in the
transient case. This may be because the higher peak flows occurring in the
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transient case result in increased deposition of the larger particle sizes.
Interestingly, percent differences in MMADs for aerosols at specific locations are
less than approximately 2% between steady state and transient cases.
MMADs of the polydisperse aerosol entering each bifurcation (B1–B15)
are presented in Fig. 7.5 for steady and transient inhalation conditions. For both
conditions, significant growth is observed to occur through approximately B3.
Thereafter, minor growth is observed through approximately B8, and some size
decrease occurs between B8 and B15. This decrease may arise due to deposition
of the larger particles. Percent differences in MMADs for aerosols entering each
bifurcation were less than approximately 10% between steady and transient
inhalation conditions (t=2 s).

Aerosol Deposition
Particle deposition locations of individual droplets are illustrated for the
900 nm aerosol for steady and transient inhalation conditions in Fig. 7.6. The
droplets are colored based on their size at the time of deposition. Deposition
efficiencies were calculated for each bifurcation and then combined to represent
the total deposition efficiencies for the sections reported along the individual path.
For both inhalation conditions, the MT deposition efficiencies remain very small
(~1%) as observed by Hindle and Longest (2010). In contrast, deposition
efficiencies in Trachea-B3 are increased approximately 2 times compared with the
steady state conditions. Percent differences in DE between steady and transient
inhalation conditions in B4–B7 and B8–B15 are approximately 9% and 13%,
respectively. Predicted total DE of the TB airways under transient conditions is
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approximately 12% higher (relative difference) than the total DE under steady
state conditions.
To approximate whole lung retention of the aerosol, the predicted MT-TB
deposition fractions are combined with the alveolar deposition efficiency in vivobased correlations of Stahlhofen et al. (1989) and Chan and Lippmann (1980). An
inhalation rate of 500 cm3/s was employed along with a volume of 1500 cm3. As
observed from Table 7.2, total lung deposition fractions under steady and
transient inhalation conditions are 91% and 95%, respectively.

7.4

Discussion

In this study, a CFD model was used to evaluate the effect of a transient
inhalation waveform on the ECG delivery of respiratory aerosols, using the
realistic MT-TB single path model. The CFD model results were then compared
with steady inhalation conditions. Results of this study indicate that both steady
and transient conditions produce very little deposition and aerosol loss in the MT.
The drug deposition in the TB airways increased approximately 10% for transient
inhalation conditions. The low MT deposition values of the current study are in
good agreement with the experimental upper airway results of Hindle and Longest
(2010), which further supports the validity of the current simulations.
Limitations of the current study are associated with simulation conditions.
Constant wall temperatures consistent with mean body conditions were previously
assumed. The wall temperature of the upper respiratory airways is known to be
below average body temperature conditions.
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This change in wall surface

temperature will alter the RH surrounding the inhaled nanoparticles and modify
condensational growth rates.
A number of factors will affect targeted deposition to specific lung region
when the ECG approach is employed.

These include initial aerosol size,

temperature and humidity of the incoming air, hygroscopicity, inhalation flow rate
and the release time of the aerosol during the breathing cycle. Modifying the
release time of the aerosol, or bolus delivery, is a potentially useful method to
target deposition in the lungs. Coupling bolus release with ECG may provide the
control required for effectively targeting inhaled aerosols.
In conclusion, an ECG delivery approach under transient inhalation
conditions was shown to increase aerosol deposition in the TB airways by only a
small amount (relative difference of 12%), as compared with steady state
conditions. Future studies are needed to consider transient ECG aerosol delivery
under variable wall temperature conditions. The influence of inhalation flow rate,
saturated air temperature, and release time of the aerosol also need to be
considered.
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Table 7.1.

900 nm

Inlet conditions considered.
Aerosol inlet

Humidified air inlet

Q: 9 L/min (150 cm3/s)

Q: 20 L/min (333.3 cm3/s)

T: 39 OC

T: 39 OC

RH: 97.5%

RH: 100%
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Table 7.2.

Pulmonary and total deposition fractions.

Steady state

MMAD at the
B15 outlet
(µm)
2.23

t=2 s

2.24

Predicted DFMT-TB
0.39

DFalveolar
(Stahlhofen et al.,
1989; Eq. 19)
0.52

0.91

0.43

0.52

0.95
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DFtotal

Figure 7.1.

Transient inhalation waveform.
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Figure 7.2.

Predicted temperature conditions for (a) steady state, (b) t=0.5 s ,
and (c) t=2 s.
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Figure 7.3.

Predicted relative humidity (RH) conditions for (a) steady state,
(b) t=0.5 s, and (c)

t=2 s.
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Figure 7.4.

CFD predictions of exiting polydisperse size distributions for
initially 900 nm monodisperse aerosol during (a) steady state and
(b) transient inhalation (t=2 s).
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Figure 7.5.

Comparisons of the mass median aerodynamic diameters (MMAD)
with the aerosol entering one branch of each bifurcation through
bifurcation 15 (B15) for steady and transient inhalation conditions
(t=2 s).

184

Figure 7.6.

Particle deposition locations and regional deposition efficiencies
(DE) of drug mass for an initially 900 nm aerosol for (a) steady
state and (b) transient inhalation (t=2s).
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Chapter 8.

Effects of Inhalation Profiles on the Deposition of MDI and

DPI Generated Aerosols in a Representative Model of the Mouth-Throat
and Tracheobronchial Airways
8.1

Introduction

A number of recent studies have reported deposition in model geometries
of the upper tracheobronchial (TB) airways for environmental and pharmaceutical
aerosols (Kleinstreuer and Zhang 2009; Liu et al. 2007; Xi and Longest 2008b; Xi
et al. 2008; Zhang et al. 2005; Zhang et al. 2009). Other studies have focused on
the deposition of pharmaceutical aerosols from metered dose inhalers (MDIs) and
dry powder inhalers (DPIs) in the MT models (Kleinstreuer et al. 2007; Longest
and Hindle 2009a; Longest and Hindle 2009b; Longest et al. 2009; Longest et al.
2007; Longest et al. 2008a; Longest et al. 2008b). For current MDIs,
approximately 25-60% of drug is lost in the mouth-throat (MT), and for current
DPIs, MT deposition is approximately 70% (Cheng et al. 2001; Longest et al.
2008a; Zhang et al. 2007). CFD studies of inhaler performance have highlighted
the underlying causes of large MT deposition as high spray momentum for MDIs
(Longest et al. 2008a; Longest et al. 2008b) and large jet effects for DPIs
(DeHaan and Finlay 2004). Current studies have also highlighted the significant
size change of MDI droplets (Longest et al. 2008a). Considering the substantial
loss of drug, system complexity, and the associated variability in lung dose, a
better understanding of MDI and DPI delivery in the MT and upper
tracheobronchial (TB) airways is needed.

The objective of this study is to

develop a CFD model of orally inhaled drug products that can account for inhaler
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attributes (spray or jet momentum), physicochemical properties (polydisperse
aerodynamic size distribution), and physiological parameters (breathing pattern,
airway geometry) in determining local and regional deposition in a realistic MT
and TB model of the upper airways.

8.2

Methods

Upper MT-TB Geometries
In this study, MT and TB deposition will be evaluated for two
representative inhalers. The MT geometry is the elliptical model developed by Xi
and Longest (2007b) and the upper TB airways are considered extending from the
trachea to the third bifurcation (B3). This asymmetrical model was generated
using the anatomical cast dimensions reported by Yeh and Schum (1980) and
scaled to a functional residual capacity (FRC) of 3.5 L, which is consistent with
an adult male (ICRP 1994). Further details of the upper TB model are provided in
the Chapter 6. For the current study, cartilaginous rings were added to the trachea
of the TB geometry and a crescent-shaped or D-shaped tracheal cross section was
adapted. Both of these features are expected to influence deposition and are
intended to improve the realism of the model. Crescent-shaped tracheal crosssections arise due to pressure from the esophagus. This distortion may change
depending on the position of the subject (supine, prone, standing) and may also be
different during inhalation vs. exhalation.

As a general approximation, one-

quarter of the tracheal cross-section was assumed to be compressed into a flat
profile, which is consistent with in-house medical scans.

The cadaver

measurements of Russo et al. (2008) were used to include the effects of the
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cartilaginous rings on the tracheal geometry. Thirteen rings, spaced 2.98 mm
apart, were included protruding into the trachea by a distance of 0.254 mm. A
sinusoidal wave was used to approximate the effect of the ring impressions on the
soft tissue. The thickness of the rings was 3.21 mm, except near the top of the
trachea, where the thickness was 3.07 mm for two of the rings. This was done to
allow the rings to fit without altering the geometry of the existing MT.
The elliptical MT model of Xi and Longest (2007b) was modified to fit both
the MDI and DPI devices selected for this study. For the MDI, the entire actuator
was modeled to better assess the mixing of inhaled air with the spray exiting the
nozzle. Based on measurements, the nozzle through which the spray enters the
actuator was included with a 0.5 mm diameter (Fig. 8.1a). For the DPI, inner
surfaces of the inhalers from the point of aerosol formation to the inlet of the MT
were included. These internal surfaces include the 3 mm jet through which the
aerosol enters the mouthpiece, two 0.5 mm jets, and the inner surface of the
mouthpiece (Fig. 8.1b). The MT geometry of Xi and Longest (2007b) is based on
a mouth opening of 22 mm. The MDI mouthpiece has a top to bottom outer
diameter of 16 mm, which was judged sufficiently close to the mouth opening of
the current model. As a result, modification of the current MT oral cavity was not
made and the inhaler was directly connected to the model. For the DPI, the
mouthpiece has a leading edge height of 12 mm. To account for this more closed
mouth position, the top and bottom profiles of the oral cavity were moved inward
5 mm. The inhaler was then connected to this reduced volume oral cavity. The
pharynx and larynx regions of the MT model were not altered. The resulting MT
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volumes for the MDI and DPI MT geometries were 57.7 and 55.0 cm3,
respectively.

Hollow Models of Upper MT-TB Geometries
For the in-vitro deposition experiments, hollow models of the upper MT-TB
geometries with rings included were fabricated using solid modeling software
(Gambit 2.6 and SolidWorks) and a rapid prototyping process. To improve
comparisons between the in-vitro results and CFD predictions, and to better
validate the CFD model, a sectioned upper MT-TB geometry was created. The
four sections of the geometry are MT, trachea, and upper left and right lung
bronchi.

Inhalers
In this study, aerosol deposition will be evaluated for two representative
inhalers, both delivering the same corticosteroid, in a MT and upper TB model.
For the MDI, the model inhaler considered is the Flovent HFA produced by GSK
delivering fluticasone proprionate as a suspension in a HFA 134a formulation.
The DPI model is the Flovent Diskus (GSK) delivering fluticasone proprionate as
a powder aerosol. The computational models developed in this study can be
applied to any MDI, DPI or Nebulizer. However, specific inhalers are required to
effectively evaluate MT deposition and validate the model. An investigation of
the initial aerosol size distribution was conducted in Dr. Hindle's lab. The size
distribution of the drug aerosol emitted from the Flovent HFA MDI was
determined using the next generation impactor (NGI) operated at a constant flow
189

rate of 37 L/min. The Flovent Diskus DPI was sampled directly into a NGI with a
square wave inhalation profile and a flow rate of 75 L/min.

Inhalation Waveforms
The inhalation waveforms used by patients with different inhalers and
even the same inhaler are highly variable (Byron et al. 2010; Delvadia et al. 2010;
Marielle et al. 2003; Meijer et al. 1996; Persson et al. 1997). In this study, two
representative waveforms were approximated for healthy subjects based on the
existing data. Waveforms representative of "inhale slowly and deeply" (SD) and
"inhale quickly and deeply" (QD) were developed from existing data (Byron et al.
2010; Delvadia et al. 2010; Marielle et al. 2003; Meijer et al. 1996; Persson et al.
1997). These SD and QD profiles are intended to represent correct usage of the
Flovent MDI and Flovent Diskus DPI, respectively.

Considering these two

waveforms in both of the inhalers provides a measure of patient waveform
variability and its effect on transport and deposition.
Common characteristics among studies reporting waveform characteristics
with inhalers are a nearly linear acceleration to peak flow followed by a
sinusoidal pattern during deceleration (Byron et al. 2010; Delvadia et al. 2010;
Marielle et al. 2003; Meijer et al. 1996; Persson et al. 1997). Furthermore, the
peak inhalation flow rate (PIFR) typically occurs during the first 1/6 to 1/4 of the
inhalation period. Equations describing this waveform pattern and developed for
this study are

Q(t ) =

PIFR
t
TPIFR

0 ≤ t ≤ TPIFR

(8.1)
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⎛ 2π (t − TPIFR )
Q(t ) = PIFR cos ⎜⎜
⎝ 4 (1 − TFPIFR ) T

⎞
⎟⎟
⎠

(8.2)

T

1
Q = ∫ Q(t )dt
T 0

(8.3)

where all parameters are defined in Table 8.1. To describe the SD and QD
waveforms, inhalation volume and mean inhalation flow rate need to be set. The
remaining parameters are then derived from the waveform shape. In this study,
deep inhalation is represented by a 3L inhaled volume. This value is consistent
with the study of Broeders et al. (2003), who report an approximate 3L inhalation
volume with the use of both an MDI and DPI (Diskus) for stable asthmatic and
mild to moderate COPD patients. The mean inhalation flow rate was also a
defined parameter to allow for comparisons between steady state and transient
deposition results. A mean inhalation flow rate of 37 L/min was selected for the
SD profile, as a typical value for MDI steady state testing. A mean inhalation
flow rate of 75 L/min (which is approximately twice the SD value) was selected
to represent QD inspiration. Based on observations from reported waveforms as
described above, the time fractions to peak inhalation flow rate (TFPIFR) for the
SD and QD waveforms was 1/4 and 1/6, respectively. Equations to find the
remaining inhalation parameters are shown below.
PIFR [ L / min ] × TPIFR
2 × 60

T [s] =

T

+

∫

TPIFR

⎛ 2π (t − TPIFR )
PIFR
cos ⎜⎜
60
⎝ 4 (1 − TFPIFR ) T

60V [ L ]

⎞
⎟⎟ dt = V [ L ]
⎠

(8.4)

(8.5)

Q [ L / min ]
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Results from solving these equations for the SD and QD parameters are reported
in Table 8.2. The resulting PIFRs for the SD and QD profiles are 61.4 L/min and
122.2 L/min, respectively. The SD and QD waveforms are shown in Fig. 8.2.
Considering the MDI, the typical recommended PIFR for correct usage is between
25 and 90 L/min (Broeders et al. 2003). Furthermore, Ross and Schultz (1996)
showed that inhalation flow rate had little effect on MDI drug delivery. The PIFR
of the MDI (i.e., 61.4 L/min) is approximately in the middle of the recommended
range and therefore a representative approximation of correct usage. For the
Diskus DPI, Broeders et al. (2003) observed a characteristic PIFR of
approximately 120 L/min after training among 42 patients with stable asthma and
mild to moderate COPD. Van der Palen (2003) observed an average PIFR of 118
L/min for Diskus among 50 patients that received medication for asthma and
COPD. Byron et al. (2010) reported a PIFR of approximately 120 L/min for a
single healthy subject with a Novolizer DPI, which has a similar resistance
compared with the Diskus. As a result, the PIFR of the Diskus appears consistent
with literature data for both healthy and asthmatic/COPD patients.

CFD Simulations
Based on Reynolds number conditions, laminar through fully turbulent
flow is expected in the upper airway model. To resolve these multiple flow
regimes, the low Reynolds number (LRN) k-ω model will be implemented based
on its ability to accurately predict pressure drop, velocity profiles, and shear stress
for transitional and turbulent flows on a transient basis (Ghalichi et al. 1998;
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Wilcox 1998) as well as particle deposition profiles (Longest and Vinchurkar
2007b). The Reynolds-averaged equations governing the conservation of mass
and momentum were previously reported by Longest et al. (2006). Simulations of
thermal energy and water vapor transport, along with the laminar and turbulent
governing equations, were previously described (Longest and Hindle 2010;
Longest and Xi 2008). For the MDI simulations, the firing process induces
significant spray momentum that affects the aerosol and surrounding flow field.
The resulting transport conditions are locally supersonic near the nozzle and
compressible. As a result, the individual species of air and water vapor were
assumed to behave as ideal gases. For the DPI simulations, an incompressible
flow field was assumed.
The Lagrangian transport equations governing particle motion in the upper
airways were solved using Fluent 12. Our previous validation case studies have
indicated that this CFD algorithm produces an effective solution for aerosol
transport and deposition results provided that a number of user-defined
enhancements and corrections are supplied.

These user-defined supplements

include (i) a correction for near-wall anisotropic turbulence (Longest et al. 2007),
(ii) a correction for the Brownian motion routine (Longest and Xi 2007b), and (iii)
a modification for near-wall interpolation of particle locations (Longest and Xi
2007b).

In order to produce convergent deposition results for all particle sizes

considered with the MDI inhaler, a total of 72000 particles were released over 0.2
seconds. For the DPI inhaler, a total of 36000 particles were released over 0.5
seconds. The experimentally determined initial droplet distributions were used in

193

the CFD simulations. Doubling the number of droplets considered had a
negligible impact on both total and sectional deposition results.
Model Validation
CFD simulations of aerosol deposition for the MDI and DPI inhalers are
compared to the in vitro experimental results in Fig. 8.3. The simulations were
conducted to be as similar to the in vitro experiments as possible. For the MDI
simulation, an airflow of 37 L/min was established through the actuator before the
inhaler was fired with an aerosol generation time of 0.2 s. For the DPI simulation,
a square inhalation waveform was implemented with a mean of 75 L/min. The
aerosol was released over the course of the first 0.5 s, consistent with the
experiments.
Results indicate that the CFD model predictions match the in vitro
experiments to a high degree. Differences in the MT deposition between the
model and experiments remain below 7%, which is very good considering the
complexity of the system.

Due to the presence of significant turbulence,

deposition of multiple particle sizes is observed throughout the geometry.
The MDI inhaler demonstrates less MT deposition than the DPI. However,
when the MDI actuator fraction is added with the MT loss, the amount of wasted
dose is similar between the inhalers. The DPI delivers approximately 4 times
more dose to the TB section under square waveform inhalation conditions. This
increase in deposition is clearly beneficial for bronchodilators, but is undesirable
for medicines targeted to the alveolar airways.
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8.3

Results

Velocity Fields in the Upper MT-TB Model
Velocity fields in the MDI and DPI from the CFD simulations for SD and
QD waveforms at selected times are displayed in Figs. 8.4-6. Midplane and
cross-sectional slices of velocity magnitude and velocity vectors are shown.
Times considered for each waveform are mean accelerating flow (Ta-mean), peak
inspiratory flow (TPIFR), and mean decelerating flow (Td-mean), as shown in Fig.
8.2. Flow conditions from the MDI simulations for SD and QD at Ta-mean are
shown in Figs. 8.4a and c, respectively. The activation of the inhaler and resulting
spray exiting the nozzle creates a significant source of momentum in the flow
field. As a result, high velocity and turbulent flow is induced. Under QD
conditions for the MDI, the momentum continues to increase and propagates
quickly through the flow field, creating further flow disruption at t=TPIFR (Fig.
8.5c), while the momentum change has dispersed at Td-mean (Fig. 8.6c) due to the
completion of the activation. Similarly for the SD conditions, momentum near the
MT inlet has dispersed at t=TPIFR and Td-mean (Fig. 8.5a and 8.6a). For the DPI,
significant flow disruption and a high velocity jet flow were observed in the
region near the MT inlet (Fig. 8.4b and d). At t= TPIFR, the jet velocity increases
due to acceleration (Fig. 8.5b and d). At t= Td-mean, the jet velocity decreases due
to deceleration (Fig. 8.6b and d).
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Transient MDI Drug Deposition in the Upper MT-TB Model
Figure 8.7 illustrates transient MDI simulation results for the SD and QD
waveforms. The SD waveform is considered to be the correct usage for the MDI
and has a mean flow rate of 37 L/min.

In contrast, the QD waveform is

considered incorrect use of the MDI with a mean flow rate of 75 L/min. Inhaler
deposition is markedly reduced and TB deposition is increased for both transient
waveforms compared with steady state conditions (Fig. 8.7 vs. Fig. 8.3). The
correct usage of the MDI (SD waveform) results in approximately 10% lower MT
deposition and 2% more TB deposition than with the QD inhalation. These
differences are likely small compared with expected intersubject variability.
Therefore, it is concluded that the MDI device is not largely sensitive to the
transient inhalation waveform employed.

Transient DPI Drug Deposition in the Upper MT-TB Model
Transient SD and QD waveforms results for the DPI are illustrated in Fig.
8.8. For the DPI, QD inhalation is preferred and SD inhalation can be considered
incorrect.

As expected, the QD results are the most similar to the square

inhalation waveform because both had a mean flow rate of 75 L/min. However,
reducing the mean flow rate to 37 L/min with the SD waveform only reduced MT
deposition by 2% and upper TB deposition by 1%. Compared with the MDI SD
and QD cases, the DPI inhaler delivered less aerosol to the upper TB region. This
is surprising because with the square inhalation waveform validation case (Fig.
8.3), the DPI delivered more drug dose to the TB airways. As a result, it appears
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very important to consider the transient inhalation waveform when assessing
aerosol deposition in the MT and upper TB airways, especially for MDI devices.

8.4

Discussion

In this study, a CFD model was developed to evaluate aerosol deposition
for the MDI and DPI inhalers in a realistic MT and upper TB model. Variations in
breathing profiles were considered using SD and QD conditions, based in part on
common characteristics among the reported waveforms. The CFD results were
then compared with in vitro results. Results of this study indicate that the CFD
model predictions match the in vitro experiments to a high degree. The DPI
delivers approximately 4 times more dose to the TB section under square
waveform inhalation conditions compared with MDI delivery under steady state
inhalation conditions. The CFD results also indicate that it is critical to consider
transient inhalation effects when assessing aerosol deposition, especially for MDI
devices.
This current study only considered transport and deposition in the upper
airways. However, transport and deposition in the medium and small TB airways
should be also evaluated to better understand differences in MDI and DPI delivery
to the lung under correct and incorrect inhalation profiles.
In conclusion, this study has demonstrated that transient inhalation can
significantly influence the transport and deposition of aerosol in the upper airways,
especially for MDI devices.

Future studies are needed to consider aerosol

deposition in the lower airways under both steady and transient conditions.
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Table 8.1.

Parameters describing transient inhalation waveforms.

Parameter
PIFR
Q(t)

Units
L/min
L/min
L/min

Description
Peak inspiratory flow rate
Transient inspiratory flow rate
Mean inhalation flow rate

Ta-mean
TPIFR
Td-mean

s
s
s
s

Period of inhalation
Time to mean inhalation flow rate during acceleration
Time to peak inhalation flow rate
Time to mean inhalation flow rate during deceleration

TFPIFR

--

V

L

Time fraction of peak inspiratory flow rate to total
inhalation period (T)
Total volume inhaled

Q
T

Table 8.2.

Waveform parameters for the QD and SD profiles.

Parameters
PIFR [L/min]

Q [L/min]

QD Profile
122.2
75

SD Profile
61.4
37

T [s]
Ta-mean [s]
TPIFR [s]
Td-mean [s]
TFPIFR
V [L]

2.40
0.25
0.4
1.56
1/6
3

4.86
0.73
1.22
3.38
1/4
3
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Figure 8.1.

Upper MT-TB geometries for testing drug aerosol deposition
connected to the (a) Flovent MDI and (b) Flovent Diskus DPI.
The MDI model includes a narrow air passage between the
actuator body and canister and a 0.5 mm nozzle for the
introduction of the propellant and particles/droplets. The DPI
model includes a 5 mm jet for the introduction of the drug powder
and airflow, two 0.5 mm jets, which are consistent with the Flovent
Diskus Inhaler, as well as the inner surface of the mouthpiece.
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Figure 8.2.

Inhalation waveforms for SD and QD waveforms.
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Figure 8.3.

Comparison of experimental (exp) and simulated deposition results
with steady state and square waveform inhalation flow conditions
for the (a) MDI at 37 L/min and (b) DPI at 75 L/min. The CFD
predictions are shown to match the in vitro results to a high degree.
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Figure 8.4.

Velocity vectors and contours for SD and QD waveforms
at t= Ta-mean.
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Figure 8.5.

Velocity vectors and contours for SD and QD waveforms
at t=TPIFR.
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Figure 8.6.

Velocity vectors and contours for SD and QD waveforms
at t= Td-mean.
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Figure 8.7.

CFD predicted results of MDI deposition in the MT-TB model for
(a) SD and (b) QD inhalation waveforms. Deposition results are
similar between the two inhalations. However, significant
differences are observed between the transient inhalation, shown
here, and steady state conditions shown in Figure 8.3.
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Figure 8.8.

CFD predicted results of DPI deposition in the MT-TB model for
(a) SD and (b) QD inhalation waveforms. Deposition results are
similar between the two inhalations. Furthermore, deposition
appears similar between the transient inhalation, shown here, and
square wave conditions shown in Figure 8.3.
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Chapter 9.

Development of a Stochastic Individual Path Model for

Assessing Pharmaceutical Aerosol Deposition: Effects of Transient
Inhalation Waveform and Sampling the Tracheobronchial Airways
9.1

Introduction

In Chapter 8 the deposition of pharmaceutical aerosols from metered dose
inhalers (MDIs) and dry powder inhalers (DPIs) was reported in a realistic mouththroat (MT) and upper tracheobronchial (TB) model extending to the third
respiratory bifurcation (B3). However, conditions beyond B3, where deposition is
expected to be the highest, were not considered. Lin et al. (2009) reported a
coupled 3-D and 1-D lung transport model that mimicked the entire TB region on
a patient specific basis. However,1-D models do not provide information about
aerosol distributions at the level of individual bifurcations. Koblinger and
Hofmann (1990) introduced the idea of a Monte Carlo lung simulation approach
in which paths down the airway tree were generated at random and used 1-D
algebraic predictions of lung deposition. Depositions within these "individual
paths" were used to build a representation of deposition within the lung. This
approach is applied in this study for 3-D CFD modeling and termed stochastic
individual path (SIP) modeling.
The objective of this study is to evaluate the effects of steady state vs. a
transient waveform on transport and deposition of pharmaceutical aerosols from a
DPI within the right lower lung lobe using the SIP modeling approach.
Deposition variability among different SIP paths in the right lower lung lobe will
also be assessed. The transient QD waveform, consistent with patient instructions
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to "inhale quickly and deeply" (previously developed in Chapter 8) is
implimented. The transient QD results will then be compared with steady state
(SS) conditions to determine if steady state approximations are adequate, or if
more detailed transient simulations are needed. Deposition within multiple SIP
paths is also assessed.

9.2

Methods

DPI MT-TB SIP Geometry
In this study, deposition in the lower TB airways will be evaluated for the
DPI. For this inhaler, inner surfaces of the device from the point of aerosol
formation to the inlet of the MT were included. These internal surfaces include
the 3 mm jet through which the aerosol enters the mouthpiece, two 0.5 mm jets,
and the inner surface of the mouthpiece (Fig. 9.1). The upper MT-TB geometry
previously developed in the Chapter 8 was used. Beyond the third bifurcation,
three individual paths of the right lower lung lobe are considered in which one
branch of each bifurcation is continued and one is not (Fig. 9.1). This approach
allows for upstream effects of the flow field and drug aerosol profile to be fully
integrated in a highly efficient manner. Furthermore, use of the individual path
model based on PRB units allows for the application of a hexahedral mesh, which
improves solution accuracy, and an adequate number of computational cells to
fully resolve the flow domain (Longest and Vinchurkar 2007a; Vinchurkar and
Longest 2008). Bifurcations within the model are constructed as PRB units with
the dimensions of Yeh and Schum (1980), scaled to an adult FRC of 3.5 L. Based
on available data, the bifurcations in the individual path model are symmetric and
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include a symmetric outflow assumption. At each bifurcation, continuation of the
left or right branch is selected at random. However, if the selection leads out of
the general region of the particular lung lobe, the other branch is selected.
Consecutive branches are rotated at 90o to approximate physiological conditions.
This individual path model is not intended to exactly mimic a specific connection
of bronchi in a patient specific model. Instead, it is intended to provide an
effective 3-D representation of transport and deposition in the medium and small
TB airways. Branch 15 is assumed to end with the terminal bronchioles, based on
existing anatomical data (Weibel 1963; Yeh and Schum 1980).

Stochastic Individual Path (SIP) Modeling
Koblinger and Hofmann (1990) proposed a Monte Carlo approach to
simulating deposition throughout the airways using a 1-D algebraic model. In this
method, an individual path is selected at random down the TB tree. Deposition is
then calculated in this simulated path using algebraic correlations. Additional
paths and deposition fractions are then calculated and an average deposition
fraction is estimated on a regional and local basis. Once a sufficient number of
paths have been simulated, the deposition fraction converges. In this study, paths
are selected to remain in the general region of the right lower lung-lobe, based on
the lobar position taken from CT scans. Three paths are shown in Fig. 9.1 and
considered to provide convergent local and regional deposition fractions.
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CFD Simulations
The low-Reynolds-number (LRN) k − ω model of Wilcox (1998) was
selected for simulating flow regimes in the MT-TB SIP model because it has been
shown to provide an accurate and numerically efficient solution for laminar,
transitional and turbulent flows. Furthermore, this model was found to accurately
predict aerosol transport and deposition in the airway models (Longest and Hindle
2009a; Longest et al. 2009). The Lagrangian transport equations interconnected
with user defined functions were employed to calculate deposition, near-wall
anisotropic turbulence correction (Longest et al. 2007), near-wall particle
interpolation (Longest and Xi 2007b), and Brownian motion (Longest and Xi
2007b). In order to produce convergent deposition results for all particle sizes
considered and the DPI inhaler, total of 36000 particles were released over 0.5
seconds. Experimentally determined initial droplet distributions were used in the
CFD simulations. Doubling the number of droplets considered had a negligible
impact on both total and sectional deposition results.
Model Validation
CFD simulations of aerosol deposition for the DPI inhaler in the upper
airways are compared to the in vitro experimental results in Fig. 9.2. These
results were presented in Chapter 8, but are repeated here for completeness and
discussed in more detail. The simulations were conducted to be as similar to the
in vitro experiments as possible. For the DPI simulation, a square inhalation
waveform was implemented with a mean flow rate of 75 L/min. The aerosol was
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released over the course of the first 0.5 s, consistent with experimental
observations. Results indicate that the CFD model predictions match the in vitro
experiments to a high degree. Differences in deposition fraction (DF) values in
the MT between the model and experiments remain below 7%, which is very
good considering the complexity of the system. Due to the presence of significant
turbulence, deposition of multiple particle sizes is observed throughout the
geometry.

It was necessary to simulate the square waveform used in the

experiments to match the in vitro deposition data. Use of steady state conditions
over-predicted the experimental deposition values by an unacceptable amount.

Outlet Distributions and Flow Profiles for use as Inputs in SIP models
The geometry consists of the MT region, upper TB airways (Trachea-B3)
and the middle/lower TB airways (B4-B15). Stochastic individual path (SIP)
modeling will be employed to simulate DPI deposition in the middle and lower
TB airways (B4-B15). A sufficient number of paths will be considered in each
lobe to provide convergent local and regional deposition fractions. Therefore, an
interpolation routine is needed to reduce computing time. Specifically, flow and
particle outlet conditions from the B3 outlet were used as inlet conditions for the
SIP model. The necessary interpolation modules have been developed and are
proven effective in Fig. 9.3. Specifically, the algorithm for the flow field
interpolation is the following:
1. Read data from each face in the outlet boundary zone.
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2. Store and write flow variables at each face to a data file at the end of each
time step.
3. According to the coordinates, allocate these values to the faces in the inlet
boundary zone.
Note that
1. Face (grid) size in the inlet boundary zone must be same as the previous
outlet boundary zone.
2. Time step size and number of time steps in the current simulation must be
same as the previous simulation.
The algorithm for the particle interpolation is the following:
1. Store and write particle data from the outlet boundary zone.
2. Read and assign these data onto the inlet boundary zone.

9.3

Results

DPI Drug Deposition in the MT and Upper TB Airways
Deposition results for the steady state and transient QD waveforms and the
DPI are illustrated in Fig. 9.4. It is observed that deposition fraction (DF) values
in the upper airways for the QD conditions are significantly different from steady
state conditions. Deposition fraction values are approximately 25% (relative
difference) less in the MT region and approximately 100% (relative difference)
higher in the upper TB airways for the QD conditions compared with steady state
conditions. As a result, it appears very important to consider the transient
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inhalation waveform when assessing deposition values in the upper airways, as
observed in Chapter 8.

DPI Drug Deposition in the Individual Paths of the Right Lower Lung Lobe
Deposition locations of polydisperse aerosols in the lower TB airways are
illustrated for three SIPs with SS and QD conditions in Fig. 9.5. The aerosols are
colored based on their size at time of deposition. Deposition efficiencies were
calculated for each bifurcation and then combined (e.g., Eq. (6.3)) to represent the
total deposition efficiencies (DE) for the sections reported along the three
individual paths. It is observed that DE values in both the B4-B7 and B8-B15
sections are slightly higher under QD conditions than the values under SS
conditions. However, the maximum total difference was less than 2% for all
cases considered. Furthermore, large size particles (> 9 μm) deposited in B4-B7
under QD conditions were more densely populated than under SS conditions. This
is likely due to higher flow rates associated with the QD waveform compared
with the SS case.
Fig. 9.6 compares the mean deposition efficiencies of polydisperse
aerosols in the trachea-B3, B4-B7, B8-B15, and total TB airways between SS and
QD conditions. The mean values were computed across the three SIP models
considered and the error bars in the figure represent standard deviations. The
predictions under SS conditions match the QD results well. The percentage
differences in deposition efficiency between SS and QD conditions in the
Trachea-B3, B4-B7, and B8-B15 are 10%, 8%, and 3%, respectively. To calculate
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the total DE of the TB region from the CFD predictions, the deposition
efficiencies of each bifurcation were combined from B1-B15 (e.g., Eq. (6.3)).
The relative difference in the total DE between SS and QD conditions is
approximately 8%.
The mean deposition efficiencies of polydisperse aerosols are illustrated in
Fig. 9.7 for each bifurcation of 3 SIPs between SS and QD conditions. The SS
results produced an excellent agreement with the QD results, especially between
B9 and B15. It is observed that deposition efficiency increases through B6, and
decreases between B6 and B15. A complete description of deposition efficiencies
for SS and QD conditions are reported for each bifurcation in Tables 9.1 and 9.2.

9.4

Discussion

In this study, the effects of transient vs. steady state flow fields on the
transport and deposition of pharmaceutical aerosols from a DPI were evaluated
within the right lower lung lobe using the SIP modeling approach. The transient
results were compared with steady state (SS) conditions and variability in the
results across three SIP models was assessed. Results indicate that steady state
approximations are adequate (within a total difference of 2%) to predict
deposition efficiencies in the TB airways. Therefore, a steady state inhalation
approximation can be used to evaluate deposition in the SIP model. Furthermore,
deposition estimates changed very little between the three SIP models considered
with maximum total differences of approximately 2% for the regions considered.
Therefore, it also seems reasonable that deposition within a lobe lung can be
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estimated using a single SIP geometry. However, this finding only holds true
when considering averaged regions such as B4-B7, B8-B15 and the total TB
airways in a single lobe, as assessed in this study.
The current study only considered transport and deposition in the right
lower lung lobe. However, transport and deposition values in the right upper, right
middle, left upper, and left lower lung lobes are needed to better predict total TB,
alveolar regional, and whole lung deposition.
In conclusion, this study has demonstrated that steady state inhalation can
be used to predict deposition efficiencies in the TB airways using SIP model and
that a single SIP model can be used to assess deposition within a single lobe.
Future studies are needed to generate SIP models in each lung lobe.
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Table 9.1.

Deposition efficiency under QD conditions for 3 SIP models.

QD
B4
B5
B6
B7
B8
B9
B10
B11
B12
B13
B14
B15

SIP 1 (%)
2.78
3.42
4.01
3.63
2.18
2.05
1.48
1.39
1.34
0.94
0.81
0.63

Table 9.2.

Deposition efficiency under steady state (SS) conditions for 3 SIP

SIP 2 (%)
2.64
3.06
3.48
3.23
3.1
2.72
1.34
1.25
1.07
0.72
0.72
0.54

SIP 3 (%)
1.93
3.06
3.06
2.73
2.6
1.59
1.47
1.21
0.95
0.74
0.61
0.44

Mean (%)
2.45
3.18
3.52
3.20
2.63
2.12
1.43
1.28
1.12
0.80
0.71
0.54

SD (%)
0.37
0.17
0.39
0.37
0.38
0.46
0.06
0.08
0.16
0.01
0.08
0.08

models.
SS
B4
B5
B6
B7
B8
B9
B10
B11
B12
B13
B14
B15

SIP 1 (%)
2.30
3.16
3.65
3.16
2.05
1.92
1.42
1.29
1.16
0.91
0.78
0.52

SIP 2 (%)
1.79
2.91
3.40
3.15
2.66
2.66
1.29
1.16
1.03
0.70
0.65
0.52

SIP 3 (%)
1.73
2.82
2.94
2.58
2.34
1.25
1.12
1.00
0.87
0.63
0.50
0.38
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Mean (%)
1.94
2.96
3.33
2.96
2.35
1.94
1.28
1.15
1.02
0.75
0.64
0.47

SD (%)
0.26
0.14
0.29
0.27
0.25
0.58
0.12
0.12
0.12
0.12
0.11
0.07

Figure 9.1.

MT-TB SIP geometries for testing drug aerosol deposition from a
Flovent Diskus DPI.
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Figure 9.2.

Comparison of in vitro and simulated deposition results with
square waveform inhalation flow conditions for the DPI at 75
L/min. The CFD predictions are shown to match the in vitro
results to a high degree.
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Figure 9.3.

Stochastic individual path (SIP) model extending from the end of
the MT-TB geometry into the right lower lung.

The arrow

indicates the site of velocity field and particle profile interpolation
between the upper airway model and SIP geometry.
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Figure 9.4.

CFD predicted results of DPI deposition in the upper MT-TB
model for (a) SS and (b) QD inhalation waveforms.
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Figure 9.5.

Particle deposition locations and regional deposition efficiencies
(DE) of drug mass for (a) SS for SIP 1, (b) QD for SIP 1, (c) SS
for SIP 2, (d) QD for SIP 2, (e) SS for SIP 3, and (f) QD for SIP 3.
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Figure 9.6.

Comparison of steady state and transient deposition efficiencies of
drug mass within specific regions. The error bars denote +/- one
standard deviation.
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Figure 9.7

Comparison of steady state and QD deposition efficiencies of drug
mass in each bifurcation of 3 SIPs. Symbols represent mean values
and the error bars denote +/- one standard deviation.
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Chapter 10. Conclusions and Future Work

The three objectives stated in Chapter 1 have been achieved in this
dissertation. In conclusion: (1.1) a CFD model was developed to predict the
transient absorption of inhaled vapors into a multilayer mucus-tissue-blood
(MTB) system; (1.2) a transient CFD boundary condition in a multilayer airmucus-tissue-blood (AMTB) system was developed in a nasal-laryngeal airway
model; (1.3) effects of both transient inhalation and transient absorption on
regional and local uptake in a representative upper airway model were evaluated;
(2.1) enhanced condensational growth (ECG) for respiratory drug delivery was
evaluated for models of the mouth throat (MT) and tracheobronchial (TB) region;
(2.2) effects of transient inhalation waveforms on the ECG process in the upper
TB airways were considered; (3.1) transport and deposition of pharmaceutical
polydisperse aerosols from inhalers in upper airways were evaluated; (3.2)
transport and deposition of pharmaceutical polydisperse aerosols from inhalers
throughout the TB airways were evaluated using a stochastic individual path (SIP)
modeling approach. Results of these studies and suggested topics for future
analyses are summarized below.

10.1

Transient Absorption of Inhaled Vapors.

Objective 1.1: Considering transient absorption of inhaled vapors into a
multilayer mucus-tissue-blood (MTB) system, three models of the wall were
evaluated based on dimensions for the ET2, BB, and bb regions. Results indicated
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that transient absorption can significantly influence the transport and uptake of
vapors in the walls of the conducting airways. Objective 1.2: In order to
investigate transport and absorption of inhaled vapors over time into a multilayer
air-mucus-tissue-blood (AMTB) system in a nasal-laryngeal airway model, a
transient CFD boundary condition was developed. Results indicated that
absorption was highly time dependent over the timescale of one inhalation cycle.
Objective 1.3: Evaluating the effects of both transient inhalation and transient
absorption on regional and local uptake in a model upper airway geometry, the
transient CFD boundary condition was employed for CFD simulations of gas
phase transport and mass transfer. A new dosimetry program TAOCS 1.0 was
used in conjunction with a CFD model to apply and evaluate both steady state and
transient wall absorption conditions. Results indicated that the implementation of
a transient flux boundary condition appears critical to predict total and local
deposition characteristics for even highly soluble compounds.

10.2

The Concept of Enhanced Condensational Growth.

Objective 2.1: Using both control and ECG delivery cases, the effectiveness
for

respiratory

drug

delivery

in

a

realistic

mouth-throat

(MT)

and

tracheobronchial (TB) single path model was evaluated. Results indicated that
ECG is an effective method to virtually eliminate MT depositional losses, and the
associated intersubject variability, while providing for high TB deposition and
near full lung retention of the aerosol. Objective 2.2: Considering the effects of
transient inhalation waveforms on the ECG process in the upper TB airways, CFD
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methods were employed to evaluate aerosol deposition. Results indicated that the
ECG delivery approach under transient inhalation conditions increased aerosol
deposition in the TB airways by only a small amount, as compared with steady
state conditions.

10.3

Local and Regional Deposition of Pharmaceutical Aerosols.

Objective 3.1: The effect of transient waveforms and interactions at the
patient-device interface on the transport and deposition of pharmaceutical
polydisperse aerosols from inhalers in upper airways was considered. Results
indicated that the CFD model predictions matched the in vitro experiments to a
high degree. The DPI delivers approximately 4 times more dose to the TB section
under square waveform inhalation conditions compared with MDI delivery under
steady state inhalation conditions. The CFD results also indicate that it is critical
to consider transient inhalation effects when assessing aerosol deposition,
especially for MDI devices. Objective 3.2: The stochastic individual path (SIP)
modeling approach was implemented to evaluate the transport and deposition of
pharmaceutical polydisperse aerosols from inhalers in the lower airways. Results
indicated that steady state inhalation can be used to predict deposition efficiencies
in the TB airways.
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APPENDIX A
Transient Analytic Solutions in the Mucus-Tissue-Blood System

In this section, the analytic transient solution for time-dependent variables
Cm(y,t) and Ct(y,t) is developed. Knowing the steady state solution for
C% m ( y ) and C% t ( y ) , it is appropriate to represent Cˆ m ( y, t ) and Cˆt ( y, t ) as the

transient concentration distribution (Powers 1972)
Cˆ m ( y, t ) = Cm ( y, t ) − C% m ( y ) and Cˆ t ( y, t ) = Ct ( y, t ) − C% t ( y )

(A.1)

By using these expressions, we have the following relations
∂Cˆ m ( y, t ) ∂Cm ( y, t ) dC% m ( y ) ∂Cm ( y, t )
,
=
−
=
dt
∂t
∂t
∂t

(A.2a)

∂Cˆ t ( y, t ) ∂Ct ( y, t ) dC% t ( y ) ∂Ct ( y, t )
,
=
−
=
∂t
∂t
dt
∂t

(A.2b)

∂ 2Cˆ m ( y, t ) ∂ 2Cm ( y, t ) d 2C% m ( y ) ∂ 2Cm ( y, t )
, and
=
−
=
dy 2
∂y 2
∂y 2
∂y 2

(A.2c)

∂ 2Cˆ t ( y, t ) ∂ 2Ct ( y, t ) d 2C% t ( y ) ∂ 2Ct ( y, t )
.
=
−
=
dy 2
∂y 2
∂y 2
∂y 2

(A.2d)

Therefore, we get the following Equations for Cˆ m ( y, t ) and Cˆ t ( y, t )
∂Cˆ m ( y, t )
∂ 2Cˆ m ( y, t )
= Dm
, y ∈ [0, H m ]
∂t
∂y 2

(A.3a)

∂Cˆ t ( y, t )
∂ 2Cˆ t ( y, t )
, y ∈[H m , H m + Ht ]
= Dt
∂t
∂y 2

(A.3b)

The initial conditions are
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Cˆ m ( y, 0) = Cm ( y, 0) − C% m ( y ) =

Cˆ t ( y, 0) = Ct ( y, 0) − C% t ( y ) =

λma Cair − C% m ( y ) | y = H
Hm

λtmC% m ( y ) | y = H
Ht

m

y−

m

y − λma Cair and

λtmC% m ( y ) | y = H
Ht

m

(A.4a)

( H m + H t ) . (A.4b)

The boundary conditions are
Cˆ m ( y, t ) | y =0 = Cm ( y, t ) | y =0 −C% m ( y ) | y =0 = 0 ,

(A.5a)

Cˆ t ( y, t ) | y = H m = λtmCˆ m ( y, t ) | y = H m ,

(A.5b)

− Dm

∂Cˆ m ( y, t )
∂Cˆ ( y, t )
| y = H m = − Dt t
| y = H m , and
∂y
∂y

Cˆ t ( y, t ) | y = H m + Ht = Ct ( y, t ) | y = H m + Ht −C% t ( y, t ) | y = H m + Ht = 0 .

(A.5c)
(A.5d)

Introducing a dimensionless variable ξ = y / H m , Equations (A.3a) and (A.3b)
become
∂Cˆ m (ξ , t ) Dm ∂ 2Cˆ m (ξ , t )
=
, ξ ∈ [0,1]
H m2
∂t
∂ξ 2

(A.6a)

∂Cˆ t (ξ , t )
D ∂ 2Cˆ t (ξ , t )
= t2
, ξ ∈ [1,1 + H t / H m ]
∂t
∂ξ 2
Hm

(A.6b)

Substitution of the product Cˆ m (ξ , t ) = Yˆm (ξ )T (t ) into Equation (A.3a) gives
1 d 2Yˆm H m 2 1 dT
=
= −μ 2 , μ ≠ 0
2
ˆ
ξ
d
D
T
dt
Ym
m

(A.7a)

Similarly, substitution of the product Cˆ t (ξ , t ) = Yˆt (ξ )T ′(t ) into Equation (A.3b)
after multiplying by Dt / Dm gives
Dt 1 d 2Yˆt H m 2 1 dT ′
=
= −μ 2 , μ ≠ 0
2
ˆ
Dm Yt d ξ
Dm T ′ dt
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(A.7b)

where μ 2 is a separation constant. Equations (A.7a) and (A.7b) immediately result
in four ordinary differential equations

d 2Yˆm
+ μ 2Yˆm = 0 ,
2
dξ

(A.8a)

D
dT
= − μ 2 m2 T ,
dt
Hm

(A.8b)

d 2Yˆt μ 2 Dm ˆ
+
Yt = 0 , and
dξ 2
Dt

(A.8c)

D
dT ′
= − μ 2 m2 T ′ .
dt
Hm

(A.8d)

The solutions for the spatially-dependent functions Yˆm ( y ) and Yˆt ( y ) are
obtained from Equations (A.8a) and (A.8c), and substituting for ξ gives

μy
μy
Yˆm ( y ) = A cos(
) + B sin(
) and
Hm
Hm

(A.9a)

Dm y
Dm y
Yˆt ( y ) = A′ cos( μ
) + B′ sin( μ
).
Dt H m
Dt H m

(A.9b)

The solutions for the time-variable functions T (t ) and T ′(t ) are obtained from
Equations (A.8b) and (A.8d) as
T (t ) = T ′(t ) = e

−μ2

Dm
H m2

t

>0.

(A.9c)

Considering Cˆ m (0, t ) = Yˆm (0)T (t ) =0, it follows that Yˆm (0) = 0 , which results in
A = 0 . As a result, Equation (A.9a) simplifies to

μy
Yˆm ( y ) = B sin(
).
Hm

(A.10a)
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Similarly, as Cˆ t ( y, t ) | y = H m + Ht = Yˆt ( H m + H t )T (t ) = 0 , it follows that Yˆt ( H m + H t ) = 0 ,
and Equation (A.9b) simplifies to (Jeffrey 2002)
Dm H m + H t − y
Yˆt ( y ) = P sin( μ
).
Dt
Hm

(A.10b)

Substituting (A.10a) and (A.10b) into the Equations (A.5b) and (A.5c), the
boundary conditions become,

λtm B sin( μ ) = P sin( μ

Dm H t
)
Dt H m

(A.11a)

and
− Dm B

μ
Hm

cos( μ ) = Dt P

μ
Hm

Dm
Dm H t
cos( μ
).
Dt
Dt H m

(A.11b)

Dividing Equation (A.11a) by (A.11b), the eigenvalues, µn, are the sequential
positive roots of the transcendental equation

λtm

Dt
Dm H t
tan( μ ) + tan( μ
) =0.
Dm
Dt H m

(A.12)

The eigenvalues µ can be calculated numerically using Brent’s method which
combines bisection, secant, and inverse quadratic interpolation methods. The first
five eigenvalues µ in the series, are provided in Tables A.1 – A.3 at the end of this
section.
Constants B and P come directly from the Equation (A.11a)
B = sin( μ

Dm H t
) and
Dt H m

(A.13a)

P = λtm sin( μ ) .

(A.13b)

Substituting Equations (A.13a) and (A.13b), Equation (A.11b) becomes
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−

Dm 1
Dm H t
Dm H t
sin( μ
) cos( μ ) = sin( μ ) cos( μ
).
Dt λtm
Dt H m
Dt H m

(A.14)

Substituting Equations (A.13a) and (A.13b), Equations (A.10a) and (A.10b)
become
Dm H t
μy
Yˆm ( y ) = sin( μ
) sin(
) and
Dt H m
Hm

(A.15a)

Dm H m + H t − y
Yˆt ( y ) = λtm sin( μ ) sin( μ
).
Dt
Hm

(A.15b)

The concentration solutions Cˆ m ( y, t ) and Cˆ t ( y, t ) lead to classical Fourier series
solutions that take the following form

Dm H t
μ y − μn
) sin( n )e
Dt H m
Hm

∞

Cˆ m ( y, t ) = ∑ Wn sin( μn
n =1

2

Dm
H m2

∞
Dm H m + H t − y − μn
Cˆ t ( y, t ) = λtm ∑ Wn sin( μn ) sin( μn
)e
Dt
Hm
n =1

t

, y ∈ [0, H m ]

Dm

2

H m2

t

, y ∈[H m , H m + Ht ]

(A.16a)

(A.16b)

The coefficient Wn ( g / cm3 ) can be determined by utilizing the orthogonal
relation and initial condition of zero mucus and tissue concentration.
Hm

Wn =

∫

Cˆ m ( y, 0)Yˆm ( y )dy + η

0

Hm

∫ ⎡⎣Yˆ ( y)⎤⎦

2

m

dy + η

0

H m + Ht

∫

Cˆ t ( y, 0)Yˆt ( y )dy

∫

2

Hm
H m + Ht

Hm

,

(A.16c)

⎡Yˆt ( y ) ⎤ dy
⎣
⎦

where η is a weight function that must satisfy
Hm

∫
0

Yˆmi ( y )Yˆmj ( y )dy + η

H m + Ht

∫

Yˆti ( y )Yˆtj ( y )dy = 0 , i ≠ j

Hm
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(A.16d)

By a detailed derivation, the eigen functions are orthogonal with η = 1/ λtm
over the interval [0, H m + H t ] . Thus, substituting η = 1/ λtm into Equation (A.16c),
the coefficients Wn can be determined.

These coefficients were calculated

numerically and the first five values in the series are tabulated in Tables A.1 –
A.3.
The resulting analytic transient solutions for Cm ( y, t ) and Ct ( y, t ) have the
following form

Cm ( y, t ) = Cˆ m ( y, t ) + C% m ( y )
∞

= ∑ Wn sin( μn
n =1

μ y − μn
Dm H t
) sin( n )e
Dt H m
Hm

2

Dm
H m2

t

+ λma Cair −

λma Cair − C% m ( y ) | y = H
Hm

m

y,

(A.17a)

Ct ( y, t ) = Cˆ t ( y, t ) + C% t ( y )
∞

= λtm ∑ Wn sin( μn ) sin( μn
n =1

Dm H m + H t − y − μn
)e
Dt
Hm

2

Dm
H m2

t

+

λtmC% m ( y ) | y = H
Ht

m

( H m + H t − y ),
(A.17b)

The value of C% m ( y ) | y = H m is determined from the steady state solution, shown
previously.
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Transient Analytic Solutions in the Air-Mucus-Tissue-Blood System

In this section, the analytic transient solution for time-dependent variables

Cm(y,t) and Ct(y,t) is developed. To achieve the desired solution we now construct
the transient analytic solutions Cm ( y, t ) and Ct ( y, t ) of the problem by the
superposition of the solutions of two simpler sub-problems in the form (Ozisik
1980)
Cm ( y, t ) = Cˆ m ( y, t ) + f (t )C% m ( y ) , and Ct ( y, t ) = Cˆ t ( y, t ) + f (t )C% t ( y ) ,

(A.18)

By using these expressions, we have the following system of equations
∂Cm ( y, t ) ∂Cˆ m ( y, t ) %
df (t )
=
+ Cm ( y )
,
∂t
∂t
dt

(A.19a)

∂Ct ( y, t ) ∂Cˆ t ( y, t ) %
df (t )
=
+ Ct ( y )
,
∂t
∂t
dt

(A.19b)

∂ 2Cm ( y, t ) ∂ 2Cˆ m ( y, t )
d 2C% m ( y ) ∂ 2Cˆ m ( y, t )
=
+
=
,
(
)
f
t
∂y 2
∂y 2
∂y 2
dy 2

(A.19c)

∂ 2Ct ( y, t ) ∂ 2Cˆ t ( y, t )
d 2C% t ( y ) ∂ 2Cˆ t ( y, t )
=
+ f (t )
=
,
∂y 2
∂y 2
∂y 2
dy 2

(A.19d)

where f (t ) is a time-dependent variable that can be defined as f (t ) = Cm ( y, t ) | y =0 .
This variable is used to account for an arbitrary concentration on the mucus layer
at the air-mucus interface. C% m ( y, t ) , C%t ( y, t ) , Cˆ m ( y ) , and Cˆ t ( y ) are the solutions
of the following sub-problems.
1. C% m ( y, t ) and C%t ( y, t ) are the steady state solutions with a time constant air
phase concentration.
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d 2C% m ( y )
= 0 , y ∈ [0, H m ]
dy 2

(A.20a)

d 2C%t ( y )
= 0 , y ∈[H m , H m + Ht ]
dy 2

(A.20b)

The boundary conditions from the steady state case are:

C% m ( y ) | y =0 = 1 ,

(A.21a)

C% t ( y ) | y = H m = λtmC% m ( y ) | y = H m ,

(A.21b)

− Dm

dC% m ( y )
dC% t ( y )
| y = H m = − Dt
|y=Hm ,
dy
dy

C% t ( y ) | y = H m + Ht = 0 ,

(A.21c)
(A.21d)

The analytic solutions of the steady diffusion Equations (A.3a and b) are:
C% m ( y ) = 1 −

C% t ( y ) =

1 − C% m ( y ) | y = H m
Hm

λtmC% m ( y ) | y = H
Ht

m

y , y ∈ [0, H m ]

( H m + H t − y) , y ∈[ H m , H m + H t ]

(A.22a)

(A.22b)

The concentration on the mucus side at the mucus-tissue interface C% m ( y ) | y = H m
can be obtained from Equations (A.21c), (A.22a), and (A.22b); the resulting
expression is

C% m ( y ) | y = H m =

H t Dm
,
H m λtm Dt + H t Dm

(A.23)

At steady state, Equation A.18 has the following form by substituting

f (t → ∞) = C% m ( y ) | y =0 = λma C% a′ ( y ) | y =0 ;
C% m′ ( y ) = λma C% a′ ( y ) | y =0 C% m ( y ) , and C% t′( y ) = λma C% a′ ( y ) | y =0 C% t ( y ) ,
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(A.24)

where C% m′ ( y ) and C% t′( y ) are the steady-state solutions of Equation 18. C% a′ ( y ) | y =0
is the steady-state concentration on the air side at the air-mucus interface. The
value can be obtained by solving a steady-state transport equation in the air layer.
2. Cˆ m ( y ) and Cˆ t ( y ) are the solutions of the following time-dependent problem.
∂Cˆ m ( y, t )
∂ 2Cˆ m ( y, t ) %
df (t )
= Dm
− Cm ( y )
, y ∈ [0, H m ]
2
∂t
∂y
dt

(A.25a)

∂Cˆ t ( y, t )
∂ 2Cˆt ( y, t ) %
df (t )
= Dt
− Ct ( y )
, y ∈[H m , H m + Ht ]
2
∂t
∂y
dt

(A.25b)

The initial conditions are:
Cˆ m ( y, 0) = Cm ( y, 0) − f (0)C% m ( y ) = 0 ,

(A.26a)

Cˆ t ( y, 0) = Ct ( y, 0) − f (0)C% t ( y ) = 0 ,

(A.26b)

The boundary conditions are:

Cˆ m ( y, t ) | y =0 = Cm ( y, t ) | y =0 − f (t )C% m ( y ) | y =0 = 0 ,

(A.27a)

Cˆ t ( y, t ) | y = H m = λtmCˆ m ( y, t ) | y = H m ,

(A.27b)

− Dm

∂Cˆ m ( y, t )
∂Cˆ ( y, t )
| y = H m = − Dt t
|y= Hm ,
∂y
∂y

Cˆ t ( y, t ) | y = H m + Ht = Ct ( y, t ) | y = H m + Ht − f (t )C% t ( y, t ) | y = H m + Ht = 0 ,
The concentration solutions Cˆ m ( y, t )

(A.27c)
(A.27d)

and Cˆ t ( y, t ) lead to a Fourier series

solutions that takes the following form (Ozisik 1980)
− μn 2

Dm

t

D
t
μn 2 m2 τ
⎡
⎤
e
Hm
ˆ
ˆ
Cm ( y , t ) = ∑
Ym ( μn , y ) ⎢ F ( μn ) + ∫ e
A( μn ,τ )dτ ⎥ , y ∈ [0, H m ]
n =1 N ( μ n )
⎢⎣
⎥⎦
τ =0

∞

H m2
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(A.28a)

− μn 2

Dm

t

D
t
μn 2 m2 τ
⎡
⎤
e
H
Cˆ t ( y, t ) = ∑
Yˆt ( μn , y ) ⎢ F ( μn ) + ∫ e m A( μn ,τ )dτ ⎥
n =1 N ( μ n )
⎢⎣
⎥⎦
τ =0

∞

H m2

,

y ∈[H m , H m + Ht ]

(A.28b)

where

N ( μn ) =

Hm

∫
0

F ( μn ) =

Hm

∫

2

⎡Yˆm ( μn , y ) ⎤ dy + η
⎣
⎦

Hm + Ht

∫

Hm

Cˆ m ( y, 0)Yˆm ( μn , y )dy + η

0

A( μn ,τ ) = −

2

⎡Yˆt ( μn , y ) ⎤ dy ,
⎣
⎦
H m + Ht

∫

Cˆ t ( y, 0)Yˆt ( μn , y )dy = 0 ,

(A.29a)

(A.29b)

Hm

df (τ ) ⎛
⎜
dτ ⎜⎝

Hm

∫

C% m ( y )Yˆm ( μn , y )dy + η

0

H m + Ht

∫

Hm

⎞
C% t ( y )Yˆt ( μn , y )dy ⎟ .
⎟
⎠

(A.29c)

By using methods of separating variables and the orthogonal condition, we have
Dm H t
μ y
Yˆm ( μn , y ) = sin( μn
) sin( n ) ,
Dt H m
Hm

(A.30a)

Dm H m + H t − y
Yˆt ( μn , y ) = λtm sin( μ n ) sin( μ n
),
Dt
Hm

(A.30b)

η = 1/ λtm ,

(A.30c)

The eigenvalues µn, were determined by solving the transcendental equation:

λtm

Dt
Dm H t
tan( μ ) + tan( μ
) =0,
Dm
Dt H m

(A.31)

The eigenvalues µ can be calculated numerically using Brent’s method, which
combines bisection, secant, and inverse quadratic interpolation methods. The first
five eigenvalues µ , are provided in Tables A.4 and A.5 at the end of this section.
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Based on the expressions above, the analytical solutions for Cm ( y, t ) and

Ct ( y, t ) can be obtained by using the Fourier series expansion, which results in

Cm ( y, t ) = Cˆ m ( y, t ) + f (t )C% m ( y )
∞

t

n =1

τ =0

= ∑ WnYˆm ( μ n , y ) ∫ e

− μn 2

Dm
H m2

( t −τ )

dCm ( y,τ ) | y =0
dτ

⎛ 1 − C% m ( y ) | y = H m ⎞
dτ + Cm ( y, t ) | y =0 ⎜1 −
y ⎟,
⎜
⎟
H
m
⎝
⎠
(A.32a)

Ct ( y, t ) = Cˆ t ( y, t ) + f (t )C% t ( y )
∞

t

n =1

τ =0

= ∑ WnYˆt ( μ n , y ) ∫ e

− μn 2

Dm
H m2

( t −τ )

dCm ( y,τ ) | y =0
dτ

⎛ λtmC% m ( y ) | y = H m
⎞
( H m + H t − y) ⎟ ,
dτ + Cm ( y, t ) | y =0 ⎜
⎜
⎟
Ht
⎝
⎠
(A.32b)

where
Hm

Wn = −

∫
0

C% m ( y )Yˆm ( μn , y )dy + η

H m + Ht

∫

C% t ( y )Yˆt ( μn , y )dy

Hm

,

N ( μn )

(A.33)

The coefficients Wn were calculated numerically to 4 decimal places and are
tabulated in Tables A.4 and A.5. The value of C% m ( y ) | y = H m is determined from the
steady state solution, shown in Eq. (A.23).
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Table A.1.

The first five eigenvalues µ and coefficients W (g/cm3) for the ET2
model MTB wall.

Acetaldehyde

Benzene

µ1= 0.5092

W 1=-8.5258×10-5

µ1=0.4050

W 1=-1.8697×10-8

µ2=0.9992

W 2=3.3998×10-5

µ2=0.8708

W 2=3.4088×10-9

µ3=1.4243

W 3=-2.7282×10-5

µ3=1.3677

W 3=-1.4458×10-9

µ4=1.7934

W 4=2.1203×10-5

µ4=1.8712

W 4=1.1024×10-9

µ5=2.2359

W 5=-1.5109×10-5

µ5=2.3646

W 5=-1.4375×10-9

Table A.2.

The first five eigenvalues µ and coefficients W (g/cm3) for the BB
model MTB wall.

Acetaldehyde

Benzene

µ1=0.3469

W 1=-1.1550×10-4

µ1=0.2903

W 1=-2.7590×10-8

µ2=0.6905

W 2=3.6056×10-5

µ2=0.6044

W 2=5.3716×10-9

µ3=1.0244

W 3=-2.3299×10-5

µ3=0.9366

W 3=-2.0081×10-9

µ4=1.3343

W 4=2.0736×10-5

µ4=1.2772

W 4=1.1003×10-9

µ5=1.8954

W 5=1.3921×10-5

µ5=1.9639

W 5=7.6020×10-10

252

Table A.3.

The first five eigenvalues µ and coefficients W (g/cm3) for the bb
model MTB wall.

Acetaldehyde

Benzene

µ1=0.6625

W 1=-7.2539×10-5

µ1=0.5099

W 1=-1.4215×10-8

µ2=1.2579

W 2=3.6264×10-5

µ2=1.1278

W 2=2.6088×10-9

µ3=1.7129

W 3=-2.7475×10-5

µ3=1.7827

W 3=-1.4502×10-9

µ4=2.2560

W 4=1.9307×10-5

µ4=2.4215

W 4=1.9762×10-9

µ5=2.9062

W 5=-3.7751×10-5

µ5=2.9732

W 5=-8.2184×10-9

Table A.4:

The first five eigenvalues µ and the coefficients W for the ET2
model AMTB wall.

Acetaldehyde

µ1=

Benzene

W 1=-1.4549

µ1=0.4050

W 1=-1.3355

µ2=0.9992

W 2=0.5802

µ2=0.8708

W 2=0.2435

µ3=1.4243

W 3=-0.4656

µ3=1.3677

W 3=-0.1033

µ4=1.7934

W 4=0.3618

µ4=1.8712

W 4=0.0787

µ5=2.2359

W 5=-0.2578

µ5=2.3646

W 5=-0.1027

0.5092
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Table A.5.

The first five eigenvalues µ and coefficients W for the BB model
AMTB wall.

Acetaldehyde

Benzene

µ1=0.3469

W 1=-1.9710

µ1=0.2903

W 1=-1.9708

µ2=0.6905

W 2=0.6153

µ2=0.6044

W 2=0.3837

µ3=1.0244

W 3=-0.3976

µ3=0.9366

W 3=-0.1434

µ4=1.3343

W 4=0.3538

µ4=1.2772

W 4=0.0786

µ5=1.8954

W 5=0.2376

µ5=1.9639

W 5=0.0543
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